Simultaneous quantification of first-line anti-tuberculosis drugs and metabolites in human plasma by Mazanhanga, Marian Tafadzwa
     
SIMULTANEOUS QUANTIFICATION OF FIRST-LINE ANTI-TUBERCULOSIS 
DRUGS AND METABOLITES IN HUMAN PLASMA 
 
THESIS PRESENTED IN PARTIAL FULFILMENT OF THE DEGREE OF 
MASTER OF PHILOSOPHY IN CLINICAL PHARMACOLOGY 
IN THE DIVISION OF CLINICAL PHARMACOLOGY 
DEPARTMENT OF MEDICINE 
UNIVERSITY OF CAPE TOWN 
 
 
MARIAN TAFADZWA MAZANHANGA 
STUDENT NUMBER: MZNMAR003 
SUPERVISOR: ASSOCIATE PROFESSOR LUBBE WIESNER 
CO-SUPERVISORS: MR. ANTON JOUBERT AND MRS. JENNIFER NORMAN 
10 February 2019 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 I 
I. DECLARATION
I, Marian Tafadzwa Mazanhanga, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements indicate 
otherwise) and that neither the whole work nor any part of it has been, is being, or is to be 
submitted for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole or any 
portion of the contents in any manner whatsoever. 
Signature: 
Date:  10 February 2019 
  
 II 
II.  ABSTRACT 
 
Tuberculosis (TB) currently kills more people than any other infectious disease worldwide, the 
highest burden being in Africa and Asia (1). Therapy recommended for drug sensitive TB 
consists of a cocktail of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and ethambutol 
(EMB), all given in a 2-month intensive phase, followed by only INH and RIF in a 4-month 
continuation phase. Clinical studies seeking to optimize dosing, gain more knowledge on the 
pharmacokinetics and pharmacodynamics of the drugs and compare current therapy to 
alternative regimens are required (2, 3). Therapeutic drug monitoring (TDM) is frequently 
carried out in cases responding poorly to therapy (3, 4). Both clinical studies and TDM require 
bioanalytical methods for quantifying drug concentrations in biological fluids. Several methods 
have been developed, mostly analysing individual drugs but a few analyse combinations. 
Ideally, quantification of all four drugs in one method is desirable as it is economical and allows 
high throughput. 
 
A method was developed and validated for the quantification of first line anti-tuberculosis 
drugs EMB, INH, PZA and RIF and the metabolites N-acetyl isoniazid (AcINH) and 25-
desacetyl rifampicin (desRIF). Sample preparation consisted of protein precipitation, followed 
by high performance liquid chromatography (HPLC) with tandem mass spectrometry (MS/MS) 
detection. Deuterated internal standards for each analyte (AcINH-d4, desRIF-d3, EMB-d4, 
INH-d4, PZA-15N,d3 and RIF-d3) were used. Mean recoveries of the analytes from plasma 
were as follows: AcINH 106.5%, DesRIF 123.2%, EMB 105.3%, INH 110.1%, PZA 132.0% 
and RIF 127.7%. Sample preparation was followed by reverse phase liquid chromatography on 
an Agilent 1200 series HPLC system using an Agilent Poroshell 120 EC- C18 2.7µm, 4.6 X 
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50mm analytical column. Separation of all analytes was achieved using a mobile phase gradient 
consisting of an aqueous mobile phase A (0.05% formic acid in water) and an organic mobile 
phase B (0.05% formic acid in a mixture of methanol and acetonitrile, 1:1). A T-junction 
splitter was used to reduce the mobile phase flow to the ion source by about 30%. Retention 
times for AcINH, desRIF, EMB, INH, PZA and RIF were 2.45, 5.40, 1.75, 2.22, 4.30 and 5.68 
minutes respectively. 
 
An AB Sciex API 4000 triple quadrupole mass spectrometer at unit mass resolution in the 
multiple reaction monitoring (MRM) mode was used for detection, monitoring the following 
transitions for the six analytes: AcINH 180 → 121, desRIF 784 → 752, EMB 205 → 116, INH 
138 → 79, PZA 124 → 81 and RIF 823 → 792. An electrospray ionisation (ESI) source in the 
positive ion mode was used to couple the mass spectrometer to the LC system.  
 
Accuracy and precision were assessed over three consecutive and independent runs. The 
calibration curves fit quadratic regressions for all analytes, with weighting of 1/x (where 
x=concentration) for all except PZA which had a weighting of 1/x2 over the calibration range. 
Calibration ranges in µg/ml were as follows: AcINH 0.050 – 12.5, desRIF 0.040 – 10.0, EMB 
0.020 – 5.00, INH 0.100 – 25.0, PZA 0.32. – 80.0 and RIF 0.120 – 30.0, based on peak area 
ratios.  
 
A 1:4 dilution of the QC Dilute sample showed that concentrations of up to 20.0 µg/ml for 
AcINH, 16.0 µg/ml for desRIF, 8.00 µg/ml for EMB, 40.0 µg/ml for INH, 128 µg/ml for PZA 
and 48.0 µg/ml for RIF in plasma could be analysed reliably when diluted into the calibration 
range. No significant carry-over was observed for all analytes. 
  
 IV 
The method was shown to be reproducible when human plasma samples from six different 
sources were analysed and endogenous matrix components had no significant effect on the 
assay. All analytes were stable in plasma for at least four hours on ice, and when subjected to 
three freeze-thaw cycles. Reinjection reproducibility experiments showed that all analytes 
except PZA could be reliably analysed by re-injecting an entire batch after about 48 hours. 
Quantification of AcINH, INH and RIF was not significantly affected by 2% hemolysis of 
sample while desRIF, EMB and PZA were significantly affected. Data was analysed using 
Analyst ® version 1.6.2 software. 
With wide calibration ranges, the assay is suitable for both routine TDM and PK studies. 
Concurrent analysis of metabolites allows inferences to be made on the PK of the two main TB 
drugs. The total run time of 6.5 minutes per sample combined with the simple sample 
preparation procedure, the method is more economical on both time and resources than single 
analyte assays.  
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Chapter 1 : INTRODUCTION 
 
The age-old disease continues to threaten human health across the globe, but more so in less 
developed countries, particularly in Africa and Asia. Tuberculosis, according to the World 
Health Organization (WHO), kills more people than any other infection yearly (1). Several 
drugs are available for treating the disease and with proper management, treatment is highly 
successful. The currently preferred regimen for the treatment of new cases of drug susceptible 
tuberculosis (TB) includes four drugs: isoniazid (INH), rifampicin (RIF), pyrazinamide 
(PZA) and ethambutol (EMB). These are commonly referred to as the 1st line TB drugs. All 
four drugs are administered in the initial 2-month intensive phase, followed by a 4-month 
long continuation phase with INH and RIF only. Multi-drug therapy has been shown to 
reduce the emergence of resistant mycobacterial strains and gives better efficacy (5). The four 
drugs act at different target sites, which may result in additive effects or synergy among 
them. In addition, if a pathogen develops resistance to one drug it is likely to be killed by the 
other drugs due to activity at different sites from that at which the ineffective drug acts. 
Although more effective, multi-drug therapy may subject patients to more adverse drug 
effects through drug-drug interactions, hence adequate patient monitoring is essential. 
Therapeutic drug monitoring (TDM) is one of the strategies that are used to monitor patients. 
Although it has a limited role in many settings in the treatment of TB, perhaps because 
treatment is highly successful and TDM may be expensive (6), there are cases where TDM is 
called for, such as poor or slow response to treatment and suspected adverse drug reactions. 
 
Although all the 1st line drugs were introduced more than 50 years ago, many gaps still exist 
in what is known about their pharmacodynamics (PD) and pharmacokinetics (PK). Several 
studies have shown that drug concentrations are frequently below or above the target 
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concentrations (7-9) and questions arise on whether this is due to inappropriate dosing, poor 
formulation of medicines or to patient related factors such as age, pharmacogenetics and co-
morbidities. In some cases, drug metabolites play a role in the efficacy and/or toxicity of 
drugs, hence these may need to be monitored. Clinical studies are necessary, and continue to 
be carried out, to establish optimum dosing which will result in high efficacy with minimum 
adverse drug reactions (ADRs). These studies may also help to establish PK-PD 
relationships, to identify poorly formulated medicines and to compare the existing regimens 
to new ones. 
 
Both TDM and PK-PD studies require reliable and accurate methods for the quantification of 
drugs in biological matrices. The most commonly used matrices include blood, plasma, 
serum and urine. These matrices require some level of sample preparation prior to analysis. 
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is one of the 
most commonly used techniques in bioanalysis as it is highly sensitive and selective. 
Numerous methods have been developed for the analysis of 1st line TB drugs, many of them 
looking at individual drugs (10-13) and some analysing combinations (9, 14-17). A few have 
been developed for the quantification of all four (18-20), each method being unique to other 
methods. Analysis of all 4 drugs in one method is desirable because it allows economical 
quantification of all drugs and allows high throughput. However, there are challenges in 
developing such methods because of the differences in the physicochemical properties of the 
drugs; it is difficult to reliably analyse molecules of such wide-ranging chemical structures, 
polarities and stability under the same conditions. Molecular structures and masses of 1st-line 
TB drugs are show in Figure 1.1. After development, validation is necessary to prove that the 
method can reliably measure what it purports to measure. Validation involves a set of 
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experiments under various conditions to measure important parameters such as accuracy, 
reproducibility and stability. 
 
 
 
Figure 1.1: Molecular structures and masses of 1st line TB drugs and two metabolites 
 
Although new drugs have been developed, and some relatively old ones re-purposed for TB 
treatment, the 1st line drugs remain highly effective and better tolerated, hence they are the 
preferred treatment of choice. The rise in drug resistance combined with the expensive and 
slow rate of new drug development necessitates good stewardship of the highly successful, 
well tolerated and more affordable 1st line therapy through means such as TDM and 
establishing PK-PD relationships. For these purposes, a simple, rapid and robust method was 
developed and validated to accurately and consistently quantify the 1st line anti-TB drugs and 
metabolites of the two main drugs in human plasma using LC-MS/MS. 
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Chapter 2 : LITERATURE REVIEW 
 
2.1.  Origins of the disease 
 
Tuberculosis (TB) has afflicted mankind for ages and continues to be a leading threat to 
human health worldwide. Archaeological evidence suggests that the disease dates to pre-
historic times (21, 22). Examination of skeletal remains with similar lesions to those 
diagnostic of spinal TB, and molecular identification of Mycobacterium tuberculosis (MTB) 
DNA in ancient skeletons provide an insight to the origins of the disease. Despite such 
evidence, the place and time of origin of the disease, the earliest hosts and evolution of the 
pathogen remain controversial (22).  While pre-historic archaeological evidence from Egypt 
and the Americas dates to about 50 000 years ago, TB documentation is only first seen in 
classical Greece (480 – 328 BC), where it was called “phthisis” and was well described by 
Hippocrates (21, 23). Perhaps due to urbanisation and the associated overcrowding during the 
industrial revolution in Europe, the disease continued to spread and by the early 19th century 
tuberculosis had reached epidemic levels in much of Europe and North America (21).  
 
Until 1882 the aetiology of the disease was poorly understood. Some believed that it was 
heritable while others speculated that it was contagious (21, 24). About 40 years after the 
discovery that TB is caused by MTB, the first anti-TB drugs, para-amino salicylic acid (PAS) 
and streptomycin (SM), proved useful in curing the disease, followed by other anti-TB drugs 
in the mid-20th century, leading to a decline in the incidence of the disease (24). Even 
research in the field of tuberculosis declined as the disease was no longer considered to be a 
major threat (23). However, the incidence began to increase again with the advent of the 
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Human Immunodeficiency Virus (HIV) pandemic in the 1980s (25), especially in Africa and 
Asia, and in 1993 was declared a global health emergency by the World Health Organisation 
(WHO). Today it is a leading cause of death among infectious diseases. 
 
2.2. Mycobacterium - the pathogen 
 
In 1882, MTB was identified as the causative agent of TB (21, 26). This pathogen, that has 
evaded the human immune system for millennia, is a large, rod-shaped bacterium, 2-4 µm 
long and 0.2 – 0.5 µm wide (27, 28). It is an acid-fast bacterium, so called because of the 
impermeability of the cell wall to certain dyes and stains. Once stained, acid fast bacteria will 
retain dyes when heated and treated with acidified organic compounds. In addition to the 
biopolymers peptidoglycan and arabinoglycan, the cell wall contains complex lipids, the bulk 
of which are mycolic acids which affect the permeability properties of the cell surface and 
may be involved in the defence mechanisms of the pathogen against the host immune system 
as well as in drug resistance (29). The cell wall is of paramount importance to the survival of 
the pathogen and is a target of some TB drugs. Together with seven other mycobacteria (M. 
bovis, M. africanum, M.  microti, M. caprae, M. pinnipedii, M. canetti and M. mungi) it 
belongs to the Mycobacterium tuberculosis complex (30). While some of the other members 
of the complex are known to cause human disease, MTB is the most significant threat to 
human health (31). It is an obligate human pathogen, in contrast to the bacilli belonging to the 
Mycobacterium avium complex (MAC) which cause opportunistic infections, that is, they 
cause infection almost exclusively in immunocompromised individuals and rarely cause 
disease in healthy humans. Figure 2.1 is a representation of the structure of MTB. 
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Figure 2.1: Mycobacterium tuberculosis structure (27) 
 
2.3. Epidemiology 
 
About a third of the world’s population is thought to be infected by MTB (5).  However, this 
is mostly latent TB which is characterized by having the mycobacterium inside the body 
without showing or experiencing symptoms. While active TB occurs in all parts of the world, 
over 95% of cases and deaths are in developing countries (1). South Africa is among the 
countries with the highest TB burden and was reported to be among the six countries that 
accounted for 60% of new cases in 2016, together with India, Indonesia, China, Nigeria and 
Pakistan, and an estimated incidence of 454,000 cases of active TB in 2015 (32). The global 
incidence is decreasing by about 2% annually but the disease still kills about 1.5 million 
people every year and has the highest mortality rate among all infectious diseases (1). 
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Although it is a leading cause of death, TB is both preventable and curable. Cure rates for 
drug sensitive TB are at least 80% but, without proper TB treatment, about 45% of HIV-
negative and most HIV-positive patients will die (1).  
 
Cure rates of drug resistant TB are much lower and may be as low as 22% for extensively 
drug resistant (XDR) TB. Drug resistance ranges from resistance to a single drug to 
resistance to many drugs, and is a growing concern, with a prevalence of about half a million 
worldwide, necessitating the use of second line drugs and in the case of XDR, the use of new 
drugs. Multi-drug resistant (MDR) TB, by definition, is resistant to the two most commonly 
used TB drugs isoniazid (INH) and rifampicin (RIF). XDR TB, on the other hand, is resistant 
not only to INH and RIF but also to fluoroquinolones and at least one second line injectable 
TB drug (amikacin, capreomycin or kanamycin). Cases resistant to all available TB drugs 
have been reported and have been termed “totally drug resistant” (TDR) TB (33). 
 
2.4. TB Transmission and pathogenesis 
 
When an infected person coughs, sneezes or talks, droplet nuclei, which can contain 1 – 400 
bacilli, are released into the air. Droplet nuclei 1-5 μm in size reach the alveoli when inhaled 
and MTB bacilli will be taken up mainly by alveolar macrophages as part of normal host 
defences. Most of the bacilli are killed but some may survive and multiply inside the 
macrophages (30). These will be released when the macrophage dies, and the mycobacteria 
may be taken up by new macrophages to start a new cycle, be disseminated to other body 
parts if they come into contact with the bloodstream or lymphatic system (causing 
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extrapulmonary TB) or be expelled from the lungs through, for example, coughing with the 
potential to infect other hosts (34). Various factors interplay in the transmission of TB. These 
include: the immune status of the exposed person, infectiousness of the person with TB (this 
depends on the bacterial load of the droplet nuclei produced), the environment (e.g. 
ventilation) and the exposure level (proximity, duration and frequency).  The most common 
form of the disease occurs in the lungs (pulmonary TB) but it may affect other parts of the 
body such as the brain, gastrointestinal tract, urogenital tract and bones (extra-pulmonary 
TB). 
 
Mycobacteria that enter alveolar macrophages initially reside in endocytic vacuoles called 
phagosomes, which fuse with lysosomes to form phagolysosomes, exposing the pathogens to 
a hostile environment which is acidic, contains reactive oxygen intermediates, lysosomal 
enzymes, toxic peptides and possibly reactive nitrogen intermediates (25). Virulent 
mycobacteria can evade these harsh conditions and continue to multiply inside the host, 
eventually leading to host cell death. Infected macrophages produce chemokines which 
attract inactivated monocytes, lymphocytes and neutrophils, but these are not efficient in 
killing the bacteria. However, by surrounding the infected macrophage, they form 
granulomatous focal lesions which mitigate the spread of bacteria. Some bacteria can 
withstand the acidic pH in these oxygen deprived lesions and can survive in a seemingly 
dormant state, referred to as latent TB infection (25). The mechanism by which these 
“persistent” bacteria survive in a latent form is not well understood. This latent TB may 
progress to active TB disease when the host immune system is compromised, as occurs with 
HIV infection, increasing age and use of certain drugs. 
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2.5. Clinical manifestation 
 
The signs and symptoms of TB result from the interaction between the host immune system 
and the pathogen (35). Infected dendritic cells and macrophages produce pro-inflammatory 
cytokines such as interleukin (IL)-1-α, IL-1-β, tumour necrosis factor (TNF), IL-6, IL-12, and 
interferon (IFN)-γ, which aid in the T-cell response, promotion of antigen presentation, 
production of reactive oxygen intermediates (ROI) and activation of phagocytosis (36). The 
level of immunocompetency of an individual determines the way the disease progresses. 
Relatively immunocompetent persons usually have latent TB in which they do not manifest 
clinical symptoms. In about 10% of the population active TB occurs, characterized by 
symptoms such as fatigue, malaise, weight loss, low-grade fever accompanied by chills and 
night sweats and coughing which may sometimes produce blood stained sputum. 
Inflammation in the lung tissue may cause pain and in advanced disease shortness of breath 
occurs. In some cases, extrapulmonary TB occurs, especially in immunocompromised 
patients. The most serious cases occur in the central nervous system as TB meningitis or 
space occupying tuberculomas, both of which have high mortality rates. Disseminated or 
miliary TB, which can simply be regarded as infection of the bloodstream, is also highly 
fatal. This can result in multi-organ involvement. Other forms of extra-pulmonary TB include 
lymphatic (most common form of extra-pulmonary TB), bone, gastrointestinal and 
genitourinary TB (37). 
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2.6. Treatment 
 
The introduction of drug therapy changed TB from being a chronic, sometimes lifelong 
condition to a curable disease. Effective chemotherapy of TB began in the 1940s, with the 
discovery and isolation of streptomycin (SM) and para-amino salicylic acid (PAS) around 
1943. Before the use of pharmacotherapy patients would stay in sanatoria, where they were 
isolated from the general population, and treatment was based on getting rest with controlled 
exercise, fresh air and a healthy diet (38). Drug therapy resulted in a dramatic improvement 
in treated patients, but drug resistance quickly followed, leading to relapse in some patients. 
The search for new drugs then led to the discovery of the therapeutic benefit of isoniazid 
(INH) in 1953, pyrazinamide (PZA) in 1954, cycloserine (CS) in 1955, ethionamide (ETM) 
in 1956, rifampicin (RIF) in 1957 (first used clinically in 1966) and ethambutol (EMB) in 
1962(26, 39). Looking at the history of medicine in general, and that of TB, the success in 
curing TB was a major milestone in the history of humankind, as the disease was always a 
leading cause of death. 
 
 The currently recommended first-line treatment regimen for new cases of drug sensitive TB 
comprises of INH, RIF, EMB and PZA (2). The four drugs are taken for 2 months in the 
intensive phase, followed by a 4-month continuation phase in which only INH and RIF are 
taken. In re-treatment cases, streptomycin is added to the intensive phase. Most TB cases 
respond favourably to this treatment regime. However, drug resistance, which has been 
associated with factors such as monotherapy and low drug exposure in patients, is a growing 
threat to the effective treatment of the disease. 
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The current first-line regimen was shown to be effective about 40 years ago (40) and remains 
highly effective and well tolerated. Treatment success rates with the first-line therapy usually 
exceed 85%, reaching as high as 98% in clinical trial settings (3), and the WHO estimated 
that 50 million deaths were averted due to TB treatment between 2000 and 2017 (1). 
However, the long duration of treatment may have a negative impact on compliance and 
increases the chances of adverse effects such as adverse drug reactions and drug interactions, 
which compromises the effectiveness of therapy.  
 
In addition to the long duration, TB treatment is complicated by the need to use multiple 
drugs. Use of a cocktail of drugs is known to mitigate the development of drug resistance and 
improve the efficacy of therapy. Studies have shown “…rapid onset of isoniazid resistance 
among patients receiving monotherapy and the suppression of resistance when isoniazid was 
given in combination…” (26), leading to the use of multi-drug regimens. Drug resistance was 
known to occur as early as the 1950s (41), especially when monotherapy was used. More 
recently, it has also been found to be associated with low drug concentrations in patients on 
combination therapy. 
 
In vitro studies suggest that low drug exposure leads to the development of drug resistance 
(42). Clinical studies have also shown correlation between low drug concentrations in 
patients and treatment failure (8, 43-45). These low drug concentrations may be due to 
pharmacokinetic factors such as malabsorption and pharmacogenetic variability in 
metabolism and excretion of the drugs, as well as factors like drug interactions and poor 
adherence to therapy. While resistance goes up, the discovery of new effective drugs is 
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declining and becoming more expensive, hence preserving existing therapies is of paramount 
importance. 
 
Besides chemotherapy, surgical treatment has been used, more so before the advent of 
chemotherapy (23), and can still be used in cases resistant to drugs (46). Because drug 
treatment is much safer and more effective, it remains the treatment of choice. First-line 
drugs are used in drug sensitive cases while second line and other drugs are reserved for drug 
resistant ones.  
 
2.6.1. First-line TB drugs 
 
Isoniazid (isonicotinic acid hydrazide) 
 
First synthesized in 1912, it was only tested for the treatment of tuberculosis in 1951 and by 
1952 its therapeutic benefits had been observed (23). It is a pro-drug whose conversion to the 
active form is catalysed by catalase/ peroxidase, a bacterial enzyme encoded by the gene 
katG. The active metabolite inhibits the formation of mycolic acids, important components of 
the mycobacterial cell wall, through the inhibition of the NADH-dependent enzyme enoyl 
acyl carrier protein reductase, which is encoded by the gene inhA. Mutations in the genes 
katG and inhA result in INH resistance (33). Highly active against actively growing 
mycobacteria, INH plays a leading role in the treatment of TB but is inactive against dormant 
bacilli. It is inexpensive, potent (MIC is 0.1 – 0.7 µM), well tolerated and relatively safe and 
is regarded as one of the most important TB drugs (47). 
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Isoniazid can be administered orally, intravenously or intramuscularly. Bioavailability 
approaches 100% but is significantly reduced by food intake and peak plasma concentrations 
are attained in 0.5 – 2 hours (47, 48). It has been suggested that the drug forms condensation 
products with some carbohydrates that are not absorbable. N-acetyl isoniazid (AcINH) is the 
major metabolite of isoniazid, formed by the acetylation of isoniazid by N-acetyl transferase 
2 (NAT2), mainly in the liver (49). It does not seem to exert any pharmacological effect and 
its kinetics have not been extensively studied. However, the rate of its formation in humans 
follows a bimodal distribution, which is genetically determined. Humans are classified as 
either fast or slow acetylators, and the ratio of the metabolite to analyte concentrations can be 
used to estimate the acetylator phenotype (20). The figure below shows the metabolism of 
INH to AcINH.  
 
 
Figure 2.2: Acetylation of INH to AcINH 
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INH is metabolized to AcINH in a phase 2 acetylation reaction. The slow acetylator 
phenotype is at a higher risk of experiencing hepatotoxicity, which is the most serious 
adverse reaction of INH. Peripheral neuropathy may occur, especially in under-nourished 
individuals (48). Other metabolites include isonicotinic acid, isonicotinamide, 
monoacetylhydrazine and diacetylhydrazine. (47). Of all the metabolites, only 
monoacetylhydrazine is pharmacologically active and is said to be tuberculostatic and 
hepatotoxic (48). The drug is distributed throughout the body and together with its 
metabolites is mostly excreted via the kidneys (47). The drug is a white crystalline powder, 
soluble in water (125mg/ml) (48), weakly basic and stable at room temperature (47).  
 
Pyrazinamide (analogue of nicotinamide) 
 
Introduced in the 1950s PZA has been shown to have sterilizing effects in TB lesions. It is a 
pro-drug which is hydrolysed to the active pyrazinoic acid (POA) which is further oxidised to 
5-hydroxypyrazinoic acid by xanthine oxidase. In acidic environments, POA is 
predominantly non-ionised and can passively permeate the mycobacterial cell wall. The 
inability of MTB to actively expel the drug makes PZA particularly effective. Two 
mechanisms of action have been suggested; the depletion of coenzyme A, and inhibition of 
phenolthiocerol dimycocerosate (PDIM) synthesis (33). PDIM are lipid components of the 
membrane which are involved in virulence of MTB (29). Unlike INH and EMB, PZA is more 
effective against persistors and less effective against actively growing mycobacteria (33). 
PZA has good PK properties, with peak plasma concentrations attained in 1 – 2 hours and a 
half-life of 8 – 11 hours (41). Among the 1st line anti-tuberculosis drugs, it seems to have the 
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least variability in PK parameters, particularly in its absorption (41, 50), therefore factors like 
age and HIV status do not seem to affect plasma levels of this drug greatly. However, a few 
studies have shown an age-dependant variability of PZA pharmacokinetics in younger 
children (41, 51). The drug also has relatively good central nervous system penetration (51) 
although its efficacy in the relatively neutral CNS environment is unclear. PZA has been 
identified as a major determinant of treatment success, with low plasma concentrations being 
significantly associated with treatment failure (8). The major side effect is hepatotoxicity, but 
with currently used dosages this has not been frequently reported even though the drug is 
often administered with other potentially hepatotoxic drugs (41). 
 
Ethambutol 
 
Ethambutol (EMB) was first shown to have antimycobacterial effects in mice infected with 
drug resistant strains in 1961 and subsequently showed clinical benefit in combination with 
streptomycin and INH (23). It is also active against members of the mycobacterium avium 
complex (MAC) (52). Administered at a dose of 15-25 mg/kg/day, absorption is not 
significantly reduced by food intake (53) and peak plasma concentrations are reached in 2 to 
4 hours. Plasma concentrations range from 0.95-7.5 μg/mL (39). The half life is short, and the 
drug is undetectable in plasma 24 hours after the last dose. With MICs ranging between 0.5–2 
μg/ml (54), it is bacteriostatic against actively growing bacilli by blocking arabinosyl 
transferases, inhibiting the synthesis of arabinogalactan, an important polysaccharide cell 
wall component (55). Clinical studies show good penetration in lung, liver and kidney tissue 
(12). Its major adverse effect is that of visual disturbances, including decreased visual acuity, 
colour blindness and scotoma (blind spots), which may be due to optic or retrobulbar neuritis 
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(inflammation of optic or retrobulbar nerves) (56). This may occur on one or on both eyes 
and is usually reversible upon discontinuation of the drug. Less commonly, hypersensitivity 
reactions, gastrointestinal disturbances (nausea, vomiting, loss of appetite, abdominal 
discomfort), central nervous system (CNS) effects (dizziness, confusion and hallucinations), 
and peripheral neuropathy occur. Other effects, which may possibly be due to concurrent 
medicines have also been reported. Safety in children under 13 years old has not been 
established and information regarding use in pregnancy is inadequate. However, animal 
studies showed teratogenic effects at high doses in pregnancy (55). 
 
The drug has a high polarity and as such is very water-soluble. It is a white crystalline 
powder, marketed as the dihydrochloride salt. It is also stable to heat and light (39). Due to its 
lack of a chromophore, EMB cannot be reliably detected by UV/Vis spectrophotometry. 
 
Rifampicin  
 
Rifampicin (RIF) is a semisynthetic rifamycin derived from the bacterium Streptomyces 
mediterranei (57). It binds to the β-subunit of bacterial DNA-dependent RNA polymerase, 
thereby inhibiting the transcription of messenger RNA from DNA. It is active against both 
actively growing and slowly metabolizing mycobacteria. Experiments with rifamycins started 
in 1957 and favourable results were reported in 1959 (23). Because it is well tolerated and 
highly effective, it has become one of the most important TB drugs. After the introduction of 
RIF, TB treatment became so successful that the search for new drugs slowed down and it 
took about 50 years for new TB drugs to be approved. However, its poor bioavailability from 
some formulations, particularly fixed-dose combinations (FDCs) and interaction with INH is 
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a cause for concern. It has been suggested that INH accelerates the degradation of RIF into 
the insoluble derivative 3-formyl rifamycin SV (3-FRSV) in the acidic stomach environment 
(58), thus reducing the bioavailability of RIF. Bioavailability is also reduced by concurrent 
food intake (49). 
 
 The major metabolic pathway is de-acetylation to 25-desacetyl-rifampicin (desRIF), a 
pharmacologically active metabolite. It is unknown whether this metabolite contributes to 
toxicity of the drug, but it is responsible for about 80% of antimicrobial effects of RIF in bile 
(49). The metabolism of RIF to desRIf is represented in Figure 2.3. 
 
Figure 2.3: De-acetylation of RIF to desRIF 
 
Rifampicin is a known hepatic enzyme inducer; it induces its own metabolism and that of 
other drugs, hence is susceptible to drug-drug interactions. Auto-induction of its metabolism 
results in a decrease in the maximum plasma concentration (Cmax) during long-term 
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administration. It is widely distributed in body tissues and fluids and is highly protein bound, 
mainly to γ-globulin (49). Rifampicin is generally well tolerated but may cause 
hepatotoxicity in about 1-2% of patients on monotherapy (59). Given the susceptibility of the 
bioavailability of RIF to external influences such as the presence of food and other drugs, and 
the changing metabolic rate, RIF probably has the highest variability in pharmacokinetics 
among the anti-TB drugs. 
 
Streptomycin  
 
Streptomycin, an aminoglycoside antibiotic, was the first drug to be successfully used in the 
treatment of TB. It was isolated from the soil bacterium Streptomyces griseus (33). By 
binding to the 16S subunit of rRNA it inhibits protein synthesis, thus exerting its bactericidal 
effects. Like other aminoglycosides, it is highly polar, a characteristic that gives it poor oral 
bioavailability, therefore is only administered parenterally. Intravenous, intramuscular and 
subcutaneous administration yield similar plasma concentration 2 hours post-dose (49). The 
drug may be considered as a first-line drug but is usually reserved for re-treatment cases of 
drug-susceptible TB. 
 
2.6.2. Second and third-line TB drugs (MDR-TB treatment) 
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 Fluoroquinolones 
 
This is a class of drugs including such drugs as ciprofloxacin, levofloxacin, moxifloxacin and 
gatifloxacin, which act by inhibiting the mycobacterial enzyme DNA gyrase (a type II 
topoisomerase) (33). Although fluoroquinolone-based therapy resulted in earlier sputum 
conversion in clinical studies, these regimens resulted in higher rates of relapse compared to 
the standard 1st line regimen (2, 60), hence this class continues to be used as part of 2nd line 
therapy.  Moxifloxacin has been most widely used among the fluoroquinolones for TB 
treatment, but levofloxacin is thought to be less likely to cause QT prolongation, the major 
adverse effect of this class of drugs (61). Other adverse effects include gastrointestinal 
disturbances, rashes, dizziness and headache (54). 
 
 Capreomycin, amikacin and kanamycin  
 
Capreomycin comprises of 4 isomers (lA, IB, IIA, lIB) which are cyclic peptide antibiotics, 
the majority of which are IA and IB in pharmaceutical formulations (33). Kanamycin is an 
aminoglycoside antibiotic, amikacin is its semi-synthetic derivative. Both capreomycin and 
the aminoglycosides inhibit protein synthesis (54). Aminoglycosides act by binding to the 
30S ribosomal subunit of MTB (33) while capreomycin binds to the 70S ribosome, inhibiting 
mRNA- tRNA translocation (54). Second-line TB therapy must include any one of these 
injectable drugs and the choice of which one to use is based on the likelihood of efficacy and 
availability (62). The most common adverse effects of both antibiotic families are ototoxicity 
and nephrotoxicity (54). 
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Ethionamide 
 
Ethionamide (2-ethylisonicotinamide), a derivative of isonicotinic acid, was introduced as an 
anti-mycobacterial drug in 1956 (54). It is a pro-drug, like INH, which, when activated 
inhibits the same molecular target as INH (inhA), thus inhibiting mycolic acid synthesis. 
Mutation in inhA results in resistance to both drugs (63). Frequent side effects include 
abdominal discomfort, nausea, vomiting, anorexia and hypothyroidism when used 
concurrently with para-aminosalicylic acid (PAS) (54). 
 
Cycloserine  
 
Cycloserine is a 2nd line anti-TB drug used in the treatment of MDR TB. It was discovered in 
1954 as a secretion of Streptomyces orchidaceus and its clinical benefit was published a year 
later (64). This analogue of the amino acid D-alanine, a key component of peptidoglycan, 
inhibits peptidoglycan synthesis thus preventing proper cell wall formation (33). It is rapidly 
degraded under acidic to neutral conditions and stable in alkaline solutions (49). About 10-
50% of treated patients experience neuropsychiatric adverse effects, such as psychosis and 
seizures, which are probably dose-dependent (64). Because of the neuropsychiatric effects, it 
is likely to have high central nervous system (CNS) permeability and hence be useful in 
treating TB meningitis. 
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Para-amino salicylic acid 
 
One of the first anti TB drugs to be discovered, PAS is still effective. It is thought to inhibit 
dihydropteroate synthase, an enzyme involved in folate biosynthesis (33). It is a bacteriostatic 
agent which is readily absorbed from the gastrointestinal tract (GIT) (49). Because of 
possible gastrointestinal irritation, concurrent food intake is recommended. With the 
introduction of more efficacious, less toxic drugs, the use of PAS is now mainly limited to 
treating XDR-TB. 
 
2.6.3. New and repurposed drugs 
 
New drugs were approved for the treatment of TB after about 50 years of no new discoveries. 
Previously registered drugs for other indications have also been re-purposed for MDR-TB. 
 
 Bedaquiline 
 
Bedaquiline, a diarylquinoline that is currently in Phase III clinical trials, received conditional 
approval by the Food and Drug Administration (FDA) in December 2012. It has been 
included in the WHO’s guidance for the treatment of XDR TB since no cross resistance with 
other drugs has been reported (46, 65). It blocks mycobacterial ATP synthase, a novel 
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mechanism of action, and is bactericidal to both replicating and non-replicating bacteria (65). 
Early bactericidal activity (EBA) is comparable to INH and RIF after 5 days and is active 
against drug sensitive and drug resistant TB (including XDR) TB (33). Although it causes QT 
prolongation, no clinically significant adverse outcomes relating to QT prolongation have 
been reported. Elevation of liver enzymes has been reported but no serious hepatotoxicity has 
been reported (66). 
 
Delamanid 
 
Delamanid belongs to the nitro-dihydroimidazoxazole class of drugs, a derivative of the 
antimicrobial metronidazole, which was approved for use by the European Medicines Agency 
(EMA) and Japan’s Pharmaceuticals Medical Devices Agency in 2014. It is a pro-drug which 
is converted to the active desnitroimidazole and probably inhibits methoxy-mycolic and keto-
mycolic acid synthesis (33, 66). Effective in replicating and non-replicating organisms, it has 
good tolerability (67) and EBA and potency, with an MIC of 0.006–0.024 mg/ml. No cross 
resistance with first-line drugs has been found. 
 
Carbapenems 
 
This is a class of broad spectrum anti-microbials, active against gram positive and negative, 
aerobic and anaerobic bacteria. Pre-clinical studies in mice and some case reports have shown 
efficacy of the drugs in TB treatment (66). Meropenem, imipenem and ertapenem have been 
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used to treat MDR and XDR TB with some success (60). However, use is limited by the need 
for parenteral, mainly intravenous administration. 
 
Linezolid 
 
Linezolid is an oxazolidinone antimicrobial used for XDR TB. It has a high frequency of side 
effects mainly of hematological and neurological nature (46, 66). In a clinical trial “…82% of 
patients developed significant adverse events, namely myelosuppression, peripheral 
neuropathy and optic neuropathy.” (60). It acts by binding to the ribosomal 50S subunit, thus 
interfering with protein synthesis (33). With a narrow therapeutic index, TDM and MIC 
measurements are recommended (68). Because it has remarkable sterilizing effect and an 
unfavourable toxicity profile, new oxazolidinones including sutezolid (PNU-100480), 
posizolid (AZD-5847), torezolid, and radezolid are under development. 
 
Clofazimine 
 
Developed as an anti-leprosy agent in the 1950s it was overshadowed as a TB drug by more 
effective drugs such as INH introduced in the same period (46). The drug has a long duration 
of action and is effective against dormant bacilli. It rapidly attains high concentrations in 
macrophages making it highly desirable in treating TB (66). Pre-clinical studies have shown 
good activity against drug resistant strains and low toxicity (66). It has been suggested that 
clofazimine may shorten treatment of MDR TB. Its major toxicities include skin 
pigmentation (and causes urine discoloration) and GI upset. 
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Pretomanid 
 
A bicyclic nitroimidazofuran compound currently in phase III clinical trials, it releases 
nitrogen oxide (NO) which inhibits ATP synthesis in non-replicating mycobacteria (69). 
Pretomanid also inhibits ketomycolates that are necessary for cell wall synthesis. It is active 
against MDR TB and no cross resistance with other TB drugs has been seen. It is also active 
against non-replicating bacteria and is less effective when PZA is not present (33). 
 
2.7. Bioanalysis  
 
Bioanalysis refers to the qualitative or quantitative determination of analytes in biological 
fluids such as blood, plasma and urine. Analytes may be endogenous (e.g. proteins, peptides, 
nucleic acids) or exogenous (drugs, metabolites, environmental pollutants). It is frequently 
applied throughout the drug development process, from pre-clinical, clinical, to 
pharmacovigilance studies. Bioanalysis is a multi-step process, starting from sample 
collection, through sample preparation, analysis and detection to data analysis and reporting. 
An analytical method provides step by step details of the techniques, materials and equipment 
used in performing an assay. The method development process tries to identify parameters 
that are critical in a bioanalytical method, and to minimise any factors that may be 
detrimental to the sensitivity, accuracy and robustness of the assay. The choice of analytical 
methodology takes into account various factors, most importantly the physicochemical 
properties of analytes, the purpose of the analysis and availability of resources (70).  
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Commonly used techniques for the quantitative determination of drugs and metabolites in 
biological matrices include gas chromatography (GC), thin-layer chromatography (TLC) and 
high-performance liquid chromatography (HPLC) for separation of analytes, coupled to 
detectors such as spectrophotometers (ultraviolet/visible (UV/vis), infrared (IR) and 
fluorescence), mass spectrometry (MS) and electrochemical methods. High performance 
liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is probably the 
most widely used bioanalytical technique (71). 
 
2.7.1. Mass spectrometry 
 
Before much method development takes place, it is necessary to decide on the detection 
technique suitable for the analytes. For MS analysis, analytes must first be infused into the 
instrument, usually as neat solutions, using an infusion pump. Infusion flow rates typically 
range from 1 to 20 µl/min. The mass spectrometer will detect the mass to charge ratio (m/z) 
of the molecular ion and that of any fragment(s) produced when the analyte passes through 
the collision cell. In many cases molecules will have only a single charge, rendering the m/z 
equivalent to the molecular mass of the species. The specific transition from a precursor 
molecule (parent/precursor ion) m/z to fragment or product (daughter/product ion) m/z is 
highly specific and forms the basis of detection. Infusion of a known reference standard 
produces a unique transition pattern (from parent ion to fragment ion(s)) which will be used 
to identify the presence of that compound when samples are injected into the MS. When the 
mass spectrometer is set-up to monitor the fragmentation of an analyte into more than one 
product ion it is referred to as multiple reaction monitoring (MRM). 
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An example of the MRM for INH is shown in Fig 2.4 below. 
 
 
Figure 2.4: Fragmentation of isoniazid in mass spectrometry 
 
The mass spectrometer comprises of three basic components namely: ion source, mass 
analyser and detector (72). The ion source operates at atmospheric pressure while the mass 
analyser and detector are under vacuum. Ions are driven from the ion source to the detector 
through the mass analyser by both a pressure gradient and potential differences between the 
compartments (72).     
       
Mass spectrometry analyses charged molecules in the gas phase. Most samples to be 
analysed, however, are liquid solutions. The ion source enables the transition of molecules 
from liquid solution to ionized gaseous molecules (72). Generally polar solvents, like water, 
methanol, acetonitrile, are used as mobile phases as they aid in the ionisation process (73). 
Volatile mobile phases are preferred for easier evaporation in the ion source. The two most 
commonly used source types are Electrospray Ionisation (ESI) and Atmospheric Pressure 
Chemical Ionisation (APCI). 
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The mass analyser sorts and separates ions according to their mass to charge ratio (m/z value) 
(72). Types of mass analysers include magnetic or electric sector mass analyser, linear 
quadrupole ion trap (LIT), three-dimensional quadrupole ion trap (QIT), orbitrap and time-of-
flight mass analyser (TOF). 
 
From the mass analyser the separated ions are transferred to the detector which measures 
their concentration. The ions and their concentrations are displayed on a graph called a mass 
spectrum. The peak height is proportional to the number of ions that hit the detector (72). 
 
2.7.1.1. Matrix Effects 
 
The major drawback of mass spectrometry is the “matrix effects” phenomenon. This occurs 
when other sample components interfere with the ionisation of the analyte(s) and/or droplet 
formation and evaporation. It affects aspects of method performance including sensitivity, 
reproducibility and accuracy (74). Matrix effects, when present, may be reduced or avoided 
by altering the sample clean-up process, chromatography or using stable isotopically labelled 
(SIL) internal standards (75). 
 
2.7.1.2. Internal standards 
 
Internal standards are used to compensate for process and instrument related variability, 
based on the assumption that the internal standard will be subjected to the same processes, 
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matrix effects and instrument conditions as the analyte. They are usually structural analogues 
of analytes or the analytes which have some of the atoms substituted by stable isotopes, 
commonly called “stable isotope labelled (SIL) internal standards”. SIL internal standards 
resemble the analytes more than structural analogues and are therefore preferred. Most 
quantification processes use the analyte to internal standard ratio rather than the absolute 
analyte signal due to the vulnerability of analyte signal to matrix effects (74). Generally, 13C, 
15N or 18O-labeled internal standards are preferable to deuterium labelled analogues because 
deuterium labelled IS may exhibit slightly different physicochemical properties relative to the 
analytes and back exchange reactions can occur between deuterium labelled internal 
standards and analytes (76). It is ideal to use one internal standard for each analyte when 
there is more than one analyte. 
 
2.7.2. Liquid chromatography 
 
Chromatography involves an intricate physicochemical interaction between analytes and the 
stationary and mobile phases. Each chemical entity has a distinct affinity for the stationary 
phase relative to the mobile phase, hence chemical entities will have different velocities and 
separate as they flow through the stationary phase column (77). In its various forms it is 
probably the most widely used analytical technique for separating compounds in a sample 
mixture (78). Depending on the physical state of the mobile phase, chromatography may be 
classified as gas chromatography (GC), supercritical fluid chromatography (SFC) and liquid 
chromatography (LC). Liquid chromatography is further divided into sub-types such as 
reverse phase (RP), normal phase, ion exchange and hydrophilic interaction liquid 
chromatography (HILIC). In reverse phase liquid chromatography, analytes are separated 
based on their relative hydrophobicity; the more hydrophobic an analyte is, the longer it is 
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retained on the stationary phase. Elution of compounds can be achieved through either 
isocratic or gradient flow. Isocratic flow is when a constant proportion of organic versus 
aqueous mobile phase flows throughout the run whereas in gradient flow the proportion of 
organic relative to aqueous mobile phase changes according to pre-selected program. 
Gradient HPLC gives better sensitivity to analytes with longer retention times since it results 
in narrower and higher peaks.    
 
2.7.3. Sample preparation 
 
Pre-treatment of biological samples is necessary to make the sample more suitable for 
analysis and prevent deleterious effects on the LC-MS system. It is sometimes called sample 
clean-up and aids in ensuring maximum sensitivity and reproducibility (79). This is usually 
the most tedious and time-consuming step in bioanalysis. It is performed to remove sample 
components that would potentially interfere with detection of the analyte or cause 
malfunction of the analytical instrument. The most commonly used sample preparation 
methods include protein precipitation (PP), liquid-liquid extraction (LLE) and solid phase 
extraction (SPE). 
 
Protein precipitation  
 
PP is a commonly used sample processing technique which involves the use of salts, acids, 
heat or organic solvents to precipitate proteins in the sample. It is simple and can be used for 
both polar and non-polar molecules. The precipitated proteins form a pellet at the bottom of 
the tube when the sample is centrifuged, and the supernatant can be directly injected into the 
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LC-MS/MS system or subjected to further sample clean-up. PP is recommended whenever 
high-throughput and low extraction variability are required (80) 
 
Liquid-liquid extraction  
 
LLE is highly selective and has been shown to give extracts with the least ion suppression 
(79). An aqueous sample is mixed with an immiscible organic solvent and the analyte 
partitions into the organic phase. It may, however, not be suitable for hydrophilic compounds 
and the formation of emulsions can make it difficult to isolate the extraction. Its main 
disadvantages are the need for large amounts of organic solvents and the fact that it is not 
possible to automate LLE when the solvent needs to be evaporated (73). 
 
Solid phase extraction  
 
SPE involves the use of silica or polymer-based sorbents to adsorb analyte(s), washing and 
eluting with suitable solvents. It can be easily automated, and a wide variety of sorbents are 
available for wide ranging selectivity, hence it is the most popular sample preparation 
technique (79).    
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2.8. Bioanalysis of first-line TB drugs 
 
First-line TB drugs have been in clinical use for over 50 years, yet their PK and PK-PD 
relationships are not fully understood. Several studies have shown that these drugs are 
frequently below the expected concentrations in patients given the recommended doses (7-9, 
50, 81, 82). This necessitates therapeutic drug monitoring (TDM) to ensure patients attain 
therapeutic drug concentrations with minimal toxicity.  
 
Assays have been developed for the quantification of these drugs individually and in 
combination. Quantification of all drugs is ideal because it saves both time and resources. 
This was first done by Song et al. who developed a method for quantifying the four first- line 
drugs and the metabolites AcINH and desRIF (20). In this method the authors used 
structurally related compounds as internal standards, namely rifabutin for RIF and desRIF, 
and 6-aminonicotinic acid for the rest of the analytes. Baietto et al. also developed a method 
for the simultaneous quantification of first-line anti-TB drugs (18). Similarly, the authors also 
used other compounds (thymidine and 6,7-dimethyl-2,3-di(2-pyridyl)quinoxaline)) as internal 
standards, hence matrix effects and stability concerns may not have been adequately 
compensated for. Prahl et al. developed a method for the analysis of all four drugs using 
deuterated internal standards for each analyte (19). This method, however, did not include 
metabolites. In this project, we developed and validated a method for the simultaneous 
quantification of the four first-line oral anti-TB drugs and the two major metabolites for 
application in TDM and clinical PK studies.  This method furthermore incorporates the use of 
isotopically labelled structural analogues of each analyte, thereby allowing adequate 
compensation for any potential variability during sample preparation and on-instrument. 
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Chapter 3 : AIM, OBJECTIVES and RATIONALE 
 
3.1. Aim 
 
The aim of this project was to develop and subsequently validate an assay for the 
quantification of the four first-line oral anti-tuberculosis drugs and the metabolites acetyl 
isoniazid and des-rifampicin in human plasma. 
 
3.2. Objectives 
 
1.  To develop a method that can quantitate isoniazid, rifampicin, ethambutol, 
pyrazinamide, acetylisoniazid and desacetylrifampicin simultaneously in human 
plasma. 
2. To validate the method that can quantitate the four first-line anti-tuberculosis drugs 
and the two major metabolites. 
 
3.3. Rationale 
 
Tuberculosis is a leading cause of morbidity and mortality worldwide whose treatment can be 
highly successful but may be compromised by factors such as drug resistance and variability 
in the pharmacokinetics of the drugs. Many gaps still exist in the characterization of the 
pharmacokinetics, pharmacodynamics and the pharmacokinetics-pharmacodynamics 
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relationship of the first-line drugs, despite all of them having been introduced more than 50 
years ago. Some metabolites of these drugs are also pharmacologically active and need to be 
monitored. Quantification of metabolites may give useful information on the pharmacology 
of these drugs. Studies are required to generate knowledge to cover these knowledge gaps. 
Simple, accurate and robust assays are necessary for quantifying these drugs and metabolites 
in biological fluids. It is ideal to measure all drugs in a single assay to allow processing of 
samples in a simple, timely and cost-effective manner. A method was therefore developed 
and validated for this purpose. This method can also be used to carry out therapeutic drug 
monitoring of all four drugs in TB treatment cases that are problematic, either due to poor 
response to treatment or to adverse drug reactions. 
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Chapter 4 : METHOD DEVELOPMENT 
 
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is a widely used 
technique in bioanalysis. One of its major advantages is the ability to analyse a wide range of 
compounds without complicated derivatisation steps. It is also highly sensitive and selective. 
Therefore, it was chosen for this project. Ethical approval for use of human plasma during 
method development and validation was granted by the University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee (approval letter attached in Appendix). 
 
Selecting a suitable LC system is usually one of the first steps in method development. It was 
planned that this project would be carried out using reverse-phase chromatography on a 
micro-LC system, which uses columns and tubing of minute internal diameters, less than 1 
mm, and flow rates less than 100 µl/min. Micro-LC is not as commonly used as normal flow-
LC, but is thought to have several advantages, including fast analysis time, use of less 
materials (mobile phase, sample size and stationary phase), more efficient chromatographic 
separation and good sensitivity (due to use of less mobile phase hence less dilution). The next 
section describes the method development that was carried out on an Eksigent micro-LC 
system, coupled to an AB Sciex API 2000 triple quadrupole mass spectrometer. 
 
4.1. Micro-LC and API 2000 
MS has been used successfully in previous analytical methods to detect all of the analytes in 
this project. Solutions of reference standards of the 6 analytes at 500 ng/ml were prepared 
from 1 mg/ml stock solutions and were individually infused. Table 4.1 shows the four most 
abundant product ions obtained for each analyte after fragmentation in the collision cell. 
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Table 4.1: MRM transitions for the 4 most abundant product ions 
 
m/z (Da) 
Analyte AcINH desRIF EMB INH PZA RIF 
Precursor 180.1 781.1 204.2 138.1 124.1 823.2 
Product 1 138.2 748.7 116.3 121.0 107.2 791.5 
Product 2 120.5 748.0 115.5 119.3 104.0 790.3 
Product 3 121.1 749.1 113.7 118.5 103.8 790.8 
Product 4 137.5 746.9 114.4 117.4 102.1 791.6 
 
 
Only the 2 most abundant product ions were chosen to be used for multiple reaction 
monitoring (MRM). The most abundant product ion would be used for quantification while 
the 2nd most abundant would be used as a qualifier, to confirm the identity of the compound. 
The infusion process also produced data on the optimum potential differences between 
different compartments in the MS. These were: declustering potential (DP), focussing 
potential (FP), entrance potential (EP), collision cell entrance potential (CEP), collision 
energy (CE) and collision cell exit potential (CXP). The results are shown in Table 4.2 below. 
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Table 4.2: MS parameters optimized during analyte infusion 
Analyte 
Instrument parameters (volts) 
Dwell 
(msec) DP  FP EP CEP CE CXP 
AcINH 16 290 8 12 27 12 150 
desRIF 6 370 5 36 41 56 150 
EMB 16 290 9 12 29 10 150 
INH 16 230 8.5 10 31 58 150 
PZA 21 330 8.5 10 129 46 150 
RIF 6 370 10 24 45 58 150 
 
 
Initially the source parameters were arbitrarily chosen to fall within ranges commonly used. 
Table 4.3 shows the source parameters used. 
 
Table 4.3: Initial source parameters on micro-LC system 
Parameter CUR (psi) TEM (0C) GS1 (psi) GS2 (psi) CAD (psi) Ionspray voltage (V) 
Value 10 250 20 20 10 5000 
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A polar C18 column (Phenomenex Lunar Omega) with 1.6 µm particles, 0.5 mm internal 
diameter and 5 cm length was chosen. It was speculated that since 4 out of the 6 analytes are 
highly polar, a more polar stationary phase would have better retention than a conventional 
RP C18 column. A short column (5 cm) was preferred as it reduces analysis time (shorter 
retention and equilibration time) and reduces system back pressure. A gradient was chosen 
over an isocratic elution because the polarity range among analytes is wide. Mobile phase A 
was a 0.1% formic acid (FA) aqueous solution and mobile phase B was 0.1% FA in a 1:1 
mixture of acetonitrile and methanol. The following gradient (Table 4.4) was used at a flow 
rate of 50 µl/min: 
 
Table 4.4: Initial gradient table on the micro-LC system 
Time (min) % A % B Flow rate (µl/ml) 
0 90 10 50 
0.5 90 10 50 
1 10 90 50 
3 10 90 50 
3.1 90 10 50 
5 90 10 50 
 
 
At first sensitivity was relatively low, and PZA practically had no peaks. Chromatography 
was also poor, especially for INH and AcINH which had split peaks. The chromatograms in 
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Figure 4.1 and Figure 4.2 below were produced after injecting a solution containing all 
analytes at 10 µg/ml. 
 
 
Figure 4.1: Chromatogram of INH in early method development 
 
XIC of +MRM (12 pairs): 138.086/121.000 Da ID: INH from Sample 2 (TB Drug Mix) of 1010.wiff (Turbo Spray) Max. 806.7 cps.
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Figure 4.2:Chromatogram of AcINH in early method development 
 
The mass spectrometer was cleaned and re-calibrated, and analytes were infused again. The 
same product ions were obtained as those obtained during the first infusion for all analytes 
except PZA. In the first infusion, only product ions greater than 100 amu (atomic mass units) 
were detected, therefore the most abundant fragment of PZA with m/z value of 78 was not 
detected, resulting in lack of sensitivity for this analyte. The following transitions (Table 4.5 
and 4.6) were selected from the second infusion: 
 
 
 
 
XIC of +MRM (12 pairs): 180.117/138.200 Da ID: Ac INH from Sample 2 (TB Drug Mix) of 1010.wiff (Turbo Spray) Max. 1420.0 cps.
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Table 4.5 MRM transitions after 2nd infusion 
analyte m/z 
  AcINH desRIF EMB INH PZA RIF 
precursor 180.1 781.3 205.2 138.1 124.0 823.4 
product 1 137.7 749.2 116.1 120.9 78.9 791.4 
product 2 121.1 399.2 115.4 118.6 107.2 151.1 
 
 
Table 4.6: Re-infusion of internal standards on the micro-LC system 
Internal standard Q1 m/z 
Product ion 
m/z 
AcINH-d4 184 142 
desRIF-d3 785 752 
EMB-d4 209 120 
INH-d4 142 83 
PZA-15N,d3 128 84 
RIF-d3 826 794 
 
 
Injection of a solution with 1 µg/ml of each analyte produced the following chromatogram: 
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Figure 4.3: Chromatogram after re-infusion 
 
The chromatogram above shows good peak retention and resolution. However, RIF and 
desRIF had low intensities. 
 
4.1.1. Effect of ascorbic acid 
 
 RIF and its metabolite are thought to undergo oxidation, and this was suspected to be 
causing low signal intensities for these analytes (83). Ascorbic acid, an anti-oxidant, is likely 
to counteract the oxidation. Ascorbic acid was therefore added to injection solutions at 25, 50 
and 100 µg/ml concentrations and the results are shown in Figure 4.4. 
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Figure 4.4:  Effect of ascorbic acid 
 
For all analytes except RIF and its metabolite, there was a clear downward trend in peak area 
as the ascorbic acid concentraton increased. Peak areas for RIF and desRIF were relatively 
high with 25 µg/ml ascorbic acid, dropped when 50 µg/ml was used but rose again when 100 
µg/ml was used. Although peak areas were lower in the presence of ascorbic acid, peak 
shapes for INH, RIF and desRIF seemed to improve.  Ascorbic acid may alter the pH of the 
mobile phase, thus affecting peak shapes. Poor peak shapes of INH in the absence of ascorbic 
acid were seen when fresh mobile phase was used but seemed to improve with older mobile 
phase. A possible chemical interaction between MeOH, a proton donor, and ACN, a proton 
acceptor, could result in alteration of the mobile phase character, hence the change in peak 
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shape. The figures (Figure 4.5 and 4.6) below show the differences in peak shape in solutions 
with and without ascorbic acid when fresh mobile phase was used. 
 
Figure 4.5: Chromatogram when injection solution contains ascorbic acid 
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Figure 4.6: Chromatogram when injection solution does not contain ascorbic acid 
 
4.1.2. Organic mobile phase composition 
 
The impact of changing the organic mobile phase (Mobile phase B) composition was also 
tested using mixtures of different proportions of methanol: acetonitrile. All analytes except 
INH and PZA had the highest peak areas with a 50:50 mixture. The highest peak areas for 
INH and PZA were seen with a 40:60 (MeOH:ACN) mixture although the difference 
compared to 50:50 was very small. Peak areas for RIF and desRIF were not satisfactory with 
all mobile phase compositions. The results are summarized in Figure 4.7. 
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Figure 4.7: Effect of varying organic mobile phase composition 
 
4.1.3. Source parameters 
 
4.1.3.1.  Temperature (TEM) 
 
The effect of source temperature was tested, and the results are summarized in Figure 4.8. 
  
 
Figure 4.8: Effect of source temperature on peak intensity using micro-LC 
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Generally, sensitivity dropped as temperature increased for all analytes, except for RIF which 
did not show a clear trend. Both RIF and desRIF had low peak intensities at all temperature 
levels. 
 
4.1.3.2. Ionspray voltage (IS) 
 
Ionspray voltage was optimised and the results are shown in Figure 4.9 below: 
 
 
Figure 4.9: Effect of Ionspray voltage on peak areas 
 
Peak areas increased as ionspray voltage increased for all analytes. Peak intensity was still 
not satisfactory for RIF and desRIF at all ionspray voltage levels. 
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4.1.3.3. Gas 1 and Gas 2 
 
Gas 1 and Gas 2 were also optimized, and results are presented in Figures 4.10 and 4.11.  
 
 
Figure 4.10: Effect of Gas 1 on peak areas 
 
 
 
Figure 4.11: Effect of Gas 2 on peak areas 
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Optimizing source parameters did not significantly improve RIF and desRIF peak intensities. 
Reproducibility was also poor for these two analytes. Different gradients were tried, and 
stock solutions were sonicated before preparing injection solutions to ensure total dissolution 
of all analytes. These strategies also did not improve RIF and desRIF sensitivities. It was then 
decided that the project be moved to a more sensitive mass spectrometer: API 3200 Q-trap. 
The micro-LC system would continue to be used. 
 
4.2. Micro-LC with API 3200 Q-trap 
 
All analytes dissolved in 50% methanol were infused at 10µl/min using a syringe pump, the 
following transitions (Table 4.7) were obtained: 
 
Table 4.7: Product ions from infusion on a 3200 Q-trap mass spectrometer 
Analyte m/z (Da) 
  Precursor 
Transition 
1 
Transition 
2 
Transition 
3 
Transition 
4 
AcINH 180.0 121.0 138.1 79.0 52.1 
desRIF 781.3 749.4 399.3 151.2 123.2 
EMB 205.2 116.1 44.1 55.1 43.6 
INH 138.1 79.1 52.1 93.0 51.6 
PZA 124.0 81.1 54.1 79.0 52.0 
RIF 823.3 151.0 123.2 163.1 106.9 
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Although the LC system was the same, peak shapes were altered on moving to the 3200 Q-
trap. All analytes had split peaks and/or tailing.  We speculated that this was due to hardware 
malfunction on the micro-LC system and decided to move the project to a normal-LC system.  
A Shimadzu Prominence LC system was available. 
 
4.3. Shimadzu LC coupled to 3200 Q-trap 
 
In contrast to micro-LC which utilizes flow rates less than 100 µl/min, normal-LC flow rates 
range from 100 µl/min to 10ml/min (84). An Agilent RP C18, 2.7µm particle size, 4.6mm 
internal diameter (ID) and 5cm long column was chosen. A flow rate of 400 µl/min and the 
gradient in Table 4.7 was chosen to start with.  An initial chromatogram is presented in 
Figure 4.12. 
 
Table 4.8: Initial gradient on the Shimadzu LC system 
Time % A % B 
0.00 80 20 
0.10 80 20 
0.75 20 80 
3.25 20 80 
3.75 80 20 
5.00 80 20 
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Figure 4.12: Initial chromatography on a Shimadzu LC system 
 
Peak shapes were acceptable, but the polar analytes were not well separated, especially INH 
and its metabolite which were practically co-eluting. With MS as the detection method 
analytes do not have to separate completely as they are detected based on m/z ratio. However, 
cross talk may occur between analytes with fragment ions that have the same m/z value if the 
dwell time is short. Since separation was not critical at this stage, we decided to optimize 
source parameters, to ensure optimum sensitivity of all analytes. Figure 4.13 and Figure 4.14 
show results from the optimization of temperature and IS voltage, respectively. 
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Figure 4.13: Effect of source temperature using normal-LC 
 
INH, AcINH and EMB peak areas increased with increasing temperature while desRIF peak 
area decreased with increasing temperature. RIF had highest peaks at intermediate 
temperatures and PZA showed the opposite trend. Because desRIF peak areas were generally 
the lowest, and were the most sensitive to temperature changes, the optimum temperature for 
desRIF, 2500C, was chosen to be the source temperature. 
Results of IS voltage optimization are shown below. Although an IS voltage value of 3000 
had the highest peak area for all analytes, the reproducibility was poor at this voltage and 
higher voltages were better for all analytes. 
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Figure 4.14: Effect of Ionspray voltage when using normal-LC 
 
Sensitivity tests after optimization showed that sensitivity was poor for all analytes. The 
sensitivity and specificity experiments were done using plasma samples from six different 
sources. For sensitivity, plasma was spiked with working solution resulting in plasma with 
the lowest required concentration in the calibration range. For specificity, blank plasma 
samples were analysed. After sensitivity was found to be inadequate, precipitating solvent 
was optimized. Solvents tested were: acetonitrile, acetonitrile: dimethylsulphoxide (DMSO) 
1:1 mixture and acetonitrile:methanol 1:1 mixture. Samples extracted using all solvents had 
low signal to noise ratios, especially for INH and AcINH. It was speculated that this was due 
to ion suppression by matrix components. The AcINH chromatogram in Figure 4.15 below 
suggests that this analyte was eluting concurrently with ion suppressing compounds and this 
was seen by the reduction in the noise intensity. 
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Figure 4.15: Chromatogram of AcINH eluting in an ion suppressed region 
 
Proteins, phospholipids and other organic and inorganic ions cause ion suppression in LC-
MS/MS analysis (85). Since the sample preparation method was protein precipitation, it was 
plausible to assume that the samples had very little proteins. Hence, phospholipids were 
suspected to be involved in causing matrix effects. Changing the extraction method can 
eliminate or reduce the effects of matrix components. A phospholipid removal step was 
incorporated using Phree phospholipid removal columns after protein precipitation. Signal to 
noise ratio was still low for INH, AcINH and desRIF. RIF had a high signal to noise ratio, but 
peaks were not as intense as those seen with protein precipitation only. The Phree 
phospholipid removal was possibly causing lower recovery of RIF. PZA and AcINH had 
higher signal intensity when Phree columns were used compared to when protein 
precipitation was used. INH did not show a significant difference. RIF and desRIF had higher 
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peak intensity with protein precipitation than when Phree was used. These analytes probably 
have some affinity for the Phree column hence the lower recovery. The use of Phree columns 
was discontinued because it did not result in the required sensitivity.  Protein precipitation 
with Phree column extraction vs. protein precipitation data is presented in Figure 4.16. 
 
 
Figure 4.16: Protein precipitation versus protein precipitation with Phree column extraction 
 
Source temperature and gas settings were altered with the hope of eliminating or reducing 
matrix effects. Modifying source parameters is usually the simplest strategy to mitigate 
matrix effects (74). However, this also failed to give satisfactory results. Chromatography 
was then modified by adjusting the gradient, resulting in better separation of the polar 
compounds, the most impressive of which was between INH and AcINH (presented in Figure 
4.17). The run time also increased from 5 minutes to 6 minutes.  
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Figure 4.17: Chromatography after adjusting the gradient on the Shimadzu-LC 
 
The flow program used was a multi-step gradient, at a constant flow rate of 400 µl/min, 
meant to increase separation between INH and AcINH without compromising peak 
intensities. Mobile phase A was an aqueous solution of 0.05% formic acid and mobile phase 
B was 0.05% formic acid in a 1:1 mixture of methanol and acetonitrile. The gradient profile 
is shown below in Table 4.9. 
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Table 4.9: Final gradient program on the Shimadzu-LC 
Time (min) % mobile phase A % mobile phase B 
0.0 95 5 
1.4 95 5 
1.8 45 55 
3.5 10 90 
3.7 10 90 
2.8 30 70 
4.5 95 5 
6.0 95 5 
 
Sensitivity for INH was still too low. Flow Injection Analysis (FIA) was performed to 
optimize source parameters, then a calibration curve check was done. While there was 
linearity for all analytes, variability was high, especially at lower concentrations. Injection of 
the same samples onto an AB Sciex API 4000, a more sensitive mass spectrometer, coupled 
to an Agilent 1200 series LC system showed lower variability, mostly within the required 
limits. It was thereafter decided that the project be moved to the more sensitive API 4000 
mass spectrometer. 
 
4.4. API 4000 – Agilent 1200 
Infusion of 200 ng/ml solutions of all analytes and deuterated internal standards for each 
analyte was carried out to create an MS method. Methanol: water, 50:50 
 was used as the solvent. The infusion rate was 10 µl/min. The transitions monitored are 
shown in Table 4.10 and 4.11 for analytes and internal standards respectively.  
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Table 4.10: Product ions obtained after infusion on the API 4000 mass spectrometer 
Analyte Q1 m/z  product ion m/z 
AcINH 180 121 
desRIF 781 750 
EMB 205 116 
INH 138 79 
PZA 124 81 
RIF 824 792 
 
 
Table 4.11: MRM transitions of internal standards 
Internal standard Q1 m/z Product ion m/z 
AcINH-d4 184 142 
desRIF-d3 785 752 
EMB-d4 209 120 
INH-d4 142 83 
PZA-15N,d3 128 84 
RIF-d3 826 794 
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A simple gradient method was developed, with 0.05% formic acid in water solution as mobile 
phase A and 0.05% formic acid in a 1:1 mixture of methanol and acetonitrile as mobile phase 
B. An Agilent RP C18, 2.7µm particle size, 4.6mm internal diameter (ID) and 5cm long 
column was used. Reasonable separation was attained, although peak shapes were not 
impressive. The gradient is shown in Table 4.12.  
 
Table 4.12: Initial gradient program on the Agilent 1200-LC system coupled to the API 4000 mass 
spectrometer 
Step Time(min) 
Flow 
Rate(µl/min) A (%) B (%) 
0 0 400 95 5 
1 0.1 400 95 5 
2 1 400 20 80 
3 2 400 20 80 
4 3 400 95 5 
5 6 400 95 5 
 
 
An initial chromatogram is presented in Figure 4.18. 
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Figure 4.18: Initial chromatography on the Agilent 1200-LC system 
 
We were not certain what was causing the peak “fronting” seen in Figure 4.22. This usually 
happens when the column is damaged or when the injection volume is too high causing a 
mass overload. Mass overload was unlikely considering the relatively large diameter of the 
column and the injection volume of 5 µl.   
 
4.4.1. Extraction optimization 
 
The protein precipitating solvent was optimized; peak intensities obtained using different 
precipitating solvents were compared. Mixtures of acetonitrile with DMSO and with 
methanol were compared. DMSO is a universal polar solvent, capable of dissolving polar and 
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non-polar compounds. The DMSO: acetonitrile mixture did not result in higher peak signal 
hence a simple 1:1 mixture of methanol and acetonitrile was chosen.  
 
The supernatant obtained after protein precipitation, being highly organic, would result in 
poor peak shapes, as is usually the case when samples with a high organic content are 
injected into a highly aqueous environment. The supernatant, therefore had to be diluted by 
an aqueous component. Three aqueous phases; water, 0.05% formic acid solution and 0.05% 
acetic acid, were compared. INH, AcINH and PZA had the highest peak area when 0.05% 
acetic acid was used. EMB ionized best with 0.05% formic acid while desRIF preferred 
water. RMP had similar peak areas when water and when 0.05% formic acid was used, and 
0.05% acetic acid gave lower intensities. Figure 4.19 shows the results for the six analytes. 
 
 
Figure 4.19: Aqueous diluent optimization 
 
 
Aqueous Diluent Optimization
AcINHdesRIF EMB INH PZA RIF
0
100000
200000
300000
400000
500000
600000
water
0.05% formic acid
0.05% acetic acid
Analyte
pe
ak
 a
re
a 
(c
ps
)
  61 
4.4.2. Effect of ascorbic acid 
 
RIF, as well as desRIF, tended to show two peaks, as if two separate bands of the same 
compound would form in the chromatographic column. This phenomenon was prevented by 
adding ascorbic acid to the aqueous diluent. The first peak is possibly an oxidation product 
formed by the loss of two hydrogen atoms (86), which appears on the mass spectrum because 
the mass spectrometer may not be able to resolve the m/z values of the oxidized and non-
oxidized species. However, this phenomenon is still poorly understood. The effect of ascorbic 
acid is demonstrated in the chromatograms in Figure 4.20 and 4.21. 
 
 
Figure 4.20: Chromatogram showing RIF (and desRIF) with two peaks in the absence of ascorbic acid 
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Figure 4.21: Chromatogram showing RIF (and desRIF) with a single peak in the presence of ascorbic 
acid 
 
Ascorbic acid decreased peak areas of INH, AcINH, EMB and PZA and increased those of 
RIF and desRIF. The reproducibility was better for all analytes in the presence of ascorbic 
acid. Ultimately, addition of ascorbic acid was considered beneficial. The results are 
summarized in Table 4.13. 
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Table 4.13: Peak areas and coefficient of variability in the presence and in the absence of ascorbic 
acid 
Analyte 
No ascorbic acid (N=5) with ascorbic acid (N=5) 
Peak area mean (cps) %CV Peak area mean (cps) %CV 
AcINH 361200 2.8 319400 2.0 
desRIF 40980 10.2 190800 3.7 
EMB 166800 11.7 141400 4.9 
INH 205800 5.2 149400 2.1 
PZA 865200 5.7 730000 1.2 
RIF 223000 5.7 885400 1.6 
 
 
The low variability (when ascorbic acid is included) shown in Table 4.13 above indicated that 
the method was reproducible and thus ready for validation. Sensitivity and specificity were 
tested and were satisfactory. The chromatograms obtained at the lowest level of 
quantification and from blank plasma are shown in Figure 4.22 and Figure 4.23. 
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Figure 4.22: Chromatogram obtained at LLOQ 
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Figure 4.23: Chromatogram obtained when blank plasma was injected 
 
The method was sensitive enough with signal to noise ratios above 5 for all analytes. The 
method was to be validated using protein precipitation as the sample preparation method. 
Two microliter injections would be made, and chromatographic separation achieved by 
gradient elution on an Agilent 1200 LC system and an AB Sciex API 4000 would be used for 
detection. 
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Chapter 5 : THE METHOD 
 
This chapter gives details of the assay that is the final product of the method development 
process outlined in Chapter 4. This assay simultaneously quantified six compounds: AcINH, 
desRIF, EMB, INH, PZA and RIF, deuterated internal standards were used for each 
compound. The method used the LC-MS/MS technique and was validated on an AB-Sciex 
API 4000 triple quadrupole mass spectrometer, coupled to an Agilent 1200 liquid 
chromatography system. The calibration ranges and internal standards used for each analyte 
are presented in table 5.1. 
 
Table 5.1: Analytes, calibration ranges and internal standards 
Analyte Calibration range 
(μg/ml) 
LLOQ (μg/ml) Internal standard 
Rifampicin  0.120-30.0 0.120 Rifampicin-d3 
25-des-rifampicin 0.040-10.0 0.040 25-des-rifampicin-d3 
Isoniazid  0.100-25.0 0.100 Isoniazid-d4 
N-acetyl-isoniazid 0.050-12.5 0.050 N-acetyl-isoniazid-d4 
Pyrazinamide  0.320-80.0 0.320 Pyrazinamide-15N,d3 
Ethambutol  0.020-5.00 0.020 Ethambutol-d4 
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5.1. Solution Preparation 
 
5.1.1. Preparation of stock solutions 
 
Stock solutions of analytes: RIF, desRIF, INH, AcINH, PZA and EMB, and internal 
standards: rifampicin-d3 (RIF-d3), 25-desacetyl-rifampicin-d3(desRIF-d3), isoniazid-
d4(INH-d4), N-acetyl isoniazid-d4(AcINH-d4), pyrazinamide-15N,d3 (PZA-15N,d3) and 
ethambutol-d4 (EMB-d4) were prepared by weighing the analyte or internal standard into a 
container and dissolving this in the desired volume of solvent.  The weighed mass of the 
analytes was adjusted where applicable (purity, salt, etc.).  All stock solutions were kept at ~-
80C until required.  Two stock solutions were prepared for each analyte by different 
analysts. These were analysed and compared to verify accuracy. These stock solutions were 
used to prepare working solutions or to spike blank biological matrix as required. Tables 5.2 
to 5.13 show representative preparation of analyte and internal standard stock solutions  
 
Table 5.2:Representative preparation of RIF stock solution 
Solvent  Volume Weighed Adjusted SS1 
used solvent mass of analyte mass of analyte Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.920 2.81 2.76 3000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 98.2% 
* Calculation:(2.81/100x98=2.760 mg) 
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Table 5.3: Representative preparation of desRIF stock solution 
Solvent  Volume Weighed Adjusted* SS1 
used solvent mass of analyte mass of analyte Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.430  1.32 1.29 3000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 98% 
* Calculation:(1.32/100x98=1.29mg) 
 
Table 5.4: Representative preparation of RIF-d3 stock solution 
Solvent  Volume Weighed Adjusted ISS1 
used solvent mass of ISTD mass of ISTD Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.500 0.500 0.500  1000  
 
 
Table 5.5: Representative preparation of desRIF-d3 stock solution 
Solvent  Volume Weighed Adjusted ISS1 
used solvent mass of ISTD mass of ISTD Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.00  1.00  1.00  1000  
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Table 5.6: Representative preparation of INH stock solution 
Solvent  Volume Weighed Adjusted* SS1 
used solvent mass of analyte mass of analyte Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.133 3.47  3.40 3000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 98.0% 
* Calculation: 3.47mg x 98.0/100 = 3.40 mg 
 
Table 5.7: Representative preparation of AcINH stock solution 
Solvent  Volume Weighed Adjusted* SS1 
used solvent mass of analyte mass of analyte Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.167 3.57 3.50  3000 
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 98.0 % 
* Calculation: 3.57mg x 98.0/100 = 3.50 mg 
 
Table 5.8: Representative preparation of INH-d4 stock solution 
Solvent  Volume Weighed Adjusted ISS1 
used solvent mass of ISTD mass of ISTD Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.00  1.00  1.00  1000  
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Table 5.9: Representative preparation of AcINH-d4 stock solution 
Solvent  Volume Weighed Adjusted ISS1 
used solvent mass of ISTD mass of ISTD Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.00  1.00  1.00  1000  
 
 
Table 5.10: Representative preparation of PZA stock solution 
Solvent  Volume Weighed Adjusted* SS1 
used solvent mass of analyte mass of analyte Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.008  5.14  5.04  5000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 98.0 % 
* Calculation: 5.14 mg x 98.0/100 = 5.04 mg 
 
 
Table 5.11: Representative preparation of PZA-15N,d3 
Solvent  Volume Weighed Adjusted ISS1 
used solvent mass of ISTD mass of ISTD Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.00  1.00  1.00  1000  
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Table 5.12: Representative preparation of EMB stock solution 
Solvent  Volume Weighed Adjusted* SS1 
used solvent mass of analyte mass of analyte Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.810  3.36  2.43 3000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Salt + Purity 98.0 % 
* Calculation: 3.36 mg x 204.31/277.23 x 98.0/100 = 2.43 mg 
 
Table 5.13: Representative preparation of EMB-d4 stock solution 
Solvent  Volume Weighed Adjusted ISS1 
used solvent mass of ISTD mass of ISTD Concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 1.00  1.00  1.00  1000  
 
 
5.1.2. Preparation of Reference standard Working Solutions (WS) 
 
The SS1 analyte stock solutions were used to prepare working solutions WS1 – WS8 in 
methanol containing concentrations of analytes as depicted in Table 5.15 (see Table 5.14 for 
spiking volumes used to prepare WS1 and WS11). These working solutions were used to 
spike individual calibration standards (Section 5.3). The SS2 analyte stock solutions were 
used to prepare working solutions WS11 – WS16 in methanol containing concentrations as 
depicted in Table 5.16. Working solutions WS11 - WS16 were used to prepare individually 
spiked quality control samples as well as a system suitability test sample (Section 5.4).   
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 Table 5.14: Spiking volumes of stock solutions 
Analyte 
Concentration 
(µg/ml) 
Solvent  
Volume (µl) of SS1 spiked 
into WS1 and SS2 spiked into 
WS11 
Acetyl Isoniazid 3000 Methanol 50.0 
25-Desacetyl Rifampicin 3000 Methanol 40.0 
Ethambutol 3000 Methanol 20.0 
Isoniazid 3000 Methanol 100 
Pyrazinamide 5000 Methanol 192 
Rifampicin 3000 Methanol 120 
 
 
Table 5.15: Preparation of working solutions used to prepare calibration standards 
Working 
Solution 
(WS) 
Blank 
solvent 
volume 
(µl) 
Spiking 
solution 
Spiking 
solution 
volume (µl) 
Final 
WS 
volume 
(µl) 
WS Concentration (µg/ml) 
AcINH Des-RIF EMB INH PZA RIF 
WS1 78.0 SS1 x 6 
50.0+40.0+ 
20.0+100+ 
192+120 
600 250 200 100 500 1600 600 
WS2 200 WS1 400 600 167 133 66.7 333 1067 400 
WS3 200 WS2 200 400 83.3 66.7 33.3 167 533 200 
WS4 300 WS3 200 500 33.3 26.7 13.3 66.7 213 80.0 
WS5 300 WS4 200 500 13.3 10.7 5.33 26.7 85.3 32.0 
WS6 300 WS5 200 520 5.33 4.27 2.13 10.7 34.1 12.8 
WS7 300 WS6 180 480 2.00 1.60 0.80 4.00 12.8 4.80 
WS8 300 WS7 300 600 1.00 0.800 0.400 2.00 6.40 2.40 
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Table 5.16: Preparation of working solutions used to prepare quality control samples 
Working 
Solution 
(WS) 
Blank 
solvent 
volume 
(µl) 
Spiking 
solution 
Spiking 
solution 
volume 
(µl) 
Final 
WS 
volume 
(µl) 
WS Concentration (µg/ml) 
AcINH 
Des-
RIF 
EMB INH PZA RIF 
WS11 228 SS x 6 
50.0+40.0
+ 
20.0+100+ 
192+120 
750 200 160 80.0 400 1280 480 
WS12 250 WS11 250 500 100 80.0 40.0 200 640 240 
WS13 400 WS12 200 600 33.3 26.7 13.3 66.7 213 80.0 
WS14 400 WS13 200 600 11.1 8.89 4.44 22.2 71.1 26.7 
WS15 417 WS14 100 517 2.15 1.72 0.860 4.30 13.8 5.16 
WS16 230 WS15 200 430 1.00 0.800 0.400 2.00 6.40 2.40 
 
 
5.2. Preparation of calibration standards 
 
Calibration standards were prepared by individually spiking blank plasma (anticoagulant 
K3EDTA) on crushed ice. A mixture of all analytes in working solutions (WS1 – WS8) was 
spiked into blank plasma to obtain the desired calibration standard concentrations 
(STD 1 - STD 8) as presented in Table 5.17. Multiple 120 µl aliquots of each calibration 
standard were stored in individual 1.5 ml polypropylene tubes and stored at approximately ~-
80°C. 
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Table 5.17: Preparation of calibration standards 
Working 
Solutions 
(WS) 
Volume (µl) WS 
spiked into 1.90 
ml plasma 
Calibration 
Standard 
Analyte Plasma Concentration (µg/ml) 
A-INH 
Des-
RIF 
EMB INH PZA RIF 
WS1 100 STD 1-ULOQ 12.5 10.0 5.00 25.0 80.0 30.0 
WS2 100 STD 2 8.33 6.67 3.33 16.7 53.3 20.0 
WS3 100 STD 3 4.17 3.33 1.67 8.33 26.7 10.0 
WS4 100 STD 4 1.67 1.33 0.667 3.33 10.7 4.00 
WS5 100 STD 5 0.667 0.533 0.267 1.33 4.27 1.60 
WS6 100 STD 6 0.267 0.213 0.107 0.533 1.71 0.640 
WS7 100 STD 7 0.100 0.0800 0.0400 0.200 0.640 0.240 
WS8 100 STD 8 - LLOQ 0.0500 0.0400 0.0200 0.100 0.320 0.120 
 
 
5.3. Preparation of quality controls 
 
Quality control standards were prepared by individually spiking blank plasma (anticoagulant 
K3EDTA) on crushed ice. A mixture of all analytes in working solutions (WS11 – WS16) 
was spiked into blank plasma to obtain quality control standards at five concentration levels: 
QC Dil, QC High, QC Medium, QC Low and LLOQ as well as samples for system suitability 
checks (SYS 1) as depicted in Table 5.18. 
 
 
 
 
  75 
Table 5.18: Preparation of quality control samples 
Working 
Solutions 
(WS) 
Volume (µl) WS 
spiked into 1.90 
ml plasma 
Quality Control 
Analyte Plasma Concentration µg/ml 
A-INH 
Des-
RIF 
EMB INH PZA RIF 
WS11 100 QC H 10.0 8.00 4.00 20.0 64.0 24.0 
WS12 100 QC M 5.00 4.00 2.00 10.0 32.0 12.0 
WS13 100 SYS 1 1.67 1.33 0.667 3.33 10.7 4.00 
WS14 100 SYS 2 0.556 0.444 0.222 1.11 3.56 1.33 
WS15 100 QC L 0.107 0.0860 0.0430 0.215 0.688 0.258 
WS16 100 LLOQ 0.0500 0.0400 0.0200 0.100 0.320 0.120 
 Volume (µl) WS 
spiked into 0.90 
ml plasma 
      
       
WS11 100 QC Dil 20.0 16.0 8.00 40.0 128 48.0 
 
 
5.4. Verification of Calibration Standards and Quality Control Samples 
 
The calibration standards and quality control samples were analysed in a batch prior to 
method validation to confirm their accuracy.  Quality controls prepared independently by 
another analyst were used to verify the initial set of calibration standards. The independently 
prepared quality controls were within 85-115% of the target concentration, demonstrating no 
significant bias.  
 
 
  76 
5.5. Preparation of Internal Standard Working Solution 
 
The internal standard working solution (ISS2) was prepared by spiking appropriate volumes 
from each of the internal standard stock solutions (10.0 µl of ISS1-AcINH-d4, 10.0 µl of 
ISS1-desRIF-d3, 5.0 µl of ISS1-EMB-d4, 20.0 µl of ISS1-INH-d4, 40.0 µl of ISS1-PZA-
15N,d3 and 25.0 µl of ISS1-RIF-d3) into 20.000 ml of acetonitrile: methanol mixture (1:1, 
v/v) to obtain the desired individual concentrations (refer to Table 5.19). . A volume of 200 
µl of the internal standard working solution is added to each sample (excluding double blank 
samples), as described in section 5.7 of this chapter. 
 
Table 5.19: Internal standard working solution 
Working 
standard ID 
Volume of 
ISS1 (µl) 
Volume of 
ACN:MeOH 
(ml) 
Concentration of internal standard in working solution (µg/ml) 
A-INH Des-RIF EMB PZA INH RIF 
ISS2 
10.0+10.0+ 
5.0+20.0+40.0
+25.0 
20.000 0.500 0.500 0.250 2.00 1.00 1.25 
 
5.6. Buffers and other solutions 
 
5.6.1. Mobile phase A: 0.05% Formic Acid in water:  
1 litre water was added into a bottle, 0.5 ml formic acid was added, no pH adjustment was 
made, and the solution was stored at room temperature in normal light for a period of 2 weeks 
before being replaced. Helium was used to de-gas. 
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5.6.2. Mobile phase B: 0.05% Formic acid in acetonitrile: methanol (1:1, v/v). 
500 ml acetonitrile was added to 500 ml methanol and 0.5 ml formic acid was added. This 
solution may be used within 1 week. 
5.6.3. Autosampler needle wash: 50% methanol, (v/v).  
500 ml methanol was added to 500ml water. This solution can be kept at room temperature 
for up to 2 weeks. 
5.6.4. 0.05% formic acid in 25 μg/ml ascorbic acid solution.  
1.25 mg ascorbic acid was dissolved in 50 ml water. 25 μl formic acid was added. 
 
5.7. Extraction Procedure: 
• An analytical batch was defined as follows: A single extraction procedure applied to a 
series of unknown samples, which must include a SYS sample (of sufficient volume 
to inject at least ten times), a minimum of eight calibration standards analysed in 
duplicate, three levels of quality controls analysed in six-fold, a blank and a double 
blank sample. 
• Calibration standards were spread in duplicate throughout the run to capture 
instrument drift. 
• Quality control samples were also spread in six-fold over the run to control the 
analysis appropriately. 
• Double blanks and blanks were run after the highest calibration standard, 
consecutively to ascertain the level of carryover for the batch.  
I. Plasma samples were thawed on crushed ice and vortexed briefly.50 µl plasma was 
aliquoted into 1.50 ml microcentrifuge tubes. 
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II. 200 µl of the internal standard working solution (acetonitrile: methanol (1:1, v/v) 
containing the internal standards, refer to Table 5.19 above) was added to the samples 
(not more than 4 to 8 samples at a time) and vortexed for 30 seconds. NB: the double 
blank was extracted with an aliquot of internal standard-free acetonitrile: 
methanol (1:1, v/v).  
III. The samples were centrifuged at approximately 20 238 rcf for 5 minutes. 
IV. 150 µl aliquots of an aqueous 0.05% formic acid in 25 µg/ml ascorbic acid solution 
(see section 5.7.4) were transferred into a 96-well plate. 
V. 50 µl of the supernatant were added and mixed using the pipette 
VI. 2 µl was injected onto the HPLC column. 
VII. For dilutions: Only a 1:4 (sample: plasma, v/v) was validated. Dilutions were 
performed singly. The following procedure was used for performing dilution repeats: 
VIII. 20 µl of sample (unknown or QC-dil) was pipetted into a labelled polypropylene tube.  
IX. 80 µl of blank plasma was added to this sample and vortexed to mix.  
X. 50 µl of this mix was pipetted into a clean labelled polypropylene microcentrifuge 
tube and extraction then proceeded as per normal. 
 
5.7.1. Special Precautions: (e.g. waste diverting, column switching, washes, stability) 
 
Samples were precipitated in groups of not more than 4 to 8 at a time. Some analytes (INH 
and AcINH) are temperature sensitive and all procedures were carried out on ice. On ice, 
ambient light stability has been shown for up to 4 hours for all analytes. The method was 
validated with a flow split at the MS source. A flow split is a tube which diverts some of the 
flow coming from the LC system and delivers it to waste to reduce the flow that enters the 
MS. Lower flow rates are associated with better sensitivity and less need to clean the MS. 
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5.7.2. Used Reagents, Chemicals, Consumables and Equipment 
 
Reagents, chemicals, consumables and equipment required are listed in Tables 5.20 to 5.22. 
 
Table 5.20: Reagents and chemicals 
Reagent Grade Supplier 
Formic acid High purity Merck 
Acetonitrile High purity B&J Honeywell 
Methanol High purity B&J Honeywell 
Water High purity B&J Honeywell 
Ascorbic acid  N/A Sigma-Aldrich 
Rifampicin reference material N/A  USP 
Rifampicin-d3 reference material N/A  TRC 
25-Desacetyl-Rifampicin reference material N/A  TRC 
25-Desacetyl-Rifampicin-d3 reference material N/A  TRC 
Isoniazid reference material N/A  TRC 
Isoniazid-d4 reference material N/A  TRC 
N-acetyl isoniazid reference material N/A  TRC 
N-acetyl isoniazid-d4 reference material N/A  TRC 
Pyrazinamide reference material N/A  TRC 
Pyrazinamide-15N,d3 reference material N/A  TRC 
Ethambutol reference material N/A  TRC 
Ethambutol-d4 reference material N/A  TRC 
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Table 5.21: Necessary consumables 
Description Supplier 
96 well plates Agilent 
Sealing mats Agilent 
Microcentrifuge tubes Lasec SA 
Analytical Column: Agilent C18, 2.7µm, 50 x 4.6 mm Agilent 
Pipette tips (white) LASEC 
Pipette tips (yellow) LASEC 
Pipette tips (blue) LASEC 
 
 
Table 5.22: Equipment required 
Name Model  Manufacturer 
Vortex Vortex Genie 2 Scientific Industries 
Centrifuge 5424 Eppendorf 
Pipette: 2-20 µl Various Various 
Pipette: 20 – 200 µl Various Various 
Pipette: 200-1000 µl Various Various 
Sartorius CPA2P Micro balance CPA2P Carl Zeiss (Pty Ltd) 
Sonicator 703 Labotec (Pty Ltd) 
 
 
5.8. Instrument and chromatographic conditions 
 
The instrument used, and chromatographic conditions are presented in Table 5.23 
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Table 5.23: Instrument and chromatographic conditions 
Instrument used 
 
API4000 
 
Project 2017-12 TB Drugs 
Acquisition method Multiplex_first-lineTBdrugs.dam 
Analytical Column Agilent, 2.7µ, C18, 50 x 4.6 mm 
Column Temperature ~30°C 
Mobile Phase and Flow 
Gradient 
Mobile phase A: 0.05% formic acid in water 
Mobile phase B: 0.05% formic acid in 1:1 Acetonitrile:Methanol mixture (v/v)  
Time (minutes)      %Mobile phase A       %Mobile phase B   Flow rate (μl/min) 
0.00                            100                           0.00                       300 
0.10                            100                           0.00                       300 
1.00                             20.0                         80.0                       300  
2.50                             20.0                         80.0                       300 
2.55                             20.0                         80.0                       400 
3.50                             100                          0.00                       400 
6.00                             100                          0.00                       400 
6.10                             100                          0.00                       300   
Pump Type  Agilent 1200 Quaternary Pump 
Autosampler Type  Agilent 1200 
Sample arrangement 96-well plate 
Injection Volume 2 µl 
Autosampler Temperature ~8°C 
 
5.8.1. System Suitability Requirements 
 
The system suitability test was done before each validation batch, a SYS sample was injected 
at least 10 times and the acceptance criteria was that the peak area ratio of the last 6 injected 
samples must be below 5%. 
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5.9. Detection details 
 
5.9.1. Detection settings 
 
The mass spectrometer used for detection and mode of detection are presented in Table 5.24. 
Table 5.24:Detection settings 
Mass Spectrometer Identity API4000 
APCI/ESI ESI 
 
5.9.2. Electrospray ionization settings 
 
The settings in the electrospray ion source are presented in Table 5.25. 
Table 5.25: Ion source parameter settings 
Nebuliser gas (Gas 1) (arbitrary unit) 40 
Turbo gas (Gas 2) (arbitrary unit) 60 
CUR (curtain gas) (arbitrary unit) 40 
CAD (collision gas) (arbitrary unit) 10 
TEM (Source Temperature) (°C) 300 
IS (Ion Spray Voltage) (V) 5000 
 
 
5.9.3. MS/MS settings 
 
The MS/MS settings used for each analyte are presented in Table 5.26. 
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Table 5.26: MS/MS settings 
 RIF Des-RIF RIF-d3 
Des-
RIF-d3 
INH 
INH-
d4 
AcINH 
AcINH-
d4 
PZA 
PZA-
15N,d3 
EMB 
EMB-
d4 
Protonated molecular ion 
mass (m/z) [M+H]+ 
823.4 781.5 826.4 784.5 137.9 142.0 180.0 184.0 
124.
0 
127.9 205.1 209.1 
Product ion mass (m/z)  
Quantifier 
791.6 749.5 794.4 752.4 79.1 83.1 121.0 142.1 81.0 84.0 116.1 120.1 
Product ion mass (m/z)  
Qualifier 
151.1 399.3   93.1  138.0  79.0  81.0  
Dwell time (ms) 80 80 80 80 80 80 80 80 80 80 80 80 
Declustering potential (V) 91 66 86 71 51 51 61 61 51 51 51 46 
Entrance potential (V) 10 10 10 10 10 10 10 10 10 10 10 10 
Collision energy (eV) 25 19 27 19 39 41 31 23 25 25 21 23 
Collision cell exit potential 
(V) 24 22 22 20 6 6 10 12 6 6 10 10 
 
 
5.9.4. Scan description 
 
The scan type, polarity and pause time are presented in Table 5.27. 
 
Table 5.27: Scan description 
Scan Type MRM 
Polarity Positive 
Pause Time (ms) 5 
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5.9.5. Spectra  
 
Analyte: RIF 
 
The following is a mass spectrum of rifampicin after collision induced dissociation in the 
fragmentation cell, showing the RIF precursor ion at m/z 823 as well as the product ions. 
 
Figure 5.1: RIF mass spectrum 
 
Internal standard: RIF-d3 
 
The following is a mass spectrum of RIF-d3 after collision induced dissociation in the 
fragmentation cell, showing the RIF-d3 precursor ion at m/z 826 as well as the product ions. 
 +MS2 (823.43) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Rifampicin_InitProduct_Pos.wiff (Turbo Spray) Max. 1.0e6 cps.
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Figure 5.2: RIF-d3 mass spectrum 
 
Analyte: DesRIF 
 
The following is a mass spectrum of desRIF after collision induced dissociation in the 
fragmentation cell, showing the desRIF precursor ion at m/z 781 as well as the product ions. 
 
 +MS2 (826.37) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Rifampicin-d3_InitProduct_Pos.wiff (Turbo Spray) Max. 5.4e5 cps.
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Figure 5.3: DesRIF mass spectrum 
 
Internal standard: DesRIF-d3 
 
The following is a mass spectrum of desRIF-d3 after collision induced dissociation in the 
fragmentation cell, showing the desRIF-d3 precursor ion at m/z 784 as well as the product 
ions. 
 +MS2 (781.47) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of 25-desRifampicin_InitProduct_Pos.wiff (Turbo Spray) Max. 2.4e5 cps.
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Figure 5.4: DesRIF-d3 mass spectrum 
 
Analyte: INH 
 
The following is a mass spectrum of INH after collision induced dissociation in the 
fragmentation cell, showing the INH precursor ion at m/z 138 as well as the product ions. 
 +MS2 (784.48) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of 25-desRifampicin-d3_InitProduct_Pos.wiff (Turbo Spray) Max. 4.2e4 cps.
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Figure 5.5: INH mass spectrum 
 
Internal standard: INH-d4 
 
The following is a mass spectrum of INH-d4 after collision induced dissociation in the 
fragmentation cell, showing the INH-d4 precursor ion at m/z 142 as well as the product ions. 
 +MS2 (137.93) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Isoniazid_InitProduct_Pos.wiff (Turbo Spray) Max. 4.0e6 cps.
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Figure 5.6: INH-d4 mass spectrum 
 
Analyte: AcINH 
 
The following is a mass spectrum of AcINHsoniazid after collision induced dissociation in 
the fragmentation cell, showing the AcINH precursor ion at m/z 180 as well as the product 
ions. 
 +MS2 (141.99) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Isoniazid-d4_InitProduct_Pos.wiff (Turbo Spray) Max. 2.7e6 cps.
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Figure 5.7: AcINH mass spectrum 
 
Internal standard: AcINH-d4 
 
The following is a mass spectrum of AcINH-d4 after collision induced dissociation in the 
fragmentation cell, showing the AcINH-d4 precursor ion at m/z 184 as well as the product 
ions. 
 
 +MS2 (180.01) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Acetyl-Isoniazid_InitProduct_Pos.wiff (Turbo Spray) Max. 3.7e6 cps.
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Figure 5.8: AcINH-d4 mass spectrum 
 
Analyte: PZA 
 
The following is a mass spectrum of the analyte PZA after collision induced dissociation in 
the fragmentation cell, showing the PZA precursor ion at m/z 124 as well as the product ions. 
 +MS2 (183.96) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of acetyl-Isoniazid-d4_InitProduct_Pos.wiff (Turbo Spray) Max. 2.2e6 cps.
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Figure 5.9: PZA mass spectrum 
 
 Internal standard: PZA-15N,d3 
 
The following is a mass spectrum of the internal standard PZA-15N,d3 after collision induced 
dissociation in the fragmentation cell, showing the PZA-15N,d3 precursor ion at m/z 128 as 
well as the product ions. 
 +MS2 (123.97) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Pyrazinamide_InitProduct_Pos.wiff (Turbo Spray) Max. 1.3e6 cps.
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Figure 5.10: PZA-15N,d3 mass spectrum 
 
Analyte: EMB 
 
The following is a mass spectrum of the analyte EMB after collision induced dissociation in 
the fragmentation cell, showing the EMB precursor ion at m/z 205 as well as the product 
ions. 
 +MS2 (127.91) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Pyrazinamide-15N,d3_InitProduct_Pos.wiff (Turbo Spray) Max. 2.1e6 cps.
60 65 70 75 80 85 90 95 100 105 110 115 120 125 130
m/z, Da
0.0
1.0e5
2.0e5
3.0e5
4.0e5
5.0e5
6.0e5
7.0e5
8.0e5
9.0e5
1.0e6
1.1e6
1.2e6
1.3e6
1.4e6
1.5e6
1.6e6
1.7e6
1.8e6
1.9e6
2.0e6
2.1e6
In
te
ns
ity
, c
ps
128.0
84.2
83.0
81.8 100.0
109.8
87.072.2
  94 
 
Figure 5.11: EMB mass spectrum 
 
Internal standard: EMB-d4 
 
The following is a mass spectrum of the internal standard EMB-d4 after collision induced 
dissociation in the fragmentation cell, showing the EMB-d4 precursor ion at m/z 209.3 as 
well as the product ions. 
 +MS2 (205.14) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Ethambutol_InitProduct_Pos.wiff (Turbo Spray) Max. 4.1e5 cps.
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Figure 5.12: EMB-d4 mass spectrum 
 
5.10. Recording and integration 
 
5.10.1. Quantitation parameters 
 
Quantitation parameters are presented in Table 5.28. 
 
 
 
 
 
 
 +MS2 (209.13) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of Ethambutol-d4_InitProduct_Pos.wiff (Turbo Spray) Max. 7.2e5 cps.
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Table 5.28: Quantitation parameters 
 
Analyte:  
RIF 
ISTD:  
RIF-
d3 
Analyte: 
25-Des-
RIF 
ISTD: 
25-Des-
RIF-d3 
Analyte: 
INH 
ISTD: 
INH-
d4 
Analyte: 
AcINH 
ISTD: 
AcINH
-d4 
Analyte: 
PZA 
ISTD:  
PZA-
15N,d3 
Analyte: 
EMB 
ISTD: 
EMB-
d4 
Software Analyst 1.6.2 
Algorithm Analyst Classic 
Calibration 
Fit Type 
Quadratic Quadratic Quadratic Quadratic Quadratic Quadratic 
Parameter Area ratio Area ratio Area ratio Area ratio Area ratio Area ratio 
Curve 
Weighting 
1/x 1/x 1/x 1/x 1/x2 1/x 
Bunching 
factor 
1 1 1 1 1 1 1 1 1 1 1 1 
Number of 
smoothes 
5 5 5 5 5 5 5 5 5 5 5 5 
 
5.10.2. Precursor and product ions monitored 
 
All precursor and product ions monitored (analytes and internal standards) are presented in 
Table 5.29. 
Table 5.29: Precursor and product ions monitored 
 Precursor Ion Mass (amu) Product Ion Mass (amu) 
Analyte 1: RIF 823.4 791.6 
ISTD 1: RIF-d3 826.3 794.4 
Analyte 2: DesRIF 781.5 749.5 
ISTD 2: DesRIF-d3 784.5 752.4 
Analyte 3: INH 137.9 79.1 
ISTD 3: INH-d4 142.0 83.1 
Analyte 4: AcINH 180.0 121.0 
ISTD 4: AcINH-d4 184.0 142.1 
Analyte 5: PZA 124.0 81.0 
ISTD 5: PZA-15N,d3 127.9 84.0 
Analyte 6: EMB 205.1 116.1 
ISTD 6: EMB-d4 209.1 120.1 
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5.10.3. Retention times 
 
Approximate retention times for all analytes and internal standards are presented in Table 
5.30. 
Table 5.30: Retention times 
Analyte: Time (min) 
RIF ~ 5.7 
DesRIF ~ 5.4 
RIF-d3 ~5.7 
DesRIF-d3 ~ 5.4 
INH  ~2.2 
AcINH ~2.4 
INH-d4 ~2.2 
AcINH-d4 ~2.4 
PZA ~4.3 
PZA-15N,d3 ~4.3 
EMB  ~1.7 
EMB-d4 ~1.7 
 
5.11. Acceptance criteria 
 
5.11.1. Calibration standards 
 
75% of the standards used must fall within 15% of the nominal concentration (i.e. 85-115%), 
except for the LLOQ, which should be within 20% (i.e. 80-120%) of the nominal value.  The 
%CV for duplicate observations should be less than 15% for all points, except for the LLOQ 
which may display a 20% CV.  Duplicate points (and not averages) are used to construct the 
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calibration curve.  Failed points must be excluded from the calibration curve regression 
determination.  Should both values fail to meet the acceptance criteria, then this point should 
not be used to construct the calibration curve and must be excluded from the experiment. This 
may necessitate a reanalysis of the unknown samples contained in the failed run.  Goodness 
of fit criteria should be monitored but are not the ideal way of assessing the validity of a 
calibration curve.  
 
5.11.2. Quality control 
 
A minimum of four quality control levels (2 x high (~80% of the ULOQ), 2 x medium, 2 x 
low (~3 x LLOQ) and 2 x LLOQ) are run with every analytical batch.  Two thirds of the 
quality controls analysed must meet the acceptance criteria of 85-115% accuracy and less 
than 15% CV.  The allowable failures may not be of the same concentration, i.e. 50% of 
controls run at every level must pass.  Failure to meet these acceptance criteria will 
necessitate a reanalysis of the unknown samples. Additional quality controls may be run to 
ensure against a failed batch owing to failed ULOQ or LLOQ standards. 
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Chapter 6 : VALIDATION 
 
Validation is the process of proving that an analytical method is accurate and precise, thus 
ensuring the integrity of results produced. Essential parameters to ensure the acceptability of 
the performance of a bioanalytical method are accuracy, precision, selectivity, sensitivity, 
reproducibility and stability (87). Linearity of calibration curves, matrix effects and recovery 
are also frequently assessed. This chapter outlines the validation experiments that were 
conducted, meeting the requirements of the American Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) (88, 89).   
 
6.1. Accuracy and precision and reproducibility 
 
Accuracy is expressed as a percentage of the observed concentration over the nominal 
concentration (% Accuracy). It must be within 15% over the entire calibration curve and can 
be within 20% at the LLOQ. Precision is expressed as the coefficient of variation (% CV) and 
must also be within 15% over the entire calibration range and within 20% at the LLOQ. Three 
validation batches were run on separate days to demonstrate both within-run and inter-occasion 
accuracy and precision. Each batch had eight calibration standards, STD1 to STD8, with 
concentrations covering the calibration range (Chapter 5, Table 5.17) and quality control 
standards at four concentration levels: LLOQ, QCL, QCM and QCH (Chapter 5, Table 5.18), 
to ensure the accuracy of the calibration standards and the precision of the method. A quality 
control sample above the limit of quantification (QC Dil) was diluted with plasma four times 
its volume and analysed to prove that samples with concentrations above the limits of 
quantification can be diluted and accurately assayed. The calibration standards and quality 
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controls were previously prepared as outlined in Chapter 5 and stored at -800C. Calibration 
standards were analysed in duplicate and quality control standards were analysed in six 
replicates in each validation batch. 
 
AcINH 
 
The overall accuracy and precision of calibration standards and QCs for AcINH are 
summarised in Tables 6.1 and 6.2. 
 
Table 6.1: Overall Summary of Calibration Standard Accuracy and Precision: Validation 1-3: AcINH 
  
Sample ID 
STD 8 - 
LLOQ 
STD 7 STD 6 STD 5 STD 4 STD 3 STD 2 STD 1  
Nominal Conc. 0.05 0.1 0.27 0.67 1.67 4.17 8.33 12.5 
  µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
Validation 
1 
Data Point 1 0.0566 0.100  * 0.624 1.54 4.32 8.65 12.0 
Data Point 2 0.0550 0.100 0.242 0.631 1.71 4.20 8.20 12.9 
Validation 
2 
Data Point 1 0.0514 0.0976 0.258 0.665 1.68 4.26 8.06 12.2 
Data Point 2 0.0529 0.105 0.253 0.654 1.68 4.23 8.37 12.9 
Validation 
3 
Data Point 1 0.0564 0.111 0.260 0.672 1.63 4.26 8.13 12.4 
Data Point 2 0.0410 0.102 0.257 0.689 1.65 4.15 8.38 12.7 
  N 6 of 6 6 of 6 5 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 
  Mean 0.0522 0.103 0.254 0.656 1.65 4.24 8.30 12.5 
  
Standard Dev. 0.00586 0.00491 0.00727 0.0248 0.0593 0.0567 0.216 0.377 
%CV 11.2 4.8 2.9 3.8 3.6 1.3 2.6 3.0 
  Accuracy 104.4 102.6 94.1 97.9 98.7 101.6 99.6 100.1 
*Failed to meet acceptance criteria 
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Table 6.2: Overall Quality Control Accuracy and Precision Estimation: AcINH 
  Sample ID LLOQ  QCL      QCM                     QCH        QC DIL  
Nominal 
Conc. 
0.0500 0.107 5.00 10.0 20.0 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
  Replicates Observed Conc. Observed Conc. Observed Conc. Observed Conc. Observed Conc. 
Validation 
1 
Data Point #1 0.0490 0.0898 4.38 10.2 18.5 
Data Point #2 0.0472 0.0871 4.38 9.70 18.2 
Data Point #3 0.0486 0.102 4.73 10.1 18.7 
Data Point #4 0.0570 0.104 4.55 10.4 18.0 
Data Point #5 0.0470 0.0952 4.63 10.1 18.9 
Data Point #6 0.0455 0.0994 4.78 10.2 17.8 
Validation 
2 
Data Point #1 0.0407 0.100 5.48 10.6   
Data Point #2 0.0491 0.0973 5.44 10.6   
Data Point #3 0.0531 0.0917 5.17 10.8   
Data Point #4 0.0493 0.0936 5.27 10.8   
Data Point #5 0.0484 0.0946 5.32 11.2   
Data Point #6 0.0434 0.0875 5.20 10.7   
Validation 
3 
Data Point #1 0.0505 0.0990 5.15 10.8   
Data Point #2 0.0551 0.0993 5.27 10.4   
Data Point #3 0.0532 0.0962 5.16 11.0   
Data Point #4 0.0535 0.107 5.11 10.4   
Data Point #5 0.0456 0.105 5.26 10.5   
Data Point #6 0.0487 0.106 5.37 10.8   
  N 18 of 18 18 of 18 18 of 18 18 of 18 6 of 6 
  Mean 0.0492 0.0974 5.04 10.5 18.4 
  Standard Dev. 0.00412 0.00603 0.361 0.372 0.424 
  %CV 8.4 6.2 7.2 3.5 2.3 
  Accuracy 98.3 91.1 100.7 105.1 91.8 
 
desRIF 
 
The overall accuracy and precision of calibration standards and QCs for desRIF are 
summarised in Tables 6.3 and 6.4. 
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Table 6.3: Overall Summary of Calibration Standard Accuracy and Precision: Validation 1-3: desRIF 
  Sample ID STD 8 - 
LLOQ 
STD 7 STD 6 STD 5 STD 4 STD 3 STD 2 STD 1  
Nominal Conc. 0.0400 0.0800 0.213 0.533 1.33 3.33 6.67 10.0 
  µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
Validation 
1 
Data Point #1 0.0416 0.0800 0.192 0.568 1.30 3.19 7.27 9.00 
Data Point #2 0.0480 0.0700 0.187 0.523 1.51 3.23 6.30 11.3 
Validation 
2 
Data Point #1 0.0402 0.0875 0.199 0.514 1.36 3.29 6.59 10.8 
Data Point #2 0.0384 0.0860 0.193 0.546 1.35 3.35 6.72 9.40 
Validation 
3 
Data Point #1 0.0426  * 0.214 0.504 1.30 3.03 6.94 11.1 
Data Point #2 0.0384 0.0780 0.217 0.528 1.43 3.57 6.44 9.10 
  N 6 of 6 5 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 
  Mean 0.0415 0.0810 0.200 0.531 1.37 3.28 6.71 10.1 
  Standard Dev. 0.0384 0.0702 0.187 0.504 1.30 3.03 6.3 8.96 
  %CV 8.6 8.6 6.2 4.3 6 5.4 5.3 10.6 
  Accuracy 103.8 100.6 94.1 99.6 103.3 98.4 100.6 101.2 
*Failed to meet acceptance criteria 
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Table 6.4: Overall Quality Control Accuracy and Precision Estimation: desRIF 
  Sample ID LLOQ  QCL      QCM                     QCH        QC DIL  
Nominal Conc. 0.0400 0.0860 4.00 8.00 16.0 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Replicates Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Validation 1 Data Point #1 0.0372 0.0791 3.48 8.93 15.0 
Data Point #2 0.0377 0.0848 3.53 8.40 14.5 
Data Point #3 0.0387 0.0848 4.14 7.63 15.6 
Data Point #4 0.0450 0.0990 4.24 8.84 14.3 
Data Point #5 0.0377 0.0789 3.67 8.13 16.9 
Data Point #6 0.0410 0.0972 4.02 8.50 15.2 
Validation 2 Data Point #1 0.0320 0.0882 4.11 7.67   
Data Point #2 0.0359 0.0872 4.01 7.30   
Data Point #3 0.0441 0.0791 3.74 8.63   
Data Point #4 0.0323 0.0706 4.05 11.4*   
Data Point #5 0.0383 0.0776 4.13 8.46   
Data Point #6 0.0301 0.0775 3.99 8.89   
Validation 3 Data Point #1 0.0510 0.0821 3.60 7.74   
Data Point #2 0.0412 0.0869 3.66 6.95   
Data Point #3 0.0564 0.0914 3.78 8.27   
Data Point #4 0.0511 0.0764 3.61 8.96   
Data Point #5 0.0384 0.0903 3.84 8.20   
Data Point #6 0.0348 0.0683 3.38 8.38   
  N 18 of 18 18 of 18 18 of 18 18 of 18 6 of 6 
  Mean 0.0402 0.0833 3.83 8.40 15.2 
  Standard Dev. 0.00706 0.00829 0.261 0.947 0.934 
%CV 17.6 9.9 6.8 11.3 6.1 
  Accuracy 100.4 96.9 95.8 105.1 95.3 
 
 
EMB 
 
The overall accuracy and precision of calibration standards and QCs for EMB are summarised 
in Tables 6.5 and 6.6 
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Table 6.5: Overall Summary of Calibration Standard Accuracy and Precision: Validation 1-3: EMB 
  Sample ID STD 8 – 
LLOQ 
STD 7 STD 6 STD 5 STD 4 STD 3 STD 2 STD 1  
Nominal Conc. 0.0200 0.0400 0.107 0.267 0.667 1.67 3.33 5.00 
  µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
Validation 
1 
Data Point #1 0.0232 0.0380  * 0.273 0.603 1.59 3.36 4.80 
Data Point #2 0.0184  * 0.100 0.297 0.651 1.71 3.51 5.09 
Validation 
2 
Data Point #1 0.0223 0.0387 0.0993 0.246 0.675 1.70 3.18 4.91 
Data Point #2 0.0213 0.0436 0.100 0.251 0.655 1.71 3.48 5.07 
Validation 
3 
Data Point #1 0.0213 0.0431 0.0980 0.253 0.630 1.60 3.33 4.82 
Data Point #2 0.0202 0.0380 0.0991 0.302 0.666 1.81 3.28 5.20 
  N 6 of 6 5 of 6 5 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 
  Mean 0.0211 0.0403 0.0994 0.271 0.647 1.69 3.36 4.98 
  Standard Dev. 0.00166 0.00283 0.001 0.0246 0.0264 0.0809 0.124 0.162 
  %CV 7.8 7.0 1.0 9.1 4.1 4.8 3.7 3.3 
  Accuracy 105.7 100.7 92.9 101.3 97.0 100.9 100.8 99.6 
*Failed to meet acceptance criteria 
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Table 6.6: Overall Quality Control Accuracy and Precision Estimation: EMB 
  Sample ID LLOQ  QCL      QCM                     QCH        QC DIL  
Nominal Conc. 0.0200 0.0430 2.00 4.00 8.00 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Replicates Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Validation 
1 
Data Point #1 0.0180 0.0384 1.71 3.98 8.10 
Data Point #2 0.0184 0.0411 1.70 3.98 7.17 
Data Point #3 0.0201 0.0461 1.88 3.85 7.90 
Data Point #4 0.0178 0.0474 2.05 4.51 7.83 
Data Point #5 0.0210 0.0425 2.00 4.10 7.98 
Data Point #6 0.0197 0.0387 1.87 4.08 7.52 
Validation 
2 
Data Point #1 0.0196 0.0370 2.16 4.04   
Data Point #2 0.0209 0.0397 2.16 4.19   
Data Point #3 0.0203 0.0366 2.06 4.49   
Data Point #4 0.0202 0.0412 2.07 4.14   
Data Point #5 0.0219 0.0429 2.08 4.30   
Data Point #6 0.0201 0.0384 1.96 4.28   
Validation 
3 
Data Point #1 0.0196 0.0357 1.86 4.41   
Data Point #2 0.0198 0.0365 2.01 4.36   
Data Point #3 0.0177 0.0383 2.05 4.27   
Data Point #4 0.0180 0.0395 2.07 4.07   
Data Point #5 0.0198 0.0420 2.23 4.33   
Data Point #6 0.0176 0.0406 2.11 4.03   
  N 18 of 18 18 of 18 18 of 18 18 of 18 6 of 6 
  Mean 0.0195 0.0401 2.00 4.19 7.75 
  Standard Dev. 0.00127 0.00321 0.148 0.188 0.344 
  %CV 6.5 8.0 7.4 4.5 4.4 
  Accuracy 97.4 93.3 100.1 104.7 96.9 
 
 
INH 
 
The overall accuracy and precision of calibration standards and QCs for INH are summarised 
in Tables 6.7 and 6.8. 
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Table 6.7: Overall Summary of Calibration Standard Accuracy and Precision: Validation 1-3: INH 
  Sample ID STD 8 - 
LLOQ 
STD 7 STD 6 STD 5 STD 4 STD 3 STD 2 STD 1  
Nominal Conc. 0.100 0.200 0.533 1.33 3.33 8.33 16.7 25 
  µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
Validation 
1 
Data Point #1 0.106 0.191  * 1.42 3.04 8.37 17.2 24.8 
Data Point #2  * *  0.503 1.38 3.39 8.26 16.6 25.0 
Validation 
2 
Data Point #1 0.106 0.191 0.396 1.42 3.04 8.37 17.2 24.8 
Data Point #2 0.130 0.248 0.503 1.38 3.39 8.26 16.6 25.0 
Validation 
3 
Data Point #1 0.119  * 0.489 1.27 3.11 8.25 16.7 24.5 
Data Point #2 0.109 0.192 0.491 1.32 3.37 8.45 17.5 25.0 
  N 5 of 6 4 of 6 5 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 
  Mean 0.110 0.199 0.495 1.32 3.25 8.39 16.9 24.9 
  Standard Dev. 0.00523 0.00979 0.00782 0.0681 0.16 0.163 0.409 0.2 
  %CV 4.7 4.9 1.6 5.2 4.9 1.9 2.4 0.8 
  Accuracy 110.2 99.3 92.8 99.1 97.5 100.7 101.2 99.4 
*Failed to meet acceptance criteria 
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Table 6.8: Overall Quality Control Accuracy and Precision Estimation: INH 
  Sample ID LLOQ  QCL      QCM                     QCH        QC DIL  
Nominal Conc. 0.100 0.215 10.0 20.0 40.0 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
  Replicates Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Validation 
1 
Data Point #1 0.0815 0.163 8.26 20.3 39.4 
Data Point #2 0.0826 0.176 8.55 19.6 38.8 
Data Point #3 0.108 0.188 9.85 20.4 38.2 
Data Point #4 0.0986 0.185 9.74 20.1 37.5 
Data Point #5 0.104 0.209 9.66 19.9 37.4 
Data Point #6 0.113 0.205 9.32 20.0 39.2 
Validation 
2 
Data Point #1 0.0694 0.181 10.2 21.5   
Data Point #2 0.107 0.208 10.5 20.8   
Data Point #3 0.113 0.195 10.3 20.4   
Data Point #4 0.105 0.202 10.2 22.0   
Data Point #5 0.0872 0.229 10.8 21.4   
Data Point #6 0.110 0.189 10.4 21.0   
Validation 
3 
Data Point #1 0.115 0.200 10.3 21.3   
Data Point #2 0.110 0.243 10.3 20.9   
Data Point #3 0.0900 0.178 10.8 21.3   
Data Point #4 0.109 0.183 10.3 21.0   
Data Point #5 0.106 0.243 10.9 21.3   
Data Point #6 0.103 0.236 10.6 20.6   
  N 18 of 18 18 of 18 18 of 18 18 of 18 6 of 6 
  Mean 0.101 0.201 10.0 20.8 38.4 
  Standard Dev. 0.0129 0.0237 0.727 0.646 0.858 
  %CV 12.9 11.8 7.2 3.1 2.2 
  Accuracy 100.6 93.4 100.5 103.9 96 
 
 
PZA 
 
The overall accuracy and precision of calibration standards and QCs for PZA are summarised 
in Tables 6.9 and 6.10. 
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Table 6.9: Overall Summary of Calibration Standard Accuracy and Precision: Validation 1-3: PZA 
  Sample ID STD 8 - 
LLOQ 
STD 7 STD 6 STD 5 STD 4 STD 3 STD 2 STD 1  
Nominal Conc. 0.320 0.640 1.71 4.27 10.7 26.7 53.3 80 
  µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
Validation 
1 
Data Point #1 0.321 0.647 1.53 4.24 10.6 *  59.6 72.7 
Data Point #2 0.323 0.649 1.698 4.00 11.7 29.0  * 76.0 
Validation 
2 
Data Point #1 0.323 0.651 1.592 4.18 10.6 28.3 50.7 *  
Data Point #2 0.306 0.704 1.613 4.24 10.8 27.9 58.1 72.2 
Validation 
3 
Data Point #1 0.339 0.646 1.563 4.31 10.2 25.4 56.8 72.6 
Data Point #2 0.293 0.692 1.633 4.37 11.0 28.5 59.7 72.7 
  N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 5 of 6 5 of 6 5 of 6 
  Mean 0.317 0.665 1.604 4.22 10.8 27.8 57.0 73.2 
  Standard Dev. 0.016 0.0263 0.0597 0.130 0.497 1.39 3.71 1.58 
  %CV 5 4 3.7 3.1 4.6 5.0 6.5 2.2 
  Accuracy 99.2 103.9 93.8 98.9 101.1 104.2 106.9 91.5 
*Failed to meet acceptance criteria 
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Table 6.10: Overall Quality Control Accuracy and Precision Estimation: PZA 
  Sample ID LLOQ  QCL      QCM                     QCH        QC DIL  
Nominal Conc. 0.320 0.688 32.0 64.0 128 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
  Replicates Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Validation 
1 
Data Point #1 0.298 0.620 25.1 64.7 121 
Data Point #2 0.270 0.641 27.3 61.3 122 
Data Point #3 0.281 0.623 28.6 64.9 120 
Data Point #4 0.301 0.592 28.1 63.3 120 
Data Point #5 0.290 0.617 29.6 60.2 123 
Data Point #6 0.297 0.652 28.4 67.7 117 
Validation 
2 
Data Point #1 0.317 0.652 28.7 63.4   
Data Point #2 0.308 0.624 29.2 64.4   
Data Point #3 0.356 0.646 29.0 65.6   
Data Point #4 0.343 0.674 30.1 65.6   
Data Point #5 0.340 0.635 29.9 66.3   
Data Point #6 0.303 0.661 30.2 68.7   
Validation 
3 
Data Point #1 0.266 0.592 30.1 66.0   
Data Point #2 0.295 0.563 28.4 63.5   
Data Point #3 0.272 0.611 31.4 65.2   
Data Point #4 0.316 0.628 30.2 71.4   
Data Point #5 0.292 0.640 30.7 66.5   
Data Point #6 0.282 0.617 32.4 68.5   
  N 18 of 18 18 of 18 18 of 18 18 of 18 6 of 6 
  Mean 0.301 0.627 29.3 65.4 120 
  Standard Dev. 0.0252 0.027 1.62 2.68 2.16 
  %CV 8.4 4.3 5.5 4.1 1.8 
  Accuracy 94.2 91.2 91.6 102.2 94.0 
 
 
RIF 
 
The overall accuracy and precision of calibration standards and QCs for RIF are summarised 
in Tables 6.11 and 6.12. 
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Table 6.11: Overall Summary of Calibration Standard Accuracy and Precision: Validation 1-3: RIF 
  Sample ID STD 8 - 
LLOQ 
STD 7 STD 6 STD 5 STD 4 STD 3 STD 2 STD 1  
Nominal Conc. 0.120 0.240 0.640 1.60 4.00 10.0 20.0 30.0 
  µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
Validation 1 Data Point #1 0.119 0.265 0.570 1.70 3.83 9.95 20.6 30.3 
Data Point #2 0.117 0.249 0.608 1.62 4.10 9.95 19.8 29.5 
Validation 2 Data Point #1 0.122 0.254 0.589 1.57 4.12 10.0 19.5 29.8 
Data Point #2 0.117 0.251 0.617 1.61 3.95 10.3 19.9 30.5 
Validation 3 Data Point #1 0.134 0.250 0.586 1.61 4.04 9.62 19.7 29.5 
Data Point #2 0.109 0.250 0.611 1.63 3.96 10.1 20.9 30.1 
  N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6 
  Mean 0.120 0.253 0.597 1.62 4.00 9.99 20.1 30.0 
  Standard Dev. 0.00832 0.00621 0.0179 0.0418 0.108 0.216 0.538 0.433 
  %CV 6.9 2.5 3.0 2.6 2.7 2.2 2.7 1.4 
  Accuracy 99.7 105.5 93.3 101.5 100.0 99.9 100.3 99.9 
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Table 6.12: Overall Quality Control Accuracy and Precision Estimation: RIF 
  Sample ID LLOQ  QCL      QCM                     QCH        QC DIL  
Nominal Conc. 0.120 0.258 12.0 24.0 48.0 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
  Replicates Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Validation 1 Data Point #1 0.124 0.246 10.4 24.5 45.1 
Data Point #2 0.114 0.241 10.8 24.1 45.4 
Data Point #3 0.119 0.245 11.0 23.3 44.1 
Data Point #4 0.128 0.248 11.1 23.5 44.0 
Data Point #5 0.127 0.254 10.9 23.4 45.1 
Data Point #6 0.124 0.268 11.0 23.4 42.2 
Validation 2 Data Point #1 0.124 0.254 12.1 25.7   
Data Point #2 0.126 0.263 12.9 26.6   
Data Point #3 0.129 0.260 12.4 26.9   
Data Point #4 0.121 0.239 12.4 27.1   
Data Point #5 0.129 0.283 12.5 26.8   
Data Point #6 0.134 0.248 12.4 25.8   
Validation 3 Data Point #1 0.126 0.253 12.2 26.0   
Data Point #2 0.118 0.246 12.5 26.6   
Data Point #3 0.114 0.240 12.7 25.8   
Data Point #4 0.120 0.246 12.3 24.9   
Data Point #5 0.124 0.260 12.3 24.7   
Data Point #6 0.119 0.242 12.1 24.3   
  N 18 of 18 18 of 18 18 of 18 18 of 18 6 of 6 
  Mean 0.123 0.252 11.9 25.2 44.3 
  Standard Dev. 0.00544 0.0112 0.784 1.34 1.21 
  %CV 4.4 4.4 6.6 5.3 2.7 
  Accuracy 102.7 97.7 99.0 104.9 92.3 
 
All intra- and inter-day accuracies and precision were below 15%, hence the method is accurate 
and precise for all analytes.  
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6.2. Specificity  
 
Specificity is the ability of the assay to measure only the intended analyte(s). Representative 
chromatograms of STD 1 for each of the six analytes separately as well as a chromatogram 
showing all the analytes together are presented in Figure 6.1 to 6.6. 
 
 
Figure 6.1: Representative chromatogram of STD 1: AcINH 
 
XIC of +MRM (18 pairs): 180.011/121.000 Da ID: AcINH 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 1.1e6 cps.
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Figure 6.2: Representative chromatogram of STD 1: desRIF 
 
XIC of +MRM (18 pairs): 781.469/749.500 Da ID: desRMP 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 5.1e5 cps.
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Figure 6.3: Representative chromatogram of STD 1: EMB 
 
XIC of +MRM (18 pairs): 205.144/116.100 Da ID: EMB 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 9.8e5 cps.
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Figure 6.4: Representative chromatogram of STD 1: INH 
 
XIC of +MRM (18 pairs): 137.933/79.100 Da ID: INH 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 6.2e5 cps.
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Figure 6.5: Representative chromatogram of STD 1: PZA 
 
XIC of +MRM (18 pairs): 123.972/81.000 Da ID: PZA 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 2.7e6 cps.
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Figure 6.6: Representative chromatogram of STD 1: RIF 
 
XIC of +MRM (18 pairs): 823.428/791.600 Da ID: RMP 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 1.6e6 cps.
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Figure 6.7: Representative chromatogram of STD 1 for all six analytes: Acetyl Isoniazid, 25-
Desacetyl Rifampicin, Ethambutol, Isoniazid, Pyrazinamide and Rifampicin 
 
6.3. Sensitivity 
 
Six different lots of matrix were prepared at the LLOQ concentration and extracted, to 
determine the average signal:noise (S/N) ratio at LLOQ. Representative chromatograms for 
each analyte are presented in Figures 6.8 to 6.13. 
 
XIC of +MRM (18 pairs): 180.011/121.000 Da ID: AcINH 1 from Sample 1 (S1) of 1002.wiff (Turbo Spray) Max. 1.1e6 cps.
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Figure 6.8: AcINH Raw chromatogram: Sample 1 spiked at LLOQ 
 
XIC of +MRM (18 pairs): 180.011/121.000 Da ID: AcINH 1 from Sample 1 (LLOQ1) of 004.wiff (Turbo Spray) Max. 5075.0 cps.
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Figure 6.9: desRIF Raw chromatogram: Sample 1 spiked at LLOQ 
 
 
Figure 6.10: EMB Raw chromatogram: Sample 1 spiked at LLOQ 
XIC of +MRM (18 pairs): 781.469/749.500 Da ID: desRIF 1 from Sample 1 (LLOQ1) of 004.wiff (Turbo Spray) Max. 1525.0 cps.
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Figure 6.11: INH Raw chromatogram: Sample 1 spiked at LLOQ 
 
 
Figure 6.12: PZA Raw chromatogram: Sample 1 spiked at LLOQ 
XIC of +MRM (18 pairs): 137.933/79.100 Da ID: INH 1 from Sample 1 (LLOQ1) of 004.wiff (Turbo Spray) Max. 5125.0 cps.
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Figure 6.13: RIF Raw chromatogram: Sample 1 spiked at LLOQ 
 
Average S/N ratios of 14.2, 8.43, 44.2, 7.52, 40.2 and 28.5 for AcINH, desRIF, EMB, INH, 
PZA and RIF respectively, calculated from 6 LLOQ samples were obtained. Average S/N ratio 
must be above 5 to meet the acceptance criteria for sensitivity, therefore the method was 
sensitive enough for all analytes. 
 
6.4. Stability  
 
Various stability experiments were performed to show that all the necessary precautions were 
taken to ensure that the analyte concentrations were not affected by the assay procedure or 
associated conditions. 
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6.4.1. Stock solution accuracy and stability 
 
6.4.1.1. Stock solution accuracy 
 
Two stock solutions (SS1 and SS2) of each of the analytes AcINH, desRIF, EMB, INH, PZA 
and RIF were prepared in methanol. Accuracy was determined by comparing the stock 
solutions prepared by two different analysts on the same day using ultraviolet-visible 
spectrophotometry for all analytes except EMB. The absorbance of each stock solution, 
prepared in triplicate in methanol at 30.0 (AcINH, desRIF,  INH, RIF) or 50 μg/ml (PZA), were 
measured at specific wavelengths and compared. The stock solution accuracy of two stock 
solutions (SS1 and SS2) of EMB, prepared by two different analysts on the same day, was 
determined by LC/MS/MS analysis. Analyte solutions were prepared in triplicate in methanol 
at 3.0 μg/ml. The results are presented in Tables 6.13 – 6.18 below. 
 
Table 6.13: Stock solution accuracy of AcINH solutions measured at a wavelength of 204 nm 
 Absorbance at λ = 204 nm (AU) 
 
AJ_22Jun2018 MM_22Jun2018 
Absorbance A 1.48 1.41 
Absorbance B 1.48 1.41 
Absorbance C 1.48 1.41 
Average 1.48 1.41 
STDEV 0.00414 0.00372 
% CV 0.28 0.26 
% Difference   -4.7 
  
 
 
  124 
Table 6.14: Stock solution accuracy of desRIF solutions measured at a wavelength of 237 nm 
 Absorbance at  λ = 237 nm (AU) 
 
AJ_22Jun2018 WvD_18Jun2018 
Absorbance A 1.24 1.23 
Absorbance B 1.24 1.23 
Absorbance C 1.24 1.23 
Average 1.24 1.23 
STDEV 0.00175 0.000513 
% CV 0.14 0.04 
% Difference   -0.8 
 
 
Table 6.15: Stock solution accuracy of EMB solutions 
Reference 
   
AJ_22Jun2018 Analyte Peak area ISTD peak area Peak Area Ratio 
Injection 1 2310000 6600000 0.350 
Injection 2 2170000 6210000 0.349 
Injection 3 1740000 4950000 0.352 
Injection 4 2130000 6290000 0.339 
Injection 5 1100000 3100000 0.355 
Injection 6 1800000 5220000 0.345 
Average 1875000 5395000 0.348 
STDEV 439488 1297147 0.01 
% CV 23.4 24.0 1.6 
Test    
MM_22Jun2018 Analyte Peak area ISTD peak area Peak Area Ratio 
Injection 1 2140000 6030000 0.355 
Injection 2 2280000 6080000 0.375 
Injection 3 1340000 3720000 0.360 
Injection 4 1350000 3800000 0.355 
Injection 5 1150000 3180000 0.362 
Injection 6 1740000 4780000 0.364 
Average 1666667 4598333 0.362 
STDEV 464658 1240845 0.007 
% CV 27.9 27.0 2.0 
% Difference 3.9 
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Table 6.16: Stock solution accuracy of INH solutions measured at a wavelength of 204 nm 
 
Absorbance at λ = 204 nm (AU) 
 
AJ_22Jun2018 MM_22Jun2018 
Absorbance A 1.72 1.65 
Absorbance B 1.69 1.67 
Absorbance C 1.70 1.65 
Average 1.70 1.66 
STDEV 0.012 0.01 
% CV 0.7 0.6 
% Difference   -2.7 
 
 
Table 6.17: Stock solution accuracy of PZA solutions measured at a wavelength of 211 nm 
 Absorbance at λ = 211 nm (AU) 
 
AJ_22Jun2018 MM_22Jun2018 
Absorbance A 2.78 2.91 
Absorbance B 2.78 2.87 
Absorbance C 2.78 2.91 
Average 2.78 2.90 
STDEV 0.00355 0.0184 
% CV 0.1 0.6 
% Difference   4.1 
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Table 6.18: Stock solution accuracy of RIF solutions measured at a wavelength of 237 nm 
 Absorbance at λ = 237 nm (AU) 
 
AJ_22Jun2018 MM_22Jun2018 
Absorbance A 1.24 1.22 
Absorbance B 1.24 1.22 
Absorbance C 1.24 1.22 
Average 1.24 1.22 
STDEV 0.00182 0.000666 
% CV 0.2 0.1 
% Difference   -1.6 
 
6.4.1.2. Stock solution stability 
 
Stock solution stability was not tested in this validation because all analyte stock solutions have 
been shown to be stable at -800C in previous validations for the single drug assays (90-93). 
 
6.4.2. Working solution stability 
 
Working stock solutions, WS11 and WS15, containing AcINH, desRIF, EMB, INH, PZA and 
RIF were prepared in methanol. Aliquots of the working solutions were kept at room 
temperature and at ~4°C and frozen at ~-20°C and ~-80°C for 24 hours. The stability of the 
working solutions under these conditions for 24 hours was determined by comparing freshly 
prepared working solutions against the stored solutions. The results are shown in Tables 6.19 
- 6.24 below. 
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Table 6.19: AcINH stability in high and low concentration working solutions at room temperature, 
~4°C, ~-20°C and ~-80°C for 24 hours 
 High Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 3.34 3.31 3.46 3.57 3.22 
Peak area ratio 2 3.20 3.32 3.53 3.59 3.29 
Peak area ratio 3 2.47 3.55 3.42 2.58 3.28 
Peak area ratio 4 2.54 3.59 3.43 2.52 3.30 
Peak area ratio 5 3.52 3.40 3.65 3.70 3.32 
Peak area ratio 6 3.42 3.50 3.71 3.60 3.27 
Average 3.08 3.45 3.53 3.26 3.28 
STDEV 0.459 0.119 0.121 0.552 0.0341 
% CV 14.9 3.5 3.4 16.9 1.0 
% Difference   11.8 14.7 5.8 6.4 
 Low Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 0.0215 0.0185 0.0224 0.0218 0.0189 
Peak area ratio 2 0.0233 0.0221 0.0237 0.0191 0.0209 
Peak area ratio 3 0.0229 0.0199 0.0269 0.0226 0.0208 
Peak area ratio 4 0.0207 0.0204 0.0275 0.0196 0.0206 
Peak area ratio 5 0.0229 0.0217 0.0238 0.0216 0.0163 
Peak area ratio 6 0.0235 0.0217 0.0242 0.0206 0.0191 
Average 0.0225 0.0207 0.0248 0.0209 0.0194 
STDEV 0.00111 0.00138 0.002 0.00136 0.00177 
% CV 5.0 6.7 8.1 6.5 9.1 
% Difference   -7.8 10.2 -7.0 -13.5 
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Table 6.20: desRIF stability in high and low concentration working solutions at room temperature, 
~4°C, ~-20°C and ~-80°C for 24 hours 
 High Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 6.36 6.04 6.86 6.90 6.09 
Peak area ratio 2 6.57 6.13 7.35 6.79 5.99 
Peak area ratio 3 4.68 6.37 6.77 4.98 5.88 
Peak area ratio 4 5.24 6.20 6.33 4.87 6.91 
Peak area ratio 5 6.52 6.49 6.34 7.28 5.97 
Peak area ratio 6 7.00 6.52 6.58 6.85 6.36 
Average 6.06 6.29 6.71 6.28 6.20 
STDEV 0.897 0.198 0.383 1.06 0.385 
% CV 14.8 3.1 5.7 16.9 6.2 
% Difference   3.8 10.6 3.6 2.3 
 Low Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 0.0437 0.0405 0.0459 0.0424 0.0580 
Peak area ratio 2 0.045 0.0418 0.0482 0.0509 0.0479 
Peak area ratio 3 0.0516 0.0439 0.0604 0.0456 0.0432 
Peak area ratio 4 0.0455 0.0469 0.0630 0.0530 0.0526 
Peak area ratio 5 0.0440 0.0448 0.0497 0.0505 0.0490 
Peak area ratio 6 0.0538 0.0568 0.0557 0.0441 0.0432 
Average 0.0473 0.0458 0.0538 0.0478 0.0490 
STDEV 0.00432 0.00585 0.00696 0.00428 0.0057 
% CV 9.1 12.8 12.9 9.0 11.6 
% Difference   -3.1 13.9 1.0 3.6 
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Table 6.21: EMB Stability in high and low concentration working solutions at room temperature, 
~4°C, ~-20°C and ~-80°C for 24 hours  
 High Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 6.99 7.03 7.49 7.77 7.97 
Peak area ratio 2 7.30 7.22 7.31 7.54 7.76 
Peak area ratio 3 [5.30] 7.57 7.10 [5.50] 7.62 
Peak area ratio 4 [5.14] 7.80 6.96 5.75 7.66 
Peak area ratio 5 7.44 7.65 7.68 7.86 7.44 
Peak area ratio 6 7.41 7.51 7.43 7.82 8.16 
Average 7.29 7.46 7.33 7.35 7.77 
STDEV 0.206 0.286 0.264 0.9 0.259 
% CV 2.8 3.8 3.6 12.3 3.3 
% Difference   2.4 0.6 0.9 6.6 
[] = statistical 
Outlier      
 Low Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 0.0421 0.0452 0.0454 0.0378 0.0456 
Peak area ratio 2 0.0430 0.0468 0.0455 0.0415 0.0450 
Peak area ratio 3 0.0452 0.0428 0.0552 0.0477 0.0412 
Peak area ratio 4 0.0421 0.0411 0.0550 0.0499 0.0420 
Peak area ratio 5 0.0456 0.0446 0.0476 0.0463 0.0461 
Peak area ratio 6 0.0491 0.0389 0.0461 0.0442 0.0427 
Average 0.0445 0.0432 0.0491 0.0446 0.0438 
STDEV 0.00271 0.0029 0.00469 0.0044 0.00206 
% CV 6.1 6.7 9.5 9.9 4.7 
% Difference   -2.9 10.4 0.1 -1.7 
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Table 6.22: INH Stability in high and low concentration working solutions at room temperature, 
~4°C, ~-20°C and ~-80°C for 24 hours 
 High Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 5.52 5.43 5.81 6.38 5.63 
Peak area ratio 2 5.46 5.74 5.77 6.19 5.69 
Peak area ratio 3 4.47 5.83 5.82 4.36 5.47 
Peak area ratio 4 4.45 6.45 5.72 4.73 5.66 
Peak area ratio 5 6.00 5.56 5.92 6.57 5.65 
Peak area ratio 6 5.91 6.67 6.06 6.37 5.77 
Average 5.30 5.95 5.85 5.77 5.65 
STDEV 0.685 0.5 0.122 0.961 0.099 
% CV 12.9 8.4 2.1 16.7 1.7 
% Difference   12.2 10.3 8.8 6.5 
 Low Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 0.170 0.162 0.161 0.181 0.160 
Peak area ratio 2 0.158 0.163 0.173 0.164 0.160 
Peak area ratio 3 0.174 0.174 0.175 0.163 0.159 
Peak area ratio 4 0.168 0.168 0.174 0.173 0.175 
Peak area ratio 5 0.159 0.158 0.180 0.161 0.177 
Peak area ratio 6 0.162 0.157 0.161 0.167 0.175 
Average 0.165 0.164 0.171 0.168 0.168 
STDEV 0.00646 0.00641 0.00787 0.00755 0.0088 
% CV 3.9 3.9 4.6 4.5 5.2 
% Difference   -0.9 3.3 1.8 1.5 
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Table 6.23: PZA Stability in high and low concentration working solutions at room temperature, 
~4°C, ~-20°C and ~-80°C for 24 hours 
 High Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 5.68 5.70 5.76 5.90 5.54 
Peak area ratio 2 5.69 5.67 5.82 5.98 5.48 
Peak area ratio 3 4.55 6.16 5.63 4.56 5.58 
Peak area ratio 4 4.61 6.09 5.86 4.51 5.31 
Peak area ratio 5 6.07 5.97 5.82 5.88 5.34 
Peak area ratio 6 5.88 5.97 5.91 5.90 5.53 
Average 5.41 5.93 5.80 5.46 5.46 
STDEV 0.661 0.201 0.097 0.714 0.112 
% CV 12.2 3.4 1.7 13.1 2.1 
% Difference   9.5 7.1 0.8 0.9 
 Low Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 0.0437 0.0418 0.0464 0.0403 0.0448 
Peak area ratio 2 0.0418 0.0430 0.0449 0.0403 0.0412 
Peak area ratio 3 0.0399 0.0412 0.0523 0.0442 0.0391 
Peak area ratio 4 0.0419 0.0402 0.0563 0.0447 0.0406 
Peak area ratio 5 0.0434 0.0413 0.0466 0.0428 0.0406 
Peak area ratio 6 0.0446 0.0405 0.0470 0.0427 0.0391 
Average 0.0426 0.0413 0.0489 0.0425 0.0409 
STDEV 0.00169 0.001 0.00442 0.00187 0.0021 
% CV 4.0 2.4 9.0 4.4 5.1 
% Difference   -2.9 15 -0.1 -3.9 
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Table 6.24: RIF Stability in high and low concentration working solutions at room temperature, ~4°C, 
~-20°C and ~-80°C for 24 hours 
 High Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 5.52 5.43 5.81 6.38 5.63 
Peak area ratio 2 5.46 5.74 5.77 6.19 5.69 
Peak area ratio 3 4.47 5.83 5.82 4.36 5.47 
Peak area ratio 4 4.45 6.45 5.72 4.73 5.66 
Peak area ratio 5 6.00 5.56 5.92 6.57 5.65 
Peak area ratio 6 5.91 6.67 6.06 6.37 5.77 
Average 5.30 5.95 5.85 5.77 5.65 
STDEV 0.685 0.5 0.122 0.961 0.099 
% CV 12.9 8.4 2.1 16.7 1.7 
% Difference   12.2 10.3 8.8 6.5 
 Low Concentration 
  
Reference 
Test Control Control Control 
 (Room temp) (~ 4 ºC)   (~- 20 ºC)   (~- 80 ºC)  
Peak area ratio 1 0.0105 0.0108 0.0102 0.00946 0.0109 
Peak area ratio 2 0.00928 0.0105 0.0108 0.00969 0.00991 
Peak area ratio 3 0.0109 0.00975 0.0138 0.0106 0.0101 
Peak area ratio 4 0.00941 0.0101 0.0133 0.011 0.0108 
Peak area ratio 5 0.0105 0.00934 0.0102 0.00978 0.00973 
Peak area ratio 6 0.0107 0.0102 0.0107 0.0102 0.00970 
Average 0.0102 0.0100 0.0115 0.0101 0.0102 
STDEV 0.000691 0.000521 0.00161 0.000591 0.000532 
% CV 6.8 5.2 14.0 5.8 5.2 
% Difference   -1 12.6 -0.9 -0.2 
 
 
Acceptance Criteria:  A CV(%) higher than 15% of the measured values and a difference of 
more than 15% from the reference solution, could indicate instability in the working solution. 
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The results indicate that high and low concentrations of Ethambutol and Pyrazinamide are 
stable for 24 hours at room temperature, ~4°C, ~-20°C and ~-80°C. The CV(%) of high 
concentrations of AcINH, desRIF, INH and RIF are greater than 15% when stored at ~-20°C 
for 24 hours, suggesting that there could be instability in these working solutions under these 
conditions . However, the variability could be a result of outliers, hence further investigations 
are necessary.  
 
6.4.3. Storage stability in matrix at -80°C 
 
Stability of the analytes in plasma has been previously determined and was not repeated for 
this validation. Previous reports indicate that AcINH and INH are stable for up to 104 days at 
-80°C (92). DesRIF and RIF are stable for up to 392 and 483 days respectively at -80°C (91). 
EMB is stable for up to 564 days at -80°C (90) and PZA is stable for up to 300 days at -80°C 
(93). 
 
6.4.4. Freeze and thaw stability 
 
To ascertain freeze-thaw stability, low- and high-quality controls were frozen at ~-80ºC, and 
put through three consecutive freeze and thaw cycles.  Sample aliquots were prepared and 
frozen for at least 24 hours prior to starting this experiment.  Each cycle consisted of sufficient 
thawing time at room temperature followed by ~20 hours freezing time. These samples were 
analysed against a freshly prepared valid calibration curve and assessed for accuracy against 
the nominal QC concentration. The measured concentrations and calculated differences after 
three cycles for the two sets of quality controls are presented in Tables 6.25 – 6.30. 
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Table 6.25: Freeze and thaw stability of AcINH 
 High Concentration  Low Concentration  
 Nominal QH  Observed FT QH Nominal QL  Observed FT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 10 9.34 0.107 0.0910 
Sample 2   9.18   0.0994 
Sample 3   9.24   0.0902 
Sample 4   9.40   0.0953 
Sample 5   8.96   0.0839 
Sample 6   9.41   0.0922 
 Average 9.26 Average 0.0920 
 STDEV 0.17 STDEV 0.0052 
 % CV 1.8 % CV 5.7 
 % Difference -7.4 % Difference -14.0 
 
 
Table 6.26: Freeze and thaw stability of desRIF 
 High Concentration  Low Concentration  
 Nominal QH  Observed FT QH Nominal QL  Observed FT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 8.00 8.33 0.0860 0.0758 
Sample 2   8.16   0.0644 
Sample 3   7.34   0.0843 
Sample 4   7.58   0.0898 
Sample 5   7.55   0.0825 
Sample 6   7.89   0.0852 
 Average 7.81 Average 0.0803 
 STDEV 0.385 STDEV 0.009 
 % CV 4.9 % CV 11.2 
 % Difference -2.4 % Difference -6.6 
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Table 6.27: Freeze and thaw stability of EMB 
 High Concentration  Low Concentration  
 Nominal QH  Observed FT QH Nominal QL  Observed FT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 4.00 3.98 0.0430 0.0400 
Sample 2   3.99   0.0420 
Sample 3   3.71   0.0435 
Sample 4   3.94   0.0455 
Sample 5   4.17   0.0357 
Sample 6   4.07   0.0394 
 Average 3.98 Average 0.0410 
 STDEV 0.154 STDEV 0.0034 
 % CV 3.9 % CV 8.4 
 % Difference -0.6 % Difference -4.6 
 
 
Table 6.28: Freeze and thaw stability of INH 
 High Concentration  Low Concentration  
 Nominal QH  Observed FT QH Nominal QL  Observed FT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 20.0 20.0 0.215 0.195 
Sample 2   19.9   0.197 
Sample 3   19.2   0.200 
Sample 4   20.4   0.204 
Sample 5   19.9   0.175 
Sample 6   19.9   0.198 
 Average 19.9 Average 0.195 
 STDEV 0.387 STDEV 0.0102 
 % CV 1.9 % CV 5.2 
 % Difference -0.6 % Difference -9.4 
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Table 6.29: Freeze and thaw stability of PZA 
 High Concentration  Low Concentration  
 Nominal QH  Observed FT QH Nominal QL  Observed FT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 64.0 59.3 0.688 0.611 
Sample 2   61.4   0.655 
Sample 3   54.4   0.639 
Sample 4   61.1   0.657 
Sample 5   61.4   0.620 
Sample 6   58.2   0.600 
 Average 59.3 Average 0.630 
 STDEV 2.73 STDEV 0.0236 
 % CV 4.6 % CV 3.8 
 % 
Difference 
-7.3 % Difference -8.4 
 
 
Table 6.30: Freeze and thaw stability of RIF 
 High Concentration  Low Concentration  
 Nominal QH  Observed FT QH Nominal QL  Observed FT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 24.0 24.8 0.258 0.252 
Sample 2   24.3   0.251 
Sample 3   24.6   0.246 
Sample 4   24.7   0.258 
Sample 5   24.2   0.229 
Sample 6   24.2   0.255 
 Average 24.5 Average 0.249 
 STDEV 0.266 STDEV 0.0104 
 % CV 1.1 % CV 4.2 
 % Difference 1.9 % Difference -3.7 
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Acceptance criteria:  A CV(%) and % Difference greater than 15% of the measured values 
could indicate freeze-thaw instability. 
 
The CV(%) and % Difference for each of the six analytes were within 15%, indicating that the 
analytes are stable in plasma for at least three freeze-thaw cycles. 
 
6.4.5. Bench top stability 
 
To ascertain benchtop stability, low- and high-quality controls were frozen at ~-80ºC, and 
subsequently left on the bench, kept on ice, for approximately 4 hours (maximum anticipated 
time that future study samples will be left thawed until extracted). These samples were analysed 
against a valid fresh calibration curve.  The measured concentrations and calculated accuracies 
for the quality controls are presented in Tables 6.31 - 6.36. 
 
Table 6.31: Stability of AcINH for ~4 hours on bench on ice 
 High Concentration  Low Concentration 
 Nominal QH  Observed BT QH Nominal QL  Observed BT QL 
 (µg/ml) (µg/ml)  (µg/ml)  (µg/ml)  
Sample 1 10.0 10.4 0.107 0.0953 
Sample 2   10.5   0.0949 
Sample 3   10.5   0.0940 
Sample 4   10.8   0.0982 
Sample 5   10.6   0.106 
Sample 6   11.1   0.109 
 Average 10.7 Average 0.100 
 STDEV 0.3 STDEV 0.01 
 % CV 2.4 % CV 6.4 
 % Difference 6.5 % Difference -6.9 
  138 
Table 6.32: Stability of desRIF for ~4 hours on bench on ice 
 High Concentration  Low Concentration 
 Nominal QH  Observed BT QH Nominal QL  Observed BT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 8.00 8.06 0.0860 0.0863 
Sample 2   8.30   0.0827 
Sample 3   9.06   0.0949 
Sample 4   7.85   0.0893 
Sample 5   8.23   0.0836 
Sample 6   7.30   0.0887 
 Average 8.13 Average 0.0876 
 STDEV 0.579 STDEV 0.004 
 % CV 7.1 % CV 5.1 
 % Difference 1.7 % Difference 1.8 
 
 
Table 6.33: Stability of Ethambutol for ~4 hours on bench on ice 
 High Concentration  Low Concentration 
 Nominal QH  Observed BT QH Nominal QL  Observed BT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 4.00 4.06 0.0430 0.0415 
Sample 2   4.50   0.0385 
Sample 3   4.24   0.0383 
Sample 4   4.43   0.0366 
Sample 5   4.54   0.0384 
Sample 6   4.31   0.0384 
 Average 4.35 Average 0.0386 
 STDEV 0.18 STDEV 0.002 
 % CV 4.2 % CV 4.1 
 % Difference 8.7 % Difference -10.2 
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Table 6.34: Stability of Isoniazid for ~4 hours on bench on ice 
 High Concentration  Low Concentration 
 Nominal QH  Observed BT QH Nominal QL  Observed BT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 20.0 20.7 0.215 0.186 
Sample 2   21.4   0.180 
Sample 3   20.7   0.203 
Sample 4   22.7   0.194 
Sample 5   20.8   0.188 
Sample 6   22.0   0.198 
 Average 21.4 Average 0.192 
 STDEV 0.823 STDEV 0.008 
 % CV 3.8 % CV 4.4 
 % Difference 6.9 % Difference -10.9 
 
 
Table 6.35: Stability of Pyrazinamide for ~4 hours on bench on ice 
 High Concentration  Low Concentration 
 Nominal QH  Observed BT QH Nominal QL  Observed BT QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 64.0 66.8 0.688 0.600 
Sample 2   71.3   0.558 
Sample 3   71.2   0.622 
Sample 4   69.0   0.637 
Sample 5   70.7   0.600 
Sample 6   71.4   0.622 
 Average 70.1 Average 0.607 
 STDEV 1.83 STDEV 0.028 
 % CV 2.6 % CV 4.6 
 % Difference 9.5 % Difference -11.8 
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Table 6.36 The stability of Rifampicin for ~4 hours on bench on ice 
 High Concentration  Low Concentration 
 Nominal QH  
Observed BT 
QH 
Nominal QL  
Observed BT 
QL 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 24.0 25.4 0.258 0.247 
Sample 2   25.8   0.246 
Sample 3   26.1   0.233 
Sample 4   26.4   0.236 
Sample 5   26.1   0.245 
Sample 6   26.7   0.227 
 Average 26.1 Average 0.239 
 STDEV 0.454 STDEV 0.008 
 % CV 1.7 % CV 3.4 
 % Difference 8.7 % Difference -7.4 
 
 
Acceptance criteria:  A CV(%) and % Difference greater than 15% of the measured values 
could indicate on-bench instability. 
 
The CV(%) and % Difference for all six analytes were within 15%. All analytes were therefore 
stable in plasma for at least 4 hours when kept on ice. 
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6.4.6. Reinjection reproducibility 
 
Reinjection reproducibility is evaluated to determine if an analytical run can be reanalysed by 
reinjection in the case of instrument interruptions.  Following the injection of a validation run 
(Validation 1), the extracted samples (in the 96-well plate) remain in the autosampler at the 
method-defined temperature for the following ~48 hours.  The analytical run is reinjected in its 
entirety after ~48 hours.  This will demonstrate reinjection reproducibility for ~48 hours as 
presented in Tables 6.37 – 6.48. 
 
Table 6.37: Calibration Standards Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
AcINH 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n  
(µg/ml) (µg/ml) 
S8 0.0500 0.0519 0.001 1.6 103.9 2 of 2 
S7 0.100 0.104 0.002 1.6 104.3 2 of 2 
S6 0.270 0.243 N/A N/A 90.0 1 of 2 
S5 0.670 0.667 0.034 5.1 99.6 2 of 2 
S4 1.67 1.61 0.123 7.6 96.6 2 of 2 
S3 4.17 4.08 0.004 0.1 97.8 2 of 2 
S2 8.33 8.72 0.18 2.1 104.7 2 of 2 
S1 12.5 12.3 0.591 4.8 98.1 2 of 2 
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Table 6.38: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
AcINH 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n 
(µg/ml) (µg/ml) 
LLOQ 0.0500 0.0471 0.002 3.8 94.2 6 of 6 
QCL 0.107 0.0970 0.007 7.6 90.6 6 of 6 
QCM 5.00 4.54 0.261 5.7 90.8 6 of 6 
QCH 10.0 10.2 0.2 1.9 102.4 6 of 6 
 
 
Table 6.39: Calibration Standards Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
desRIF 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n  
ng/ml ng/ml 
S8 0.0400 0.0406 0.006 15.2 101.4 2 of 2 
S7 0.0800 0.0877 0.001 1.3 109.6 2 of 2 
S6 0.213 0.190 0.008 4.4 89.4 2 of 2 
S5 0.533 0.541 0.039 7.2 101.5 2 of 2 
S4 1.33 1.28 0.2 15.7 96.2 2 of 2 
S3 3.33 3.38 0.259 7.7 101.4 2 of 2 
S2 6.67 6.81 0.318 4.7 102.0 2 of 2 
S1 10.0 9.84 0.478 4.9 98.4 2 of 2 
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Table 6.40: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
desRIF 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n 
ng/ml ng/ml 
LLOQ 0.0400 0.0360 0.004 10.5 89.9 6 of 6 
QCL 0.0860 0.0783 0.004 5.1 91.1 6 of 6 
QCM 4.00 3.66 0.333 9.1 91.5 6 of 6 
QCH 8.00 8.23 0.48 5.9 102.8 6 of 6 
 
 
Table 6.41: Calibration Standards Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
EMB 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n  
ng/ml ng/ml 
S8 0.0200 0.0221 0.001 3.5 110.6 2 of 2 
S7 0.0400 0.0421 0.001 3.1 105.3 2 of 2 
S6 0.107 0.0985 0.005 5.0 92.0 2 of 2 
S5 0.267 0.254 0.007 2.8 95.0 2 of 2 
S4 0.667 0.632 0.033 5.3 94.8 2 of 2 
S3 1.67 1.65 0.005 0.3 99.0 2 of 2 
S2 3.33 3.52 0.285 8.1 105.7 2 of 2 
S1 5.00 4.88 0.155 3.2 97.6 2 of 2 
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Table 6.42: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: EMB 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n 
ng/ml ng/ml 
LLOQ 0.0200 0.0221 0.002 7.7 110.6 6 of 6 
QCL 0.0430 0.0429 0.001 3.2 99.7 6 of 6 
QCM 2.00 1.89 0.109 5.7 94.6 6 of 6 
QCH 4.00 4.08 0.201 4.9 102.0 6 of 6 
 
 
Table 6.43: Calibration Standards Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
INH 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n  
ng/ml ng/ml 
S8 0.100 0.110 N/A N/A 110.0 1 of 2 
S7 0.200 0.221 0.006 2.6 110.3 2 of 2 
S6 0.533 0.471 0.03 5.5 88.4 2 of 2 
S5 1.33 1.30 0.024 1.9 98.1 2 of 2 
S4 3.33 3.19 0.36 11.3 95.8 2 of 2 
S3 8.33 8.44 0.361 4.3 101.3 2 of 2 
S2 16.7 17.1 0.558 3.3 102.1 2 of 2 
S1 25.0 24.7 1.03 4.2 98.9 2 of 2 
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Table 6.44: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: INH 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n 
ng/ml ng/ml 
LLOQ 0.100 0.107 0.006 5.9 106.8 6 of 6 
QCL 0.215 0.190 0.017 9.1 88.2 5 of 6 
QCM 10.0 8.90 0.558 6.3 89.0 6 of 6 
QCH 20.0 19.8 0.358 1.8 99.2 6 of 6 
 
 
Table 6.45: Calibration Standards Accuracy and Precision – Validation 1 Reinjected after ~48 hours: 
PZA 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n  
ng/ml ng/ml 
S8 0.320 0.329 0.03 9.1 102.9 2 of 2 
S7 0.640 0.666 0.024 3.7 104.1 2 of 2 
S6 1.71 1.62 N/A N/A 94.5 1 of 2 
S5 4.27 4.31 0.098 2.3 101.0 2 of 2 
S4 10.7 9.80 0.715 7.3 91.9 2 of 2 
S3 26.7 26.7 0.583 2.2 99.9 2 of 2 
S2 53.3 57.2 0.513 0.9 107.4 2 of 2 
S1 80.0 72.4 N/A N/A 90.5 1 of 2 
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Table 6.46: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: PZA 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n 
ng/ml ng/ml 
LLOQ 0.320 0.282 0.017 6.1 88.2 6 of 6 
QCL 0.688 0.572 0.028 5.0 83.2 6 of 6 
QCM 32.0 24.4 1.34 5.5 76.4 6 of 6 
QCH 64.0 59.0 2.11 3.6 92.1 6 of 6 
 
 
Table 6.47: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: RIF 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n  
ng/ml ng/ml 
S8 0.120 0.122 0.003 2.7 101.7 2 of 2 
S7 0.240 0.261 0.008 3.2 108.6 2 of 2 
S6 0.640 0.585 0.025 4.3 91.4 2 of 2 
S5 1.60 1.60 0.036 2.2 100.3 2 of 2 
S4 4.00 3.87 0.242 6.2 96.6 2 of 2 
S3 10.0 10.0 0.226 2.3 100.2 2 of 2 
S2 20.0 20.5 0.15 0.7 102.6 2 of 2 
S1 30.0 29.6 1.42 4.8 98.7 2 of 2 
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Table 6.48: Quality Control Accuracy and Precision – Validation 1 Reinjected after ~48 hours: RIF 
Sample 
ID 
Nominal 
Conc. 
Mean Observed 
Conc. Std Dev % CV 
% 
Accuracy 
n 
ng/ml ng/ml 
LLOQ 0.120 0.125 0.005 4.0 104.0 6 of 6 
QCL 0.258 0.255 0.008 3.1 98.9 6 of 6 
QCM 12.0 10.7 0.242 2.3 89.2 6 of 6 
QCH 24.0 24.2 0.278 1.1 100.8 6 of 6 
 
 
Accuracy must be within 15% (between 85% - 115%) and precision <15%.   The CV(%) and 
% Accuracy for the all of the analytes, except PZA, were within 15% indicating that an entire 
batch, stored at 8°C in the autosampler, may be re-injected after ~48 hours for analysing these 
analytes. Re-injection after 24 hours was done as well and the CV(%) and %Accuracy for all 
of the analytes, except Pyrazinamide, are within 15% and no differences in trends in the data 
recorded after 24 and 48 hour re-injections can be observed.  
 
The data indicated that Pyrazinamide cannot be re-injected after ~48 hours when stored at 8°C 
in the autosampler as the % Accuracy of quality controls QCL and QCM does not fall within 
the acceptance criteria of 85% - 115%. The % Accuracy for the re-injection of quality control 
QCM after 24 hours also failed to meet the acceptance criteria.   
 
6.4.7. Autosampler stability 
 
To assess autosampler stability, the first validation run was reinjected twice; after 
approximately 26 (re-injection 1) and 50 (re-injection 2) hours at 8°C. The reinjected high- and 
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low-quality control peak area ratios were compared to those obtained during the first injection 
to estimate the absolute autosampler stability over ~50 hours. Results for autosampler stability 
at ~ 50 hour are presented in Tables 6.49 - 60 
 
Table 6.49:  Autosampler stability for extracted samples: High concentration for Acetyl Isoniazid 
QC H (10.0 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 1840000 285000 6.46 
Injection 2 1910000 311000 6.14 
Injection 3 1990000 312000 6.38 
Injection 4 2040000 312000 6.54 
Injection 5 2090000 327000 6.39 
Injection 6 2100000 326000 6.44 
Average 1995000 312167 6.39 
STDEV 103296 15171 0.135 
% CV 5.2 4.9 2.1 
Validation 1 
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 3380000 540000 6.26 
Injection 8 3210000 530000 6.06 
Injection 9 3150000 512000 6.15 
Injection 10 3120000 515000 6.06 
Injection 11 3140000 506000 6.21 
Injection 12 3030000 479000 6.33 
Average 3171667 513667 6.18 
STDEV 117544 21097 0.109 
% CV 3.7 4.1 1.8 
% Difference after Re-injection 1 -3.4 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 3640000 584000 6.23 
Injection 14 3650000 600000 6.08 
Injection 15 3580000 587000 6.10 
Injection 16 3530000 571000 6.18 
Injection 17 3300000 539000 6.12 
Injection 18 3480000 546000 6.37 
Average 3530000 571167 6.18 
STDEV 129923 24145 0.109 
% CV 3.7 4.2 1.8 
% Difference after Re-injection 2 -3.3 
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Table 6.50: Autosampler stability for extracted samples: Low concentration for Acetyl Isoniazid 
QC L (0.107 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 17400 298000 0.0584 
Injection 2 17200 304000 0.0566 
Injection 3 20700 311000 0.0666 
Injection 4 22700 333000 0.0682 
Injection 5 20100 324000 0.0620 
Injection 6 21000 325000 0.0646 
Average 19850 315833 0.0627 
STDEV 2157 13615 0.00458 
% CV 10.9 4.3 7.3 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 36300 543000 0.0669 
Injection 8 35200 547000 0.0644 
Injection 9 33000 521000 0.0633 
Injection 10 31900 491000 0.0650 
Injection 11 31600 505000 0.0626 
Injection 12 32300 474000 0.0681 
Average 33383 513500 0.0650 
STDEV 1924 28940 0.00211 
% CV 5.8 5.6 3.3 
% Difference after Re-injection 1 3.7 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 38800 610000 0.0636 
Injection 14 34200 622000 0.0550 
Injection 15 38700 557000 0.0695 
Injection 16 35900 564000 0.0637 
Injection 17 36300 555000 0.0654 
Injection 18 34700 541000 0.0641 
Average 36433 574833 0.0635 
STDEV 1951 32969 0.00474 
% CV 5.4 5.7 7.5 
% Difference after Re-injection 2 1.3 
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Table 6.51: Autosampler stability for extracted samples: High concentration for 25-Desacetyl 
Rifampicin 
QC H (8.00 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 1750000 165000 10.6 
Injection 2 1660000 162000 10.2 
Injection 3 1720000 179000 9.61 
Injection 4 1820000 172000 10.6 
Injection 5 1820000 182000 10.0 
Injection 6 1720000 167000 10.3 
Average 1748333 171167 10.2 
STDEV 62743 7985 0.376 
% CV 3.6 4.7 3.7 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 1520000 163000 9.33 
Injection 8 1690000 173000 9.77 
Injection 9 1680000 168000 10.0 
Injection 10 1770000 168000 10.5 
Injection 11 1810000 161000 11.2 
Injection 12 1870000 176000 10.6 
Average 1723333 168167 10.2 
STDEV 122909 5707 0.686 
% CV 7.1 3.4 6.7 
% Difference after Re-injection 1 0.3 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 1490000 137000 10.9 
Injection 14 1520000 137000 11.1 
Injection 15 1400000 135000 10.4 
Injection 16 1460000 139000 10.5 
Injection 17 1370000 121000 11.3 
Injection 18 1340000 127000 10.6 
Average 1430000 132667 10.8 
STDEV 70993 7090 0.374 
% CV 5.0 5.3 3.5 
% Difference after Re-injection 2 5.5 
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Table 6.52: Autosampler stability for extracted samples: Low concentration for 25-Desacetyl 
Rifampicin 
QC L (0.0860 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 18500 127000 0.146 
Injection 2 19900 128000 0.155 
Injection 3 19900 128000 0.155 
Injection 4 23400 130000 0.180 
Injection 5 19600 135000 0.145 
Injection 6 23200 131000 0.177 
Average 20750 129833 0.160 
STDEV 2042 2927 0.0152 
% CV 9.8 2.3 9.5 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 21000 127000 0.165 
Injection 8 19100 130000 0.147 
Injection 9 21800 134000 0.163 
Injection 10 20600 134000 0.154 
Injection 11 22500 130000 0.173 
Injection 12 24100 142000 0.170 
Average 21517 132833 0.162 
STDEV 1713 5231 0.00990 
% CV 8.0 3.9 6.1 
% Difference after Re-injection 1 1.3 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 17600 121000 0.145 
Injection 14 16100 112000 0.144 
Injection 15 16800 111000 0.151 
Injection 16 16300 101000 0.161 
Injection 17 16100 109000 0.148 
Injection 18 15200 95800 0.159 
Average 16350 108300 0.151 
STDEV 802 8858 0.00721 
% CV 4.9 8.2 4.8 
% Difference after Re-injection 2 -5.3 
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Table 6.53: Autosampler stability for extracted samples: High concentration for Ethambutol 
QC H (8.00 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 1700000 124000 13.7 
Injection 2 1640000 119000 13.8 
Injection 3 1660000 125000 13.3 
Injection 4 1780000 114000 15.6 
Injection 5 1660000 118000 14.1 
Injection 6 1660000 117000 14.2 
Average 1683333 119500 14.1 
STDEV 51251 4231 0.803 
% CV 3.0 3.5 5.7 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 2800000 189000 14.8 
Injection 8 2740000 186000 14.7 
Injection 9 2670000 182000 14.7 
Injection 10 2440000 171000 14.3 
Injection 11 2450000 168000 14.6 
Injection 12 2410000 176000 13.7 
Average 2585000 178667 14.5 
STDEV 171668 8383 0.420 
% CV 6.6 4.7 2.9 
% Difference after Re-injection 1 2.5 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 3320000 230000 14.4 
Injection 14 3130000 235000 13.3 
Injection 15 3230000 219000 14.7 
Injection 16 3010000 203000 14.8 
Injection 17 2770000 204000 13.6 
Injection 18 2890000 208000 13.9 
Average 3058333 216500 14.1 
STDEV 208271 13722 0.629 
% CV 6.8 6.3 4.5 
% Difference after Re-injection 2 0.2 
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Table 6.54: Autosampler stability for extracted samples: Low concentration for Ethambutol 
QC L (0.0430 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 24300 170000 0.143 
Injection 2 22900 151000 0.152 
Injection 3 26000 154000 0.169 
Injection 4 26600 154000 0.173 
Injection 5 24200 155000 0.156 
Injection 6 21700 151000 0.144 
Average 24283 155833 0.156 
STDEV 1839 7139 0.01253 
% CV 7.6 4.6 8.0 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 38700 254000 0.152 
Injection 8 35400 235000 0.151 
Injection 9 38800 223000 0.174 
Injection 10 36100 213000 0.169 
Injection 11 35700 221000 0.162 
Injection 12 33100 212000 0.156 
Average 36300 226333 0.161 
STDEV 2166 15895 0.00945 
% CV 6.0 7.0 5.9 
% Difference after Re-injection 1 3.0 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 45200 294000 0.154 
Injection 14 46900 291000 0.161 
Injection 15 43200 263000 0.164 
Injection 16 43400 259000 0.168 
Injection 17 42300 255000 0.166 
Injection 18 41100 247000 0.166 
Average 43683 268167 0.163 
STDEV 2076 19600 0.00512 
% CV 4.8 7.3 3.1 
% Difference after Re-injection 2 4.6 
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Table 6.55: Autosampler stability for extracted samples: High concentration for Isoniazid 
QC H (20.0 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 1290000 165000 7.82 
Injection 2 1330000 177000 7.51 
Injection 3 1360000 174000 7.82 
Injection 4 1420000 184000 7.72 
Injection 5 1440000 189000 7.62 
Injection 6 1420000 185000 7.68 
Average 1376667 179000 7.69 
STDEV 59554 8786 0.118 
% CV 4.3 4.9 1.5 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 2240000 301000 7.44 
Injection 8 2130000 292000 7.29 
Injection 9 2080000 275000 7.56 
Injection 10 2000000 276000 7.25 
Injection 11 1990000 265000 7.51 
Injection 12 1970000 269000 7.32 
Average 2068333 279667 7.40 
STDEV 103811 13938 0.127 
% CV 5.0 5.0 1.7 
% Difference after Re-injection 1 -3.9 
Validation 1  
Re-injection 
Peak area ISTD peak area Ratio 
Injection 13 2180000 296000 7.36 
Injection 14 2130000 296000 7.20 
Injection 15 2080000 289000 7.20 
Injection 16 2050000 289000 7.09 
Injection 17 2000000 282000 7.09 
Injection 18 2010000 285000 7.05 
Average 2075000 289500 7.17 
STDEV 70071 5683 0.114 
% CV 3.4 2.0 1.6 
% Difference after Re-injection 2 -6.9 
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Table 6.56: Autosampler stability for extracted samples: Low concentration for Isoniazid 
QC L (0.215 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 12700 171000 0.0743 
Injection 2 13300 168000 0.0792 
Injection 3 15200 182000 0.0835 
Injection 4 15300 186000 0.0823 
Injection 5 17000 187000 0.0909 
Injection 6 16700 185000 0.0903 
Average 15033 179833 0.0834 
STDEV 1743 8232 0.00642 
% CV 11.6 4.6 7.7 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 32200 301000 0.107 
Injection 8 31300 294000 0.106 
Injection 9 28900 270000 0.107 
Injection 10 28800 267000 0.108 
Injection 11 27600 268000 0.103 
Injection 12 27900 248000 0.113 
Average 29450 274667 0.107 
STDEV 1873 19511 0.00306 
% CV 6.4 7.1 2.9 
% Difference after Re-injection 1 28.7 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 32800 301000 0.109 
Injection 14 32200 293000 0.110 
Injection 15 35700 287000 0.124 
Injection 16 28200 290000 0.0972 
Injection 17 32600 280000 0.116 
Injection 18 32000 267000 0.120 
Average 32250 286333 0.113 
STDEV 2400 11725 0.00962 
% CV 7.4 4.1 8.5 
% Difference after Re-injection 2 35.3 
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Table 6.57: Autosampler stability for extracted samples: High concentration for Pyrazinamide 
QC H (64.0 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 3240000 279000 11.6 
Injection 2 3670000 330000 11.1 
Injection 3 4160000 357000 11.7 
Injection 4 4290000 377000 11.4 
Injection 5 4530000 414000 10.9 
Injection 6 4980000 414000 12.0 
Average 4145000 361833 11.5 
STDEV 618280 52098 0.393 
% CV 14.9 14.4 3.4 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 7930000 729000 10.9 
Injection 8 7520000 703000 10.7 
Injection 9 7560000 701000 10.8 
Injection 10 7510000 692000 10.9 
Injection 11 7430000 654000 11.4 
Injection 12 7420000 672000 11.0 
Average 7561667 691833 10.9 
STDEV 188406 26134 0.238 
% CV 2.5 3.8 2.2 
% Difference after Re-injection 1 -4.5 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 8030000 798000 10.1 
Injection 14 8370000 816000 10.3 
Injection 15 8050000 769000 10.5 
Injection 16 7860000 760000 10.3 
Injection 17 7970000 745000 10.7 
Injection 18 7900000 741000 10.7 
Average 8030000 771500 10.4 
STDEV 181879 29845 0.244 
% CV 2.3 3.9 2.3 
% Difference after Re-injection 2 -9.1 
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Table 6.58: Autosampler stability for extracted samples: Low concentration for Pyrazinamide 
QC L (0.688 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 42300 305000 0.139 
Injection 2 50600 354000 0.143 
Injection 3 53200 381000 0.140 
Injection 4 57100 430000 0.133 
Injection 5 59900 434000 0.138 
Injection 6 64900 446000 0.146 
Average 54667 391667 0.140 
STDEV 7870 55240 0.00438 
% CV 14.4 14.1 3.1 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 113000 792000 0.143 
Injection 8 104000 780000 0.133 
Injection 9 108000 756000 0.143 
Injection 10 100000 728000 0.137 
Injection 11 109000 741000 0.147 
Injection 12 104000 701000 0.148 
Average 106333 749667 0.142 
STDEV 4590 33661 0.00573 
% CV 4.3 4.5 4.0 
% Difference after Re-injection 1 1.7 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 121000 867000 0.140 
Injection 14 117000 875000 0.134 
Injection 15 111000 804000 0.138 
Injection 16 115000 807000 0.143 
Injection 17 114000 827000 0.138 
Injection 18 121000 792000 0.153 
Average 116500 828667 0.141 
STDEV 3987 34760 0.00655 
% CV 3.4 4.2 4.7 
% Difference after Re-injection 2 0.8 
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Table 6.59: Autosampler stability for extracted samples: High concentration for Rifampicin 
QC H (24.0 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 7660000 2100000 3.65 
Injection 2 7390000 2060000 3.59 
Injection 3 7650000 2190000 3.49 
Injection 4 7590000 2150000 3.53 
Injection 5 7450000 2120000 3.51 
Injection 6 7430000 2120000 3.50 
Average 7528333 2123333 3.55 
STDEV 119066 44121 0.060 
% CV 1.6 2.1 1.7 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 5980000 1650000 3.62 
Injection 8 6020000 1680000 3.58 
Injection 9 5860000 1640000 3.57 
Injection 10 5970000 1690000 3.53 
Injection 11 5940000 1610000 3.69 
Injection 12 5940000 1630000 3.64 
Average 5951667 1650000 3.61 
STDEV 53821 30332 0.056 
% CV 0.9 1.8 1.6 
% Difference after Re-injection 1 1.7 
Validation  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 4960000 1340000 3.70 
Injection 14 4990000 1340000 3.72 
Injection 15 5060000 1390000 3.64 
Injection 16 4960000 1360000 3.65 
Injection 17 4890000 1340000 3.65 
Injection 18 4980000 1350000 3.69 
Average 4973333 1353333 3.68 
STDEV 55015 19664 0.034 
% CV 1.1 1.5 0.9 
% Difference after Re-injection 2 3.6 
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Table 6.60: Autosampler stability for extracted samples: Low concentration for Rifampicin 
QC L (0.258 µg/ml) 
Validation 1  
Batch End 
Peak area ISTD peak area Ratio 
Injection 1 101000 2290000 0.0441 
Injection 2 92000 2130000 0.0432 
Injection 3 99000 2250000 0.0440 
Injection 4 99600 2240000 0.0445 
Injection 5 98500 2160000 0.0456 
Injection 6 101000 2110000 0.0479 
Average 98517 2196667 0.0449 
STDEV 3353 73121 0.00166 
% CV 3.4 3.3 3.7 
Validation 1  
Re-injection 1 
Peak area ISTD peak area Ratio 
Injection 7 72100 1600000 0.0451 
Injection 8 60400 1410000 0.0428 
Injection 9 75400 1610000 0.0468 
Injection 10 73700 1620000 0.0455 
Injection 11 74700 1680000 0.0445 
Injection 12 82000 1660000 0.0494 
Average 73050 1596667 0.0457 
STDEV 7067 96471 0.00224 
% CV 9.7 6.0 4.9 
% Difference after Re-injection 1 1.8 
Validation 1  
Re-injection 2 
Peak area ISTD peak area Ratio 
Injection 13 59100 1360000 0.0435 
Injection 14 52300 1120000 0.0467 
Injection 15 56700 1240000 0.0457 
Injection 16 53000 1150000 0.0461 
Injection 17 54400 1240000 0.0439 
Injection 18 55500 1190000 0.0466 
Average 55167 1216667 0.0454 
STDEV 2507 85010 0.00141 
% CV 4.5 7.0 3.1 
% Difference after Re-injection 2 1.2 
 
 
The CV(%) and % Difference for all analytes except INH were within 15% after both re-
injections, indicating that the internal standards compensate for any changes in the assay for 
these analytes. Absolute on-instrument stability for these analytes was indicated for at least 50 
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hours. For INH, the % Difference after reinjection was 28.7 % at ~26 hours and 35.3 % after ~ 
50 hours, indicating instability. 
 
6.4.8. Whole blood stability 
 
Previous reports indicate that AcINH INH are stable in whole blood for one and two hours 
respectively when kept on ice (VL2010-125 V3.2). PZA and RIF are stable in whole blood for 
two hours at room temperature (VL2012-144 V2.1, VL2004-107 V7.1). The stability of desRIF 
and EMB in whole blood will be determined at a later stage.  
 
6.5. Recovery  
 
The extraction recovery pertains to the extraction efficiency of the analytical process within 
the limits of variability.  It was determined by comparing the analytical response of blank 
matrix spiked with the analyte then extracted with the response of the blank matrix first 
extracted and then spiked with analyte (theoretical, represents 100% recovery).   
 
Acceptance criteria: The recovery of a quantitative drug assay method should be consistent, 
and the precision of the measured recovery, expressed as percentage coefficient of variation, 
should not exceed 15% for any concentration of the analyte at which it is determined. Recovery 
reproducibility between concentration levels should not be >15%. 
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a. Extracted (test) samples:  Six QCs at each concentration level in six different lots of matrix 
(low, medium and high) were extracted as per the analytical method. 
b. Theoretical samples: Samples from the same sources as above were spiked with analytes 
post extraction, at each QC concentration level (relative to the final concentration of the 
corresponding extracted QC’s level) in six-fold. 
 
The analyte peak areas found after extraction were compared to the theoretical peak area and 
were expressed as a percentage recovery. The results of the recovery experiments are shown in 
Tables 6.61- 6.66 below. 
 
Table 6.61: AcINH recovery  
  
High Concentration Medium Concentration Low Concentration 
(10.0 µg/ml) (5.00 µg/ml) (0.107 µg/ml) 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Sample 1 6.26 5.32 3.03 2.74 0.318 0.271 
Sample 2 5.99 5.5 2.95 2.74 0.318 0.322 
Sample 3 5.98 5.89 3 2.74 0.315 0.317 
Sample 4 5.91 5.48 2.87 2.75 0.311 0.297 
Sample 5 6.06 5.47 2.99 2.86 0.288 0.313 
Sample 6 6.1 5.47 3.1 2.85 0.319 0.303 
Average 6.05 5.52 2.99 2.78 0.312 0.304 
STDEV 0.122 0.192 0.0772 0.0583 0.0119 0.0185 
% CV 2 3.5 2.6 2.1 3.8 6.1 
% 
Recovery 
  109.6   107.6   102.5 
    Average % Recovery 106.5 
 
   Average % CV 3.4 
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Table 6.62: desRIF recovery 
  
High Concentration Medium Concentration Low Concentration 
(8.00 µg/ml) (4.00 µg/ml) (0.0860 µg/ml) 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Sample 1 10.5 8.97 6.31 5.15 0.873 0.605 
Sample 2 10.6 9.19 5.85 4.93 0.823 0.645 
Sample 3 10.6 9.19 5.98 4.89 0.909 0.659 
Sample 4 10.7 8.83 6.01 4.96 0.795 0.704 
Sample 5 10.7 8.59 6.31 5.45 0.84 0.656 
Sample 6 10.7 8.34 6.21 4.61 0.806 0.702 
Average 10.6 8.85 6.11 5 0.841 0.662 
STDEV 0.0816 0.339 0.192 0.281 0.0432 0.0373 
% CV 0.8 3.8 3.1 5.6 5.1 5.6 
% 
Recovery 
  120.1   122.3   127.1 
    Average % Recovery 123.2 
 
   Average % CV 2.9 
 
 
Table 6.63: EMB recovery 
  
High Concentration Medium Concentration Low Concentration 
(4.00 µg/ml) (2.00 µg/ml) (0.0430 µg/ml) 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Sample 1 14.4 13.4 8.08 7.26 0.834 0.822 
Sample 2 15.9 14.6 8.59 7.32 0.845 0.862 
Sample 3 14.4 14.7 8.32 7.58 0.859 0.89 
Sample 4 15.3 15 8.7 7.18 0.862 0.888 
Sample 5 15.5 14.2 8.26 7.88 0.886 0.815 
Sample 6 14.5 15.1 7.86 7.37 0.879 0.857 
Average 15 14.5 8.3 7.43 0.861 0.856 
STDEV 0.651 0.626 0.312 0.258 0.0197 0.0318 
% CV 4.3 4.3 3.8 3.5 2.3 3.7 
% 
Recovery 
  103.4   111.7   100.6 
    Average % Recovery 105.3 
 
   Average % CV 5.5 
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Table 6.64: INH recovery 
  
High Concentration Medium Concentration Low Concentration 
(20.0 µg/ml) (10.0 µg/ml) (0.215 µg/ml) 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Extracted:     
Peak Area 
Ratio 
Theoretical:       
Peak Area 
Ratio 
Sample 1 5.66 4.71 2.54 2.36 0.306 0.281 
Sample 2 5.43 4.68 2.8 2.52 0.285 0.311 
Sample 3 5.4 4.92 2.6 2.44 0.346 0.295 
Sample 4 5.58 5 2.65 2.3 0.303 0.29 
Sample 5 5.14 4.85 2.65 2.3 0.322 0.299 
Sample 6 5.35 4.95 2.66 2.23 0.311 0.291 
Average 5.43 4.85 2.65 2.36 0.312 0.295 
STDEV 0.183 0.131 0.0863 0.106 0.0205 0.0101 
% CV 3.4 2.7 3.3 4.5 6.6 3.4 
% 
Recovery 
  111.9   112.4   106 
    Average % Recovery 110.1 
 
   Average % CV 3.2 
 
Table 6.65: Pyrazinamide recovery 
  
High Concentration Medium Concentration Low Concentration 
(64.0 µg/ml) (32.0 µg/ml) (0.688 µg/ml) 
Extraction:     
Peak Area 
Ratio 
Spiked Blank:       
Peak Area 
Ratio 
Extraction:     
Peak Area 
Ratio 
Spiked Blank:       
Peak Area 
Ratio 
Extraction:     
Peak Area 
Ratio 
Spiked Blank:       
Peak Area 
Ratio 
Sample 1 13 9.6 6.93 5.15 0.841 0.609 
Sample 2 13.3 9.7 7.27 5.11 0.822 0.691 
Sample 3 12.7 10.1 6.82 5.31 0.853 0.651 
Sample 4 12.7 10.1 6.98 5.33 0.829 0.655 
Sample 5 12.9 9.7 7.05 5.27 0.851 0.676 
Sample 6 13.2 9.6 7.21 5.14 0.856 0.649 
Average 13 9.8 7.04 5.22 0.842 0.655 
STDEV 0.25 0.251 0.171 0.096 0.0139 0.0279 
% CV 1.9 2.6 2.4 1.8 1.7 4.3 
% 
Recovery 
  132.6   135   128.5 
    Average % 
Recovery 
132 
 
   Average % CV 2.5 
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Table 6.66: RIF recovery 
  
High Concentration Medium Concentration Low Concentration 
(24.0 µg/ml) (12.0 µg/ml) (0.258 µg/ml) 
Extraction:     
Peak Area 
Ratio 
Spiked 
Blank:       
Peak Area 
Ratio 
Extraction:     
Peak Area 
Ratio 
Spiked 
Blank:       
Peak Area 
Ratio 
Extraction:     
Peak Area 
Ratio 
Spiked Blank:       
Peak Area 
Ratio 
Sample 1 2.9 2.03 1.49 1.18 0.175 0.128 
Sample 2 2.2 2.08 1.49 1.2 0.17 0.15 
Sample 3 2.88 2.14 1.48 1.15 0.178 0.145 
Sample 4 2.86 2.11 1.48 1.16 0.179 0.143 
Sample 5 2.9 2.07 1.48 1.16 0.172 0.145 
Sample 6 2.79 2.11 1.56 1.12 0.168 0.14 
Average 2.76 2.09 1.5 1.16 0.174 0.142 
STDEV 0.275 0.038 0.0314 0.027 0.0044 0.0075 
% CV 10 1.8 2.1 2.3 2.5 5.3 
% 
Recovery 
  131.8   128.8   122.4 
    Average % Recovery 127.7 
 
   Average % CV 3.8 
 
 
The mean recovery of AcINH, desRIF, EMB, INH, PZA and RIF from six different lots of 
plasma over the calibration range was 106.5, 123.2, 105.3, 110.1, 132.0 and 127.7% 
respectively with CV (%) of 3.4, 2.9, 5.5, 3.2, 2.5 and 3.8% respectively which was within 
acceptable limits. All analyte recoveries were above 100%. For three of the analytes (AcINH, 
EMB and INH) the recovery was less than 115%, which could be a result of random analytical 
errors when the actual recovery was approximately 100%. For analytes with recoveries greater 
than 120% (desRIF, PZA and RIF), ion enhancement could be a possible reason, although nit 
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is not clear why matrix effects (ion enhancement) would be different when the same matrix 
was used. 
 
6.6. Matrix effects 
 
In biological analyses, matrix refers to endogenous and non-endogenous components of a 
sample other than the analyte being studied. The presence of certain matrix components may 
affect analyte and/or internal standard ionization. Factors such as haemolysis and anticoagulant 
type may also affect ionization. An appropriate ISTD which adequately resembles analyte 
behaviour compensates, to some extent, for matrix effects.  
 
Acceptance criteria:  The analyte peak areas for each concentration level in an individual 
plasma sample are used to generate regressions for that sample.  The slope variability (%CV) 
for the six different matrix sources should not be >5%.  
 
Plasma from 6 different sources were extracted (without ISTD).  Each plasma sample was 
spiked at low, medium and high concentration levels (accounting for any calculations for 
dilutions in the analytical method). The results of the regression slopes were calculated in 
Tables 6.67 – 6.72. 
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Table 6.67: AcINH regression results from 6 different matrices 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 10.0 µg/ml 5.00 µg/ml 0.107 µg/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
15-11-2017-32E 5.320 2.730 0.270 0.511 
15-11-2017-25E 5.500 2.730 0.323 0.523 
15-11-2017-33E 5.900 2.730 0.317 0.564 
15-11-2017-15E 5.480 2.750 0.296 0.524 
15-11-2017-29E 5.460 2.860 0.314 0.521 
15-11-2017-30E 5.470 2.860 0.303 0.522 
Average 5.520 2.780 0.304 0.527 
STDEV 0.195 0.0658 0.0192 0.0187 
% CV 3.5 2.4 6.3 3.5 
 
 
Table 6.68: desRIF regression results from 6 different matrices 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 8.00 µg/ml 4.00 µg/ml 0.0860 µg/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
15-11-2017-32E 8.99 5.16 0.603 1.06 
15-11-2017-25E 9.17 4.92 0.645 1.08 
15-11-2017-33E 9.21 4.9 0.662 1.08 
15-11-2017-15E 8.81 4.97 0.704 1.02 
15-11-2017-29E 8.6 5.46 0.656 1.00 
15-11-2017-30E 8.36 4.6 0.704 0.968 
Average 8.86 5 0.662 1.04 
STDEV 0.333 0.287 0.0383 0.045 
% CV 3.8 5.7 5.8 4.3 
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Table 6.69: EMB regression results from 6 different matrices 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 4.00 µg/ml 2.00 µg/ml 0.0430 µg/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
15-11-2017-32E 13.4 7.23 0.824 3.19 
15-11-2017-25E 14.7 7.34 0.859 3.5 
15-11-2017-33E 14.7 7.61 0.892 3.49 
15-11-2017-15E 15.1 7.19 0.885 3.6 
15-11-2017-29E 14.2 7.85 0.815 3.38 
15-11-2017-30E 15.1 7.35 0.86 3.6 
Average 14.5 7.43 0.856 3.46 
STDEV 0.639 0.253 0.0313 0.156 
% CV 4.4 3.4 3.7 4.5 
 
 
Table 6.70: INH regression results from 6 different matrices 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 20.0 µg/ml 10.0 µg/ml 0.215 µg/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
15-11-2017-32E 4.69 2.36 0.281 0.223 
15-11-2017-25E 4.69 2.53 0.31 0.221 
15-11-2017-33E 4.91 2.44 0.295 0.233 
15-11-2017-15E 5.02 2.3 0.289 0.239 
15-11-2017-29E 4.870 2.300 0.300 0.231 
15-11-2017-30E 4.930 2.240 0.290 0.235 
Average 4.850 2.360 0.294 0.230 
STDEV 0.136 0.106 0.0102 0.00703 
% CV 2.8 4.5 3.5 3.0 
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Table 6.71: PZA regression results from 6 different matrices 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 64.0 µg/ml 32.0 µg/ml 0.688 µg/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
15-11-2017-32E 9.6 5.15 0.608 0.142 
15-11-2017-25E 9.7 5.11 0.691 0.142 
15-11-2017-33E 10.1 5.32 0.651 0.15 
15-11-2017-15E 10.1 5.32 0.656 0.149 
15-11-2017-29E 9.7 5.26 0.676 0.142 
15-11-2017-30E 9.6 5.14 0.649 0.141 
Average 9.8 5.22 0.655 0.144 
STDEV 0.244 0.0966 0.0285 0.00382 
% CV 2.5 1.9 4.3 2.7 
 
 
Table 6.72: RIF regression results from 6 different matrices 
 High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 24.0 µg/ml 12.0 µg/ml 0.258 µg/ml v Conc.  
 Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
15-11-2017-32E 2.03 1.18 0.128 0.0801 
15-11-2017-25E 2.08 1.2 0.151 0.0811 
15-11-2017-33E 2.14 1.15 0.145 0.0839 
15-11-2017-15E 2.11 1.16 0.144 0.0828 
15-11-2017-29E 2.07 1.16 0.145 0.0811 
15-11-2017-30E 2.12 1.12 0.14 0.0833 
Average 2.09 1.16 0.142 0.0821 
STDEV 0.039 0.027 0.00758 0.00151 
% CV 1.9 2.3 5.3 1.8 
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The slope variability (%CV) for six different K3EDTA plasma samples was 3.5, 4.3, 4.5, 3.0, 
2.7 and 1.8% for AcINH, desRIF, EMB, INH, PZA and RIF, respectively. These results 
indicate that matrix effects do not adversely influence the precision of the assay. 
 
6.7. Effect of haemolysis  
 
The presence of haemolysed blood in samples could affect the ionization of the analyte and 
ISTD during assay. If ionisation suppression of the ISTD is comparable to that of the analyte, 
the ISTD is regarded as providing sufficient compensation for the analyte. Haemolysis was 
tested using 2% haemolysed blood in plasma. The ability of the internal standard to compensate 
for haemolysis effect on analyte determination was assessed by comparing normal and 
haemolysed plasma response ratios at high and low concentrations (Tables 6.73 – 6.78). 
 
Table 6.73: Effect of 2% Haemolysis: AcINH 
 
High Concentration 
(10.0 µg/ml) 
Med Concentration 
(5.00 µg/ml) 
Low Concentration 
(0.107 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Sample 1 7.05 6.46 3.4 3.35 0.0715 0.0623 
Sample 2 6.72 6.38 3.48 3.25 0.07 0.0628 
Sample 3   6.33   3.08   0.0654 
Sample 4   6.43   3.28   0.0614 
Sample 5   6.31   3.18   0.059 
Sample 6   6.24   3.21   0.0615 
Average 6.89 6.36 3.44 3.23 0.0708 0.0621 
STDEV 0.233 0.081 0.0566 0.0922 0.00106 0.00209 
% CV 3.4 1.3 1.6 2.9 1.5 3.4 
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% 
Difference 
  -7.6   -6.3   -12.3 
 
 
 
 
Table 6.74: Effect of 2% Haemolysis: desRIF 
 
High Concentration 
(8.00 µg/ml) 
Med Concentration 
(4.00 µg/ml) 
Low Concentration 
(0.0860 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Sample 1 12.7 12.6 7.59 6.81 0.189 0.162 
Sample 2 13.1 12.4 7.5 7.05 0.2 0.155 
Sample 3   11.5   6.7   0.169 
Sample 4   11.5   6.68   0.159 
Sample 5   11.5   6.84   0.182 
Sample 6   11   7.25   0.155 
Average 12.9 11.8 7.55 6.89 0.195 0.164 
STDEV 0.283 0.616 0.0636 0.221 0.00778 0.0104 
% CV 2.2 5.2 0.8 3.2 4 6.3 
% 
Difference 
  -8.9   -8.7   -15.9 
 
 
Table 6.75: Effect of 2% Haemolysis: EMB 
 
High Concentration 
(4.00 µg/ml) 
Med Concentration 
(2.00 µg/ml) 
Low Concentration 
(0.0430 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Sample 1 16.4 14.1 8.07 7.82 0.184 0.152 
Sample 2 16.6 14.7 8.44 7.53 0.199 0.168 
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Sample 3   14.5   7.82   0.15 
Sample 4   15.1   7.67   0.156 
Sample 5   15   7.92   0.154 
Sample 6   14   7.5   0.153 
Average 16.5 14.6 8.26 7.71 0.192 0.156 
STDEV 0.141 0.455 0.262 0.171 0.0106 0.0064 
% CV 0.9 3.1 3.2 2.2 5.5 4.1 
% 
Difference 
  -11.7   -6.6   -18.8 
 
Table 6.76: Effect of 2% Haemolysis: INH 
 
High Concentration 
(20.0 µg/ml) 
Med Concentration 
(10.0 µg/ml) 
Low Concentration 
(0.215 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Sample 1 7.81 7.57 3.74 3.61 0.158 0.157 
Sample 2 7.87 7.28 3.73 3.61 0.145 0.171 
Sample 3   7.21   3.56   0.161 
Sample 4   7.39   3.64   0.167 
Sample 5   6.87   3.76   0.168 
Sample 6   7.36   3.59   0.154 
Average 7.84 7.28 3.74 3.63 0.152 0.163 
STDEV 0.042 0.235 0.00707 0.0697 0.00919 0.00672 
% CV 0.5 3.2 0.2 1.9 6.1 4.1 
% 
Difference 
  -7.1   -2.9   7.6 
 
 
Table 6.77: Effect of 2% Haemolysis: PZA 
 
High Concentration 
(64.0 µg/ml) 
Med Concentration 
(32.0 µg/ml) 
Low Concentration 
(0.688 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Sample 1 11.5 10.5 6.13 5.87 0.161 0.121 
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Sample 2 11.7 10.2 6.48 5.69 0.151 0.132 
Sample 3   10.5   5.44   0.131 
Sample 4   10.5   6.02   0.124 
Sample 5   10.5   5.96   0.131 
Sample 6   10.6   5.84   0.121 
Average 11.6 10.5 6.31 5.8 0.156 0.127 
STDEV 0.141 0.137 0.247 0.2108 0.00707 0.00524 
% CV 1.2 1.3 3.9 3.6 4.5 4.1 
% 
Difference 
  -9.8   -8   -18.8 
 
Table 6.78: Effect of 2% Haemolysis: RIF 
 
High Concentration 
(24.0 µg/ml) 
Med Concentration 
(12.0 µg/ml) 
Low Concentration 
(0.258 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Normal 
2% 
Haemolysed 
Sample 1 3.6 3.15 1.81 1.72 0.0399 0.034 
Sample 2 3.33 3.23 1.82 1.7 0.041 0.0348 
Sample 3   3.24   1.67   0.0353 
Sample 4   3.25   1.76   0.034 
Sample 5   3.1   1.78   0.0358 
Sample 6   3.22   1.76   0.0345 
Average 3.47 3.2 1.82 1.73 0.0405 0.0347 
STDEV 0.191 0.0598 0.00707 0.0422 0.000778 0.00072 
% CV 5.5 1.9 0.4 2.4 1.9 2.1 
% 
Difference 
  -7.7   -4.6   -14.1 
 
 
Acceptance criteria:  A % Difference higher than 15% between the peak area ratios observed 
in haemolysed samples and normal samples and a high CV(%) (higher than 15%) indicates that 
haemolysis has an effect on the assay of the analyte and that the internal standard does not 
sufficiently compensate for the analyte.  
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The % Differences were within 15% for three of the six analytes (AcINH, INH and RIF) in  
2% haemolysed plasma samples, therefore haemolysis has no significant effect on the 
quantification of these analytes. The % Difference for desRIF, EMB and PZA was greater than 
15% at low concentrations indicating that low concentrations of these analytes cannot be 
reliably measured in plasma samples that are 2% haemolysed.  
 
6.8. Matrix anticoagulant effect 
 
To evaluate the influence of the matrix anticoagulant on the analyte and internal standard 
ionization and accuracy, a set of quality controls prepared using plasma containing K2EDTA 
as the anticoagulant, were compared to those in which K3EDTA was the anticoagulant, in a 
validation batch. The results are presented in Tables 6.79 – 6.84. 
 
Table 6.79: Effect of K2EDTA anticoagulant on AcINH 
 
High Concentration 
(10.0 µg/ml) 
Med Concentration (5.00 
µg/ml) 
Low Concentration (0.107 
µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
Sample 1 7.05 6.15 3.4 3.28 0.0715 0.0702 
Sample 2 6.72 6.14 3.48 3.35 0.07 0.0628 
Sample 3   6.17   3.32   0.0664 
Sample 4   6.44   3.28   0.0638 
Sample 5   6.23   3.19   0.0713 
Sample 6   6.25   3.18   0.068 
Average 6.89 6.23 3.44 3.27 0.0708 0.0671 
STDEV 0.233 0.112 0.0566 0.0686 0.00106 0.0034 
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% CV 3.4 1.8 1.6 2.1 1.5 5.1 
% 
Difference 
  -9.5   -5   -5.2 
 
 
 
 
 
 
Table 6.80: Effect of K2EDTA anticoagulant on desRIF 
 
High Concentration 
(8.00 µg/ml) 
Med Concentration (4.00 
µg/ml) 
Low Concentration 
(0.0860 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA K3EDTA K2EDTA 
Sample 1 12.7 12.4 7.59 7.53 0.189 0.185 
Sample 2 13.1 10.8 7.5 6.74 0.2 0.191 
Sample 3   11.6   7.07   0.186 
Sample 4   11.3   7.16   0.169 
Sample 5   12.3   6.02   0.19 
Sample 6   11   6.94   0.184 
Average 12.9 11.6 7.55 6.91 0.195 0.184 
STDEV 0.283 0.665 0.0636 0.509 0.00778 0.00794 
% CV 2.2 5.8 0.8 7.4 4 4.3 
% 
Difference 
  -10.3   -8.4   -5.3 
 
 
Table 6.81: Effect of K2EDTA anticoagulant on EMB 
 
High Concentration 
(4.00 µg/ml) 
Med Concentration (2.00 
µg/ml) 
Low Concentration 
(0.0430 µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
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K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
Sample 1 16.4 14.4 8.07 7.12 0.184 0.187 
Sample 2 16.6 15 8.44 8.01 0.199 0.156 
Sample 3   13.8   7.07   0.154 
Sample 4   14.7   7.57   0.152 
Sample 5   14.4   7.65   0.179 
Sample 6   13.6   7.44   0.153 
Average 16.5 14.3 8.26 7.48 0.192 0.164 
STDEV 0.141 0.531 0.262 0.351 0.0106 0.0154 
% CV 0.9 3.7 3.2 4.7 5.5 9.4 
% 
Difference 
  -13.2   -9.4   -14.6 
 
Table 6.82: Effect of K2EDTA anticoagulant on INH 
 
High Concentration 
(20.0 µg/ml) 
Med Concentration (10.0 
µg/ml) 
Low Concentration (0.215 
µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
Sample 1 7.81 7.07 3.74 3.72 0.158 0.134 
Sample 2 7.87 6.94 3.73 3.67 0.145 0.13 
Sample 3   6.91   3.52   0.131 
Sample 4   7   3.58   0.129 
Sample 5   6.83   3.72   0.139 
Sample 6   6.72   3.6   0.128 
Average 7.84 6.91 3.74 3.64 0.152 0.132 
STDEV 0.042 0.124 0.00707 0.0814 0.00919 0.00407 
% CV 0.5 1.8 0.2 2.2 6.1 3.1 
% 
Difference 
  -11.8   -2.7   -13 
 
 
Table 6.83: Effect of K2EDTA anticoagulant on PZA 
 
High Concentration 
(64.0 µg/ml) 
Med Concentration (32.0 
µg/ml) 
Low Concentration (0.688 
µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
  176 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
Sample 1 11.5 10.2 6.13 5.99 0.161 0.14 
Sample 2 11.7 10.1 6.48 6.04 0.151 0.137 
Sample 3   10   5.94   0.135 
Sample 4   10.3   6.04   0.139 
Sample 5   10.1   5.91   0.142 
Sample 6   10.6   6.08   0.144 
Average 11.6 10.2 6.31 6 0.156 0.14 
STDEV 0.141 0.214 0.247 0.0654 0.00707 0.00327 
% CV 1.2 2.1 3.9 1.1 4.5 2.3 
% 
Difference 
  -11.9   -4.8   -10.6 
 
Table 6.84: Effect of K2EDTA anticoagulant on RIF 
 
High Concentration 
(24.0 µg/ml) 
Med Concentration (12.0 
µg/ml) 
Low Concentration (0.258 
µg/ml) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
K3EDT
A 
K2EDTA 
Sample 1 3.6 3.09 1.81 1.72 0.0399 0.039 
Sample 2 3.33 3.06 1.82 1.74 0.041 0.0386 
Sample 3   3.05   1.71   0.0395 
Sample 4   3.1   1.69   0.0371 
Sample 5   3.11   1.68   0.0354 
Sample 6   3   1.71   0.036 
Average 3.47 3.07 1.82 1.71 0.0405 0.0376 
STDEV 0.191 0.0407 0.00707 0.0214 0.000778 0.00169 
% CV 5.5 1.3 0.4 1.3 1.9 4.5 
% 
Difference 
  -11.4   -5.9   -7 
 
 
Acceptance criteria: A % Difference higher than 15% between the peak area ratios observed 
in quality controls prepared in plasma containing K2EDTA as the anticoagulant compared to 
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K3EDTA indicates that the type of anticoagulant used affects the assay and that the internal 
standard does not sufficiently compensate for the analyte. 
 
The % Difference was less than 15% for the six analytes at high, medium and low 
concentrations, indicating that the use of K2EDTA vs K3EDTA anticoagulant has no 
significant influence on the precision and accuracy of the assay. 
 
 
6.9. Linearity  
 
Concentration was plotted against peak area ratio for each calibration standard to generate 
calibration curves for each analyte. Quadratic regressions were used for each analyte and were 
weighted by 1/concentration for all analytes except PZA, which was weighted by 
1/concentration2. Figure 6.73 to Figure 6.78 show representative calibration curves for each 
analyte. 
 
AcINH 
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Figure 6.14: Representative calibration curve for AcINH: Validation 1, Day 1. 
The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Table 6.85. 
 
Table 6.85: Regression equation: AcINH 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 -0.00346 0.667 -0.00144 0.9993 
 
 
MM_09Nov2018_Validation1_Final.rdb (AcINH 1): "Quadratic" Regression ("1 / x" weighting): y = -0.00346 x^ 2 + 0.667 x + -0.00144 (r = 0.9993)
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desRIF
 
Figure 6.15: Representative calibration curve for 25-Desacetyl-Rifampicin: Validation 1, Day 1 
The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Table 6.86. 
 
Table 6.86: Regression equation: desRIF 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 -0.0608 1.73 0.00914 0.9983 
 
 
MM_09Nov2018_Validation1_Final.rdb (desRMP 1): "Quadratic" Regression ("1 / x" weighting): y = -0.0608 x^ 2 + 1.73 x + 0.00914 (r = 0.9983)
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EMB 
 
Figure 6.16: Representative calibration curve for EMB: Validation 1, Day 1 
The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Table 6.87. 
 
Table 6.87: Regression equation: EMB 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 0.0136 3.4 0.0123 0.9991 
 
 
MM_09Nov2018_Validation1_Final.rdb (EMB 1): "Quadratic" Regression ("1 / x" weighting): y = 0.0136 x^ 2 + 3.4 x + 0.0123 (r = 0.9991)
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INH 
 
Figure 6.17: Representative calibration curve for Isoniazid: Validation 1, Day 1 
 
The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Table 6.88. 
 
Table 6.88: Regression equation: INH 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 0.000442 0.374 0.0133 0.9997 
 
MM_09Nov2018_Validation1_Final.rdb (INH 1): "Quadratic" Regression ("1 / x" weighting): y = 0.000442 x^ 2 + 0.374 x + 0.0133 (r = 0.9997)
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PZA 
 
Figure 6.18: Representative calibration curve for PZA: Validation 1, Day 1 
The regression equation used was Quadratic (weighted by 1/x2 concentration), f(x) = a + bx + 
cx2, as presented in Table 6.89. 
 
Table 6.89: Regression equation: PZA 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 -0.00056 0.215 0.00532 0.9974 
 
RIF 
MM_09Nov2018_Validation1_Final.rdb (PZA 1): "Quadratic" Regression ("1  / (x * x)" weighting): y = -0.000559 x^ 2 + 0.215 x + 0.00532 (r = 0.9974)
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Figure 6.19: Representative calibration curve for Rifampicin: Validation 1, Day 1 
 
The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Table 6.90. 
 
Table 6.90: Regression equation: RIF 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 -0.00115 0.177 0.000639 0.9998 
 
MM_09Nov2018_Validation1_Final.rdb (RMP 1): "Quadratic" Regression ("1 / x" weighting): y = -0.00115 x^ 2 + 0.177 x + 0.000639 (r = 0.9998)
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6.10. Carry over 
 
In all analytical batches, carry over was assessed by injecting a double blank sample 
(containing no analyte or internal standard) immediately after the highest calibration standard. 
A blank sample, with IS and no analyte, was also included to determine possible contamination 
of the analyte by the IS. For all analytes, there was no significant carry over from the injection 
with the highest concentration; any peaks on the double blank sample were less than 20% of 
the peaks obtained at the LLOQ. No contamination of the analyte by the IS was observed. 
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Chapter 7 : Discussion 
 
A method was developed and validated for the simultaneous quantification of first-line oral 
anti-TB drugs and two metabolites in human plasma. Although the analytes have widely 
varying physicochemical properties they were separated within 6 minutes using reverse-phase 
liquid chromatography as shown in Figure 6.7. As far as we know, one method has been 
developed to quantitate these 6 analytes (20). However, this method used structurally similar 
compounds as ISs whereas we used isotopically labelled ISs. The method by Song et al. used 
two ISs to cover the 6 analytes while the current method used an almost identical IS for each 
analyte, which could better compensate for matrix effects, process- and stability- related losses. 
The methods also had different calibration ranges for all analytes. 
 
Although deuterated ISs were used for all analytes to compensate for matrix effects, the ISs 
themselves may affect the ionization of analytes and their ionization may also be affected by 
the corresponding analytes. However, this problem is not supposed to affect the robustness of 
the method since the internal standard concentrations will be constant in each analytical batch. 
 
The method was accurate and reproducible, with accuracies and precisions less than 15% for 
all analytes. Analytes were stable on ice for at least 4 hours and samples could undergo three 
freeze-thaw cycles without negatively affecting the stability of analytes. Analysis of plasma 
samples with 2% haemolysed blood showed that the % Differences between haemolysed and 
non-haemolysed plasma were within 15% for three of the six analytes (AcINH, INH and RIF), 
hence 2% haemolysis does not negatively affect the accuracy for these analytes. The % 
Difference for desRIF, EMB and PZA was greater than 15% at the low concentrations 
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indicating that low concentrations of these analytes could not be reliably be measured in plasma 
samples that are 2% haemolysed. Previous validation reports indicate that 1% haemolysed 
plasma samples had no significant effect on the quantification of AcINH and INH (92) and 
EMB (90). However, unlike in this project, desRIF, and PZA were not significantly affected 
by 2% haemolysis (91, 93).  Re-assessment of the effect of 2% haemolysis is therefore 
necessary.  
` 
PZA showed instability on re-injection. However, a previous report showed that PZA could be 
reliably quantitated when reinjected after 24 hours (93). Therefore, the PZA data reported here 
will be re-investigated. 
 
Future work  
 
1. Due to matrix and time constraints, “fresh” vs “frozen” stability experiments still need 
to be done.   
2. Re-injection stability of PZA showed contrasting results with previous reports therefore 
the PZA data reported here will be re-investigated. 
3. The stability of desRIF and EMB in whole blood will be determined at a later stage. 
4. Analysis of patient samples. 
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